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Summary 
 
Podocyte foot processes and the interposed glomerular slit diaphragm are critical 
components of the permeability barrier in the kidney. Mutations in several podocyte 
genes have been identified as the cause for progressive kidney failure and focal 
segmental glomerulosclerosis (FSGS). Podocyte injury is a hallmark of glomerular 
disease and usually involves the rearrangement of the podocyte actin cytoskeleton. 
Cell-specific therapies targeting podocyte injury are currently not available. 
 
In 2004, a mutation in the TRPC6 ion channel was found to cosegregate with 
hereditary FSGS. Based on this finding it was hypothesized that TRPC6 is expressed 
in podocytes, and that TRPC6-mediated Ca
2+
 signaling contributes to the regulation 
of the podocyte actin cytoskeleton. According to this model, dysfunction of TRPC6 
leads to a disruption of normal cytoskeletal organization, podocyte injury, and 
proteinuric disease. To test this hypothesis, four specific aims were outlined. First, to 
explore TRPC6 mutations in genetic FSGS. Second, to investigate its association 
with the glomerular filtration barrier. Third, to study TRPC6 expression in acquired 
forms of proteinuric kidney disease. Fourth, to investigate the molecular basis of 
TRPC6 contribution to the pathophysiology of proteinuric kidney disease 
 
In genetic forms of FSGS, additional TRPC6 mutations were identified in five 
families with a history of FSGS. TRPC6-related FSGS presented as a late-onset 
disorder in individuals aged 17-57, and was not restricted to certain ethnic groups. All 
mutations occured in evolutionary conserved sites, and encoded amino acid 
substitutions at the amino- and carboxy-terminal ends of TRPC6. Two mutants, 
R895C and E897K, displayed increased current amplitudes, suggesting a pathogenic 
role of increased channel activity in TRPC6-related FSGS. 
 
In an effort to understand the molecular basis for TRPC6 in the kidney, the 
association of TRPC6 with the glomerular filter was studied. TRPC6 was found to be 
expressed in podocytes near the glomerular slit diaphragm. TRPC6 colocalized and 
associated with the slit diaphragm proteins nephrin and podocin. The presence of 
TRPC6 in podocyte foot processes and its association with slit diaphragm proteins 
supports a role of TRPC6 in the regulation of glomerular filtration. 
 
Since most proteinuric kidney diseases appear not as genetic but acquired disorders, 
TRPC6 was studied in humans with acquired glomerular diseases and in experimental 
models thereof. TRPC6 expression was induced in patients with minimal change 
disease and membranous glomerulopathy, as well as in passive Heymann nephritis 
(PHN) rats and puromycin aminonucleoside (PAN) rats. PAN-mediated podocyte 
injury correlated with increased receptor-operated calcium entry in vitro. TRPC6 
gene delivery in mice was sufficient to induce proteinuria, and studies in cultured 
podocytes suggest that TRPC6 overexpression disrupts the actin cytoskeleton. 
 
The present data suggest that in both genetic and acquired forms of proteinuric 
kidney disease, misregulation of TRPC6 – either by presence of mutated hyperactive 
channels, or by precence of too many wildtype channels – plays a pathogenic role. 
Together, the results of this work may have broad implications for the 
pathophysiology of TRPC6-related human kidney diseases, and promote the 
development of anti-proteinuric drugs interfering with TRPC6 channel function. 
ZUSAMMENFASSUNG  VII 
 
Zusammenfassung 
 
Podozyten stellen mit ihren Fußfortsätzen und der sich dazwischen befindenden 
Schlitzmembran wichtige Bestandteile der glomerulären Filtrationsbarriere in der 
Niere dar. Mutationen in mehreren Genen für wichtige Proteine in Podozyten führen 
zu proteinurischen Nierenerkrankungen und fokaler segmentaler Glomerulosklerose 
(FSGS). Die meisten Nierenerkrankungen gehen mit einer Schädigung von 
Podozyten einher. Letztere äußert sich vor allem in einer Reorganisation des Aktin-
Zytoskeletts. Derzeit gibt es keine zellspezifische Therapie bei Podozytenschädigung. 
 
Im Jahr 2004 wurde über eine Mutation im Ionenkanal TRPC6 in Patienten mit 
hereditärer FSGS berichtet. Hieraus leitete sich die Hypothese dieser Arbeit ab: 
TRPC6 ist in Podozyten exprimiert und trägt in Podozyten zur Regulation des Aktin-
Zytoskeletts bei. Dysregulation von TRPC6 führt demzufolge zu Störungen im 
Zytoskelett und Podozytenschädigung. Aus dieser Hypothese ergaben sich die Ziele 
dieser Arbeit: Untersuchung von TRPC6 (1) in hereditärer FSGS, (2) als Bestandteil 
des glomerulären Nierenfilters, (3) in erworbenen Formen proteinurischer Nierener-
krankungen sowie (4) Identifikation pathophysiologischer Mechanismen von TRPC6. 
 
Um die Rolle von TRPC6 in hereditärer FSGS näher zu beleuchten, wurden             
71 FSGS-Familien auf Mutationen im TRPC6-Gen untersucht. Es konnten fünf neue 
Mutationen identifiziert werden, darunter vier Missense-Mutationen in evolutionär 
konservierten Basenpaaren. Zwei Mutanten wiesen erhöhte Stromstärke-Amplituden 
auf. Letzteres wäre eine mögliche Erklärung für die Pathologie dieser Mutanten. 
 
Um einen Zusammenhang zwischen TRPC6 und dem Nierenfilter zu prüfen, wurden 
Expressionsstudien durchgeführt. Es zeigte sich, dass TRPC6 in den Glomerula der 
Niere exprimiert ist; TRPC6 befindet sich u.a. in Podozytenfußfortsätzen nahe der 
Schlitzmembran. Ferner konnte nachgewiesen werden, dass TRPC6 mit den 
wichtigen Schlitzmembranproteinen Nephrin und Podocin kolokalisiert und mit 
diesen koimmunopräzipitiert. Dies deutet darauf hin, dass TRPC6 als Bestandteil der 
Schlitzmembran an der Regulation der glomerulären Filtration mitwirkt. 
 
Tatsächlich ist der Großteil proteinurischer Nierenerkrankungen nicht hereditär, 
sondern erworben. Um zu klären, ob TRPC6 möglicherweise auch bei diesen 
Erkrankungen eine Rolle spielt, wurde zunächst die Expression von TRPC6 bei 
entsprechenden Patienten untersucht. Es zeigte sich, dass die Expression von TRPC6 
bei Patienten mit minimal change Glomerulonephritis und membranöser 
Glomerulonephritis erhöht war. Ähnlich verhielt es sich in Tiermodellen sowie einem 
Zellkulturmodell von glomerulärer Nierenschädigung. Ferner war die Kalzium-
aufnahme geschädigter Podozyten in vitro höher als jene von normalen Podozyten. 
Der Gentransfer von TRPC6 in Mäusen führte zu Proteinurie. Eine mögliche Ursache 
hierfür könnte die Schädigung des Aktin-Zytoskeletts von Podozyten sein, wie sie bei 
der Überexprimierung von TRPC6 in kultivierten Podozyten beobachtet wurde. 
 
Diese Arbeit impliziert eine Doppelrolle von TRPC6 in hereditären und erworbenen 
Formen glomerulärer, proteinurischer Nierenerkrankungen. Sowohl im Fall von 
TRPC6-Mutationen als auch für die erhöhte Expression des Wildtyp-Kanals legen die 
erhaltenen Daten nahe, dass eine erhöhte Kanalaktivität an der Schädigung von 
Podozyten beteiligt ist. 
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ANOVA  analysis of variance 
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I.   INTRODUCTION 
 
I.1.  Overview of kidney structure and function 
 
The kidneys are two bean-shaped organs each weighing about 150 g. They are  
anatomically complex, consisting of many different types of specialized cells 
arranged in a highly organized three-dimensional pattern. The kidneys serve to 
maintain body composition, to excrete metabolic end products and foreign 
substances, and to produce and secrete important enzymes and hormones. Many 
important body functions heavily depend on the accurate regulation of body fluid 
composition and volume. For example, cardiac output and blood pressure are 
dependent on plasma volume, and most enzymes can carry out their physiological 
function only over rather narrow ranges of pH and ionic concentrations. Furthermore, 
the concentrations of potassium and calcium affect cell membrane potentials and 
excitability. As a consequence of food intake, metabolism, environmental factors, and 
exercise, the composition and volume of body fluids is subject to permanent change.  
It is the principal job of the kidneys to correct for any perturbations, thereby keeping 
the body fluid volume and the concentration of most ions within physiological range. 
 
Each kidney is composed of functional units called nephrons. There are around one 
million nephrons in a human kidney; each nephron consists of a glomerulus and a 
long tubule (Fig. I.1.). The glomerulus is the site of blood filtration in the kidney. It is 
a twisted corpuscle of capillaries lines by endothelial cells, with the outside of the 
capillaries covered with specialized epithelial cells, called podocytes. Podocytes are 
large, highly differentiated cells that form an array of lace-like foot processes over the 
outer layer of the glomerular capillaries. An outer epithelial capsule, called 
Bowman’s capsule, acts as a pouch to capture the filtrate, and to direct it into the 
beginning of the tubule. 
 
The tubule is composed of a single layer of epithelial cells. In the tubule, the 
glomerular filtrate undergoes a series of modifications before becoming the final 
urine. These changes consist of reabsorption (removal) and secretion (addition) of 
solutes and fluid. Reabsorption, the movement of solute or water from the tubular 
lumen into blood, is the predominant process in the renal regulation of sodium, 
chloride, water, glucose, amino acids, proteins, phosphates, calcium, magnesium, 
urea, and uric acid. In contrast, secretion, i.e. the movement of solute from the blood 
or cell interior into the tubular lumen, is important in the regulation of H+, potassium, 
ammonia, and a number of organic acids and bases. 
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The nephrons are packed together tightly to make up the kidney parenchyma, which 
can be divided into regions. The outer layer of the kidney is called the cortex; it 
contains all the glomeruli, much of the proximal tubule, and some of the more distal 
portions as well. The inner section, called the medulla, consists largely of the parallel 
arrays of the loops of Henle and collecting ducts. The medulla is formed into cone-
shaped regions, called pyramids (the human kidney typically has seven to nine). The 
medulla is important for concentration of the urine: the extracellular fluid in this 
region of the kidney has much higher solute concentration than plasma – as much as 
four times higher – with highest solute concentrations reached at the papillary tips. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The kidney fulfills three essential functions in the body. These functions are 
maintenance of body composition, excretion of metabolic end products and foreign 
substances, and production and secretion of enzymes and hormones. The maintenance 
of body composition involves the coordinated regulation of blood osmolarity and 
acidity, as well as of the electrolyte concentrations in the blood, in particular sodium, 
potassium, chloride, calcium, magnesium, and phosphate. The kidney achieves this 
regulation by variation in the amounts of water and ions excreted in the urine. Among 
the substances that are excreted by the kidney are a number of products of 
metabolism, most notably urea, but also toxins and drugs belong into this category. 
The kidney is also an important endocrine organ and is responsible for the production 
Fig. I.1. Organization of the nephron. (Left) The human kidney is made up of a million nephrons, 
one of which is shown schematically here. Each nephron consists of the following parts: glomerulus, 
proximal tubule, loop of Henle, and distal tubule. Several nephrons coalesce to empty into a 
collecting duct connecting the nephrons to the urether. Kidney filtration takes place in the 
glomerulus, a twisted corpuscle of capillaries. Blood enters the glomerular capillary tuft via the 
afferent arteriole, where an ultrafiltrate of plasma is formed, and exits the glomerulus via the efferent 
arteriole. The glomerular filtrate, consisting of water, small dissolved solutes and small proteins, 
passes the glomerular filtration barrier, and is collected in the lumen of Bowman‘s capsule. From 
there, it enters the renal tubular system, to be carried over a circuitous course, successively modified 
by exposure to the sequence of specialized tubular epithelial segments with different transport 
functions. The poximal tubule absorbs approximately two thirds of the glomerular filtrate. Fluid 
remaining at the end of the proximal tubule enters the loop of Henle, the distal tubule, and finally the 
collecting duct. Along the tubule, most of the glomerular filtrate is absorbed, but some additional 
substrates are secreted. After being processed by filtration, reabsorption, and secretion, the final urine 
enters the the ureter, collects in the bladder, and is finally excreted from the body. (Right) Schematic 
representation of the glomerulus (Source: courtesy of Prof. em. Dr. med. Wilhelm Kriz, Ruprecht-
Karls-Universität Heidelberg, Germany.) 
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of Renin, Erythropoietin (EPO), and 1,25-Dihydroxyvitamin D3, the most active 
form of Vitamin D3, among others. Renin is an enzyme that catalyzes the conversion 
of angiotensinogen to angiotensin, a potent vasoconstrictor peptide contributing to 
salt balance and blood pressure regulation. Renin is produced in the kidney by the 
granular cells of the juxtaglomerular apparatus. Another important protein produced 
by the kidney is Erythropoietin (EPO), a glycosylated, 165-amino acid protein 
produced by renal cortical interstitial cells. EPO stimulates the maturation of 
erythrocytes in the bone marrow, and has become well known for its role in 
competitive sports doping practices. Finally, 1,25-Dihydroxyvitamin D3 is formed by 
kidney proximal tubule cells; this protein is a steroid hormone playing an important 
role in the regulation of body calcium and phosphate balance. 
 
The characteristic events of filtration, reabsorption, and secrection in the kidney 
depend on a highly complex organization of blood circulation in this organ. The renal 
circulation is unusual in that in breaks into two separate capillary beds: the 
glomerular bed and the peritubular bed. These two capillary networks are arranged in 
series so that all the renal blood flow passes through both. As blood leaves the 
glomerulus, the capillaries coalesce into the efferent arteriole, but then bifurcate again 
to form the peritubular capillary network. This second network of capillaries is the 
site where the fluid reabsorbed by the tubules is returned to the circulation. Pressure 
in the first capillary bed, that of the glomerulus, is rather high (about 40-50 mmHg), 
whereas pressure in the peritubular capillaries is similar to that in capillary beds 
elsewhere in the body (about 5-10 mmHg). The renal artery, which enters the kidney 
at the renal hilum, carries about one fifth of the cardiac output; this represents the 
highest tissue-specific blood flow of all larger organs in the body (about 350 ml/min 
per 100 g tissue). As a consequence of this generous perfusion, the renal 
arteriovenous O2 difference is much lower than that of most other tissues. 
 
About one fourth of the plasma that enters the glomerulus passes through the 
filtration barrier to become the glomerular filtrate. Blood cells, most proteins, and 
about 75% of the fluid and small solutes stay in the capillary and leave the 
glomerulus via the efferent arteriole. This postglomerular blood, which has a 
relatively high concentration of protein and red cells, enters the peritubular 
capillaries, where the high osmotic pressure from the high protein concentration 
facilitates the reabsorption of fluid. The peritubular capillaries coalesce to form 
venules and eventually the renal vein. 
 
 
 
 
INTRODUCTION  4 
 
 
I.1.1. The glomerular filtration barrier 
 
The function of the glomerular filtration barrier is to retain plasma proteins in the 
blood on the basis of molecular size and charge. To reach from the vascular into the 
urinary space, molecules must pass through three distinct structures (Fig. I.2.).  
 
The first structure is a fenestrated endothelium decorating the inner surface of 
glomerular capillaries. The second structure is the glomerular basement membrane 
(GBM), a thin sheet of specialized extracellular matrix. The third structure is formed 
by visceral glomerular epithelial cells (podocytes) and the interposed glomerular slit 
diaphragm. This complex three-layer barrier is freely permeable to water and small 
dissolved solutes, but retains most of the proteins and other larger molecules, as well 
as all blood particles. 
 
The main determinant of passage through the glomerular filter is molecular size. A 
molecule such as inulin (5 kD) passes freely through the filter, and even a small 
protein such as myoglobin (17 kD) is filtered to a large extent. In contrast, substances 
of increasing size are retained with increasing efficiency, until at a size about 60-70 
kD the amount filtered becomes very small. Filtration also depends on ionic charge, 
and negatively charged proteins, such as albumin, are retained to a greater extent than 
would be predicted by size alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fenestrated endothelium decorates the glomerular capillaries. The fenestrae 
between the endothelial cells are 70-100 nm in diameter. On their surface, the 
endothelial cells carry a complex of negatively-charged sialoproteins and 
proteoglycans that is referred to as the glycocalyx [Deen et al., 2001]. While the 
Fig. I.2. Ultrastructure of the glomerular filter. (Left) Scanning electron micrograph of normal rat 
glomerular capillaries. The urinary side of the capillary wall in covered by the highly branched 
podocytes. (Right) Cross-section through the glomerular filtration barrier. The arrow indicates the 
direction of fluid flow during glomerular filtration. C, podocyte cell body; M, podocyte major 
process; FP, podocyte foot processes; GBM, glomerular basement membrane; E, glomerular 
endothelial cells; US, urinary space; GC, glomerular capillary. (Source: adapted from Pavenstadt et 
al.; Physiol Rev. 2003, 83:253-307 [Pavenstadt et al., 2003] and Mundel & Kriz; Anat Embryol 
(Berl). 1995, 192:385-397 [Mundel & Kriz, 1995].) 
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negative charge of the glycocalyx constitutes a potential barrier retarding anionic 
macromolecules, there is no evidence so far for such a role of the glycocalyx. 
 
The glomerular basement membrane (GBM) is a thin sheet of specialized 
extracellular matrix [Miner, 2005] composed of four major components: laminin, 
type IV collagen, nidogen/entactin, and proteoglycans [Miner, 1999]. During 
glomerulogenesis, the GBM is built up in a combined effort by the underlying 
endothelial cells and overlying podocytes. As the case for the fenestrated 
endothelium, it is thought that that the presence of negatively-charged molecules 
within the GBM serves as a barrier retarding anionic macromolecules. 
 
The final retention barrier consists of podocytes and the interposed glomerular slit 
diaphragm [Somlo & Mundel, 2000]. This explains why podocyte damage is typically 
associated with the development of proteinuria, i.e. the loss of proteins from the 
blood into the urine, which can lead to a permanent deterioration of the glomerular 
filter. Major advances in unraveling the structures necessary for proper podocyte 
function [Tryggvason & Wartiovaara, 2001] have pointed to the crucial role of 
podocytes in the maintenance of glomerular health and filtration. Podocytes are non-
replicating, polarized epithelial cells that originate from precursor mesenchymal cells 
[Pavenstadt et al., 2003]. During nephrogenesis, these cells undergo modification 
from a classic epithelial cell phenotype to a highly specialized octopus-shaped cell. 
Podocytes cover the external surface of adjacent capillaries and interact with the 
GBM through finger-shaped extensions called pedicels or foot processes. The basal 
surface of podocyte foot processes is anchored in the GBM via ?3-/?1-integrins 
[Adler, 1992] and ?-/?-dystroglycans [Regele et al., 2000]. Podocyte foot processes 
interdigitate in a complex manner forming an intricate network surrounding the 
glomerular capillaries. 
 
Adjacent foot processes bridge their narrow 300-400 Å wide gaps by a membrane-
like structure, the glomerular slit diaphragm [Moller et al., 2006]. The slit diaphragm 
is a specialized cell-cell junction. As a thin porous membrane, it is thought to form 
the major determinant of the size selectivity of the glomerular filtration barrier 
[Tryggvason & Wartiovaara, 2001]. The slit diaphragm appears early on in 
nephrogenesis. It is thought to be a modified adherens junction that allows for the 
passage of water and solutes from the blood into the kidney ultrafiltrate while 
inhibiting the loss of larger plasma molecules auch as albumin. The slit diaphragm 
has a zipperlike structure composed of a number of proteins with large extracellular 
domains including nephrin, neph1, neph2, neph3, P-cadherin, and FAT (Fig. I.3.). 
 
 
 
INTRODUCTION  6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Four distinct functions of the slit diaphragm multi-protein complex have been 
described [Huber & Benzing, 2005].  These are: i) function as molecular sieve, ii) 
function as cell-cell contact between podocytes, iii) function as a signaling platform, 
and iv) function as an organizing center regulating podocyte actin dynamics. The slit 
diaphragm proteins nephrin and its homologues neph1, neph2, and neph3 are 
important scaffolding molecules and key players in mediating extracellular signals 
into the podocyte cell body [Benzing, 2004]. Various adaptor proteins including 
podocin [Boute et al., 2000], ZO-1 [Schnabel et al., 1990], and CD2AP [Shih et al., 
1999] connect the slit diaphragm to the podocyte intracellular space. Furthermore, it 
has been shown that the ?-actinin-4-binding protein densin and the src family protein 
tyrosine kinase Fyn are located at the slit diaphragm site [Ahola et al., 2003; Verma 
et al., 2003]. 
 
I.2.  Glomerular kidney disease 
 
Chronic kidney failure has become one of the biggest health care issues worldwide. 
In Germany alone, every year more than 15,000 patients are diagnosed with end-stage 
renal disease (ESRD), and more than 60,000 patients require dialysis. With life 
expectancy increasing and societies aging, kidney disorders are on the advance. 
 
Whereas many of the acute kidney diseases originate in kidney tubules, most chronic 
kidney diseases originate in the glomerulus. In fact, glomerulopathies account for a 
significant fraction of end-stage renal disease (ESRD). The most important symptoms 
include proteinuria, hematuria, edema, and a reduced glomerular filtration rate. With 
respect to their pathological and clinicial manifestations, glomerular diseases are 
generally classified as falling into one of the broad categories with either an 
Fig. I.3. Schematic representation of podocyte foot processes and the interposed slit diaphragm. 
FP, podocyte foot processes; GBM, glomerular basement membrane. (Source: Moller et al.; Adv 
Chronic Kidney Dis. 2006, 13:166-173 [Moller et al., 2006].) 
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inflammatory phenotype (nephritic syndrome) or a non-inflammatory phenotype 
(nephrotic syndrome). Nephritic syndrome is characterized pathologically by diffuse 
inflammatory changes in the glomeruli and clinically by abrupt-onset hematuria, mild 
proteinuria, and, often, hypertension, and edema. In contrast, nephrotic syndrome is 
characterized pathologically by a prolonged increase in the glomerular capillary wall 
permeability and clinically by heavy proteinuria and often hypoalbuminemia, severe 
edema, lipiduria, and lipemia. In many glomerular diseases, features of nephritic and 
nephrotic syndrome go hand in hand, making it difficult to identify the underlying 
cause of the disease. Likewise, many conditions referred to as glomerular diseases do 
not originate from a common, single disease-causing mechanism, but rather represent 
the pathological manifestation of a variety of associated diseases in the glomerulus. 
 
Glomerular proteinuria is a hallmark of glomerular disease and results from an 
increased permeability of the glomerular filtration barrier. Normally, proteins larger 
than albumin do not enter the urinary space whereas lower molecular weight proteins 
are filtered and partially reabsorbed in the proximal tubule. Normal excretion levels 
of protein into the urine vary between 0 and 150 mg/d. Proteinuria is clinically 
characterized by a protein loss into the urine of more than 150 mg/d. Levels of 3 g of 
urinary protein per day are generally used to define “nephrotic-range” proteinuria. 
 
While glomerular diseases can result from dysfunction in any glomerular cell type, 
including mesangial cells and endothelial cells, in many forms of glomerular diseases, 
proteinuria is correlated with podocyte injury and the podocyte has been suggested as 
the main culprit for glomerulosclerosis [Kriz et al., 1998; Shankland 2006]. The 
complexity of interactions among podocyte proteins provides several targets for 
podocytopathy and disruption of the glomerular filtration barrier [Durvasula & 
Shankland, 2006], and studies in human diabetic nephropathy [Steffes et al., 2001], 
the puromycin aminonucleoside (PAN) model of glomerulosclerosis [Kim et al., 
2001] and in TGF-? transgenic mice [Schiffer et al., 2001] provide convincing 
evidence for a correlation between damage and loss of podocytes and progression of 
glomerular diseases.  
 
Podocytes are injured in many forms of human (genetic and acquired) and 
experimental glomerular disease, including minimal change disease, focal segmental 
glomerulosclerosis (FSGS), diabetic nephropathy, membranous glomerulopathy, 
crescentic glomerulonephritis and Lupus nephritis [Endlich et al., 2001], and loss of 
the integrity of the intricate structures of the podocyte can generally be seen in 
patients with nephrotic syndrome, who clinically present with hypertension, 
proteinuria, and progressive kidney disease. 
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In patients with glomerular disease, the ultrastructural examination of kidney biopsies 
often reveals the loss of normal podocyte foot process structure, resulting in a 
flattened phenotype, where foot processes form an epithelial monolayer lacking 
functional slit diaphragms; this condition is called foot process effacement (Fig. I.4.). 
Foot process effacement is often associated with proteinuria and is accompanied by a 
reorganization of the podocyte actin cytoskeleton [Kriz et al., 1998]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recent insight into the molecular pathology of podocyte injury unraveled at least six 
major molecular causes of foot process effacement and proteinuria: i) interference 
with the negative surface charge of podocytes [Takeda et al., 2001], ii) interference 
with the activity of GLEPP1, a membrane-bound tyrosine phosphatase [Wharram et 
al., 2000], iii) interference with the actin cytoskeleton and its associated protein ?-
actinin-4 [Kaplan et al., 2000], iv) interference with the GBM or the podocyte-GBM 
interaction [Kreidberg et al., 1996], v) interference with the slit diaphragm [Kestila et 
al., 1998], and vi) induction of podocyte B7-1 expression [Reiser et al., 2004]. 
 
If early structural changes of podocytes are not reversed, severe and progressive 
glomerular damage is likely to develop [Reiser et al., 2002]. This involves podocyte 
vacuolization, pseudocyst formation, detachment of podocytes from the GBM, and 
eventually podocyte cell death. Since the highly differentiated podocytes are unable 
to proliferate, the loss of single podocytes leads to podocyte depletion over time, 
which is a major determinant of glomerulosclerosis and chronic kidney failure. 
Fig. I.4. Podocyte foot process effacement. The normal glomerular filter (left upper panel) consists 
of three components: fenestrated endothelium (arrows), the glomerular basement membrane (GBM) 
and podocyte foot processes with the interposed slit diaphragm (arrowheads). Actin filaments are 
present in normal foot processes (asterisks). In nephrotic syndrome (left bottom panel), the effaced 
foot processes form a continuous band of cytoplasm containing a dense band of actin filaments 
(asterisks) running parallel to the GBM. On injured glomerular capillaries as seen in various 
glomerulopathies, podocyte cell bodies (PO) are attenuated and pulled over the outer surface of 
capillaries, thus covering major parts of the filtration area (right panel). Interdigitating foot processes 
(FP) are hardly visible due to foot process effacement. Moreover, pseudocysts (stars) begin to 
develop. (Source: adapted from Somlo & Mundel; Nat Genet. 2000, 24:333-335 [Somlo & Mundel, 
2000] and Kriz et al.; Kidney Int. 1995, 48:1435-1450 [Kriz et al., 1995].) 
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I.2.1.  Genetic forms of glomerular kidney disease 
 
Clinical and molecular research aimed to understand glomerular disease has emerged 
to one of the most active areas in renal research at large. The unraveling of genetic 
causes resulting in proteinuria has helped to define roles for each component of the 
glomerular filtration barrier in the development of urinary protein loss. 
 
Most of the inherited glomerular diseases have in common defects in the podocyte 
[Moller et al., 2006], and a number of genetic mutations in several podocyte genes 
have been identified as culprits for progressive renal failure or increased glomerular 
disease susceptibility. 
 
Recent progress in the eludication of genetic causes of glomerular disease revealed 
four groups of genetic disorders associated with podocyte injury: i) GBM-associated 
genetic podocytopathies, ii) cytoskeleton-associated genetic podocytopathies, iii) 
organelle-associated genetic podocytopathies, and iv) slit diaphragm-associated 
podocytopathies. 
 
GBM-associated genetic podocytopathies 
 
Basement membranes have been shown to influence cell proliferation, migration, and 
differentiation. Also in the kidney, an intact GBM is necessary for proper adhesion 
and function of the underlying endothelial cells and podocytes [Miner et al., 2005].  
Inherited disruption of two components of the GBM, type IV collagen and laminin-
?2, have so far been shown to lead to glomerular disease. 
 
Type IV collagen-related diseases, including Alport syndromes and thin basement 
membrane nephropathy (TBMN), originate from defects in the genes encoding the ?-
chains of type IV collagen [Kashtan, 2005]. In four of the six identified ?-chain genes 
so far, mutations have been associated with progressive hereditary nephritis. With the 
exception of TBMN, all these gene defects lead to a thickened GBM and progressive 
hematuric glomerular disease, resulting in renal insufficiency and end-stage renal 
disease (ESRD). In contrast, patients with TBMN present with a thinnened GBM and 
asymptomatic microscopic hematuria. It is speculated that, in type IV collagen-
related diseases, an increased fragility of the GBM accounts for pathogenesis. 
 
The rare Nail-Patella syndrome is characterized by loss-of-function mutations in 
LMX1B encoding a transcription factor regulating the expression of COL4A3, 
COL4A4, NPHS1 (nephrin), NPHS2 (podocin), and CD2AP.  In most patients with 
Nail-Patella syndrome, the GBM has a characteristic moth-eaten appearance and 
contains fibrillar collagen deposits. Whereas some individuals do not present with 
any clinical nephropathy, proteinuria occurs in 30-40% of patients and, in 5-10% of 
patients, the disease leads to progressive renal failure. While the phenotype of Nail-
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Patella syndrome seems to be primarily confined to the GBM, it is likely that 
transcriptional dysregulation of slit diaphragm proteins contributes to the 
pathobiology of the disease. 
 
Gene defects in LAMB2 encoding the laminin-?2 chain lead to the rare Pierson 
syndrome. Laminin-?2 is abundantly expressed in the GBM where it is present in the 
adult GBM laminin-11 isoform (?5:?2:?1). Laminin-11 plays a key role in anchoring 
and differentiation of podocyte foot processes. Laminin-11 malfunction due to a lack 
of of functional laminin-?2 is thought to be the cause for the disease, which leads to 
the onset of nephrosis soon after birth, rapid progression to end-stage renal disease 
(ESRD), and death in the first year. 
 
Cytoskeleton-associated genetic podocytopathies 
 
The major function of podocyte foot processes is to create the outer portion of the 
glomerular filtration barrier. Because the glomerular capillary wall undergoes cyclic 
distensions, a functional adaptive cytoskeleton, providing both mechanical strength 
and flexibility, is required for maintaining podocyte structural integrity. To match this 
unique challenge, podocytes have developed a highly dynamic cytoskeletal 
architecture involving microtubules, intermediate filaments and actin microfilaments. 
Whereas the podocyte cell body and primary processes are predominantly composed 
of microtubules and intermediate filaments, podocyte foot processes contain an actin-
based contractile cytoskeletal network [Drenckhahn & Franke, 1988]. A group of 
cytoskeleton-associated proteins, including talin, paxillin, and vinculin, link actin 
filaments to the cell membrane-associated integrins at the GBM.  Parts of the actin 
cytoskeleton are also linked to the slit diaphragm via catenins, ZO-1 or CD2AP. 
 
Mutations in ACTN4 encoding ?-actinin-4 are associated with the development of 
familial focal segmental glomerulosclerosis (FSGS) [Pollak et al., 2002]. The disease 
is characterized by onset in adolescence or early adulthood, slow progression, non-
nephrotic proteinuria, and renal insufficiency. The protein ?-actinin-4 is expressed in 
podocytes, where it crosslinks F-actin filaments in foot processes. The disease-
causing mechanism appears to be linked to accelerated degradation of mutant ?-
actinin-4 by the proteasome. It is also thought that an increased affinity of mutant ?-
actinin-4 to F-actin may result in a dysregulation of actin filament formation in 
podocytes. Interestingly, ?-actinin-4 is expressed throughout the body but the human 
phenotype associated with ACTN4 mutations is apparent only in the kidney. This 
suggests that either a podocyte-specific protein-protein interaction is altered by 
human disease-associated mutations, or that the unique structure of the podocyte 
makes it particularly susceptible even to subtle changes in its cytoskeletal 
architecture. 
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Another group of cytoskeleton-associated mutations lead to podocyte injury by 
interference with the nonmuscle myosin heavy chain IIA (NMMHC-IIA), encoded by 
MYH9 [Seri et al., 2003]. MYH9-related diseases include the Epstein syndrome, 
Fechtner syndrome, May-Hegglin anomaly, and Sebastian syndrome. It has been 
suggested that these four sydromes are in fact not distinct entities but rather derive 
from a common single disorder with a continuous clinical spectrum characterized by 
a varying expressivity. Class II myosins play a well-characterized role in the 
contraction and force production in muscles and are required for cytokinesis, cell 
mobility, cell polarity, and cell architecture. In podocytes, NMMHC-IIA is thought to 
be a major component of the actin-myosin contractile apparatus in foot processes. 
The disease-causing mechanism leading to the glomerular phenotype of MYH9-
related disease remains elusive. 
 
Organelle-associated genetic podocytopathies 
 
One podocyte organelle shown to be a target of genetic defects causing glomerular 
disease, is the mitochondrion. Expression of mitochondrial gene mutations follows a 
pattern of maternal inheritance. A typical example of a mitochondrial cytopathy is the 
A3243G transition in the mitochondrial gene MTTL1 encoding for the 
tRNALeu(URR). This mutation leads to a defect in the Krebs cycle and has been 
associated with podocyte abnormalities and the development of focal segmental 
glomerulosclerosis (FSGS). Recently, an  individual with steroid-resistant nephrotic 
syndrome, FSGS and evidence of abnormal mitochodria in the podocyte was 
presented [Lowik et al., 2005]. The pathogenic impact of the A3243G mutation is not 
clearly understood. One hypothesis is that, because podocytes are terminally 
differentiated cells, they may be more susceptible to the effects of mitochondrial 
dysfunction as compared to neural and muscle cells. With the accumulation of 
abnormal mitochondria, the synthesis of mitochondrial proteins and appropriate 
oxidadive phosphorylation to generate energy for proper podocyte function may be 
absent. Most recently, another disease of potentially genetic origin was added to the 
list of mitochondria-associated podocytopathies: a mitochondrial respiratory chain 
deficiency was reported in one patient with congenital nephrotic syndrome and two 
siblings with severe congenital kidney disease and probable neprotic syndrome 
[Goldenberg et al., 2005]. In all cases, mutations in the gene NPHS1 (nephrin), which 
are the classic cause for congenital nephrotic syndrome of the Finnish type, were 
excluded. The authors suggest genetic deficiency in respiratory chain genes as a 
putative disease-causing mechanism. However, the genetic locus of such mutations 
remains elusive. 
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Another organelle associated to glomerular disease is the podocyte lysosome. The 
systemic Fabry disease, a defect in galA encoding the lysosomal enzyme                   
?-galactosidase A leads to the formation of globotriaosylceramide (GL-3) deposits in 
nearly all glomerular cell types. Even though this mainly affects the vascular 
endothelium, there are particularly dense accumulations in podocytes and distal 
tubular epithelial cells [Warnock et al., 2005]. The clinical outcome is azotemia, 
proteinuria and chronic kidney disease. In contrast to the majority of glomerular 
diseases, a promising therapeutic strategy exists with enzyme replacement therapy 
[Warnock, 2007] . 
 
Slit diaphragm-associated podocytopathies 
 
Due to the intricate organization of the slit diaphragm, it comes to no surprise that 
genetic defects in the associated proteins lead to podocyte injury. A number of genes 
associated with glomerular diseases have been identified in the past years and the 
respective clinical outcomes are well characterized [Pollak, 2002]. Among these 
diseases are the congenital nephrotic syndrome of the Finnish type caused by 
mutations in NPHS1 encoding nephrin, and the steroid-resistant nephrotic syndrome 
of the podocin type caused by mutations in the NPHS2 gene encoding podocin. 
 
The Frasier syndrome and Denys-Drash syndrome are overlapping syndromes caused 
by mutations in WT1 encoding Wilms’ tumor protein, a transcription factor regulating 
a number of podocyte genes including NPHS1 (nephrin) and NPHS2 (podocin). Both 
syndromes are characterized by glomerular disease; while Frasier syndrome shows a 
pattern of focal segmental glomerulosclerosis (FSGS) in kidney biopsies, Denys-
Drash syndrome is defined by diffuse mesangial sclerosis. 
 
In two patients with primary focal segmental glomerulosclerosis (FSGS), a nucleotide 
variant leading to CD2AP haploinsufficiency was detected [Kim et al., 2003]. The 
higher susceptibility of individuals carrying this mutation for glomerular disease 
demonstrates the pathogenic role of altered CD2AP expression levels. CD2AP is not 
only thought to be an important adaptor protein in podocytes, coupling the slit 
diaphragm to the actin cytoskeleton, but also implicated in endocytosis and lysosomal 
sorting. This, and the observation that, in CD2AP+/- mice, immunoglobulins 
accumulate in the GBM, led the authors to speculate that, in addition to its possible 
structural role, CD2AP may also be involved in targeting proteins to the degradative 
pathway. Immunoglobulin deposits in CD2AP+/- mice may reflect the impaired ability 
of the podocyte to clear plasma proteins from the GBM, suggesting a possible 
disease-causing mechanism in affected patients with CD2AP haploinsufficiency. 
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I.2.2.  Acquired forms of glomerular kidney disease 
 
In contrast to inherited forms of glomerular kidney disease, which originate due to a 
known genetic defect, acquired forms of glomerular kidney disease have no known 
underlying genetic cause. In fact, acquired forms of glomerular kidney disease 
account by far for most of the glomerular diseases since only a few of all disease 
states can currently be classified as genetic forms. 
 
Among the acquired forms of glomerular kidney disease, one can differentiate 
between three groups. The first group is represented by disease states that are 
secondary to systemic disorders such as diabetes (diabetic nephropathy), infection 
with HIV (HIV-nephropathy), high blood pressure, or obesity. In fact, diabetes and 
high blood pressure are by far the most common culprits for acquired forms of 
glomerular kidney disease. The second group is represented by kidney diseases that 
develop due to the contact with certain toxins, or the (long-term) administration of 
certain drugs. The third group is represented by idiopathic diseases, i.e. forms of 
kidney disease for which the pathogenic cause remains completely unknown. 
 
Due to the diversity of disease phenotypes and the possible causes thereof, and the 
lack of knowledge about the pathogenesis in most cases, the therapy of aquired forms 
of proteinuric kidney diseases remains a challenging task and in most cases, doctors 
are limited to ameliorating the symptoms of the disease and targeting the underlying 
systemic causes for the disease if such causes can be identified. A tissue- or cell-
specific therapeutic targeting podocytes as the main cell type affected in most types 
of glomerular kidney diseases, is currently not available, and research on such drugs 
is lacking behind due to an incomplete understanding of the mechansims underlying 
glomerular filtration and the development of glomerular disease. 
 
I.2.3.  Focal segmental glomerulosclerosis (FSGS) 
 
Focal and segmental glomerulosclerosis (FSGS) is a common, progressive 
pathological renal lesion observed in a disparate group of clinical disorders 
[Daskalakis & Winn, 2006]. Next to the aforementioned genetic predispositions 
associated with the development of FSGS, FSGS most often appears as an acquired 
glomerular kidney disease secondary to other disorders including HIV infection, 
obesity, hypertension and diabetes [Vincenti & Ghiggeri, 2005]. Furthermore, FSGS 
can also appear as an isolated, idiopathic condition. 
 
FSGS is diagnosed by renal biopsy, with histopathological findings characterized by 
partial scarring of the glomerular capillary tuft in a significant proportion of 
glomeruli (Fig. I.5.). A FSGS-typical pattern has areas of glomerular scarring in 
several, but not all glomeruli (focal lesions), and the scarring usually affects only part 
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of the glomerular tuft, not the entire glomerulus (segmental lesions). Clinically, 
proteinuria and decreasing kidney function are the most common manifestations of 
FSGS. FSGS accounts for only 5-20% of cases of idiopathic nephrotic syndrome in 
children, but for as many as 35% of cases in adults [Haas et al., 1995]. Often, renal 
insufficiency in FSGS progresses to end-stage renal disease (ESRD), a highly morbid 
state requiring either dialysis therapy or kidney transplantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In searching for the molecular origins of FSGS, one has to consider all structures of 
the glomerular filter; during glomerulogenesis, the GBM is built by the combined 
effort of endothelial cells and podocytes, and malfunction of either component can 
interfere with the other two via multiple mechanisms. Over the last two decades, an 
enormous data set has evolved, correlating podocyte damage with progressive 
glomerulosclerosis [Kretzler, 2005]. Multiple reports underscore the concept that 
podocytes are the culprit for the majority of FSGS phenotypes, whether injured 
directly (e.g. defects in podocyte genes) or indirectly (secondary to other defects, e.g. 
in the GBM) [Kriz et al., 1998; Kriz, 2002; Wiggins, 2007]. 
 
 
Fig. I.5. Schematic depicting the development of segmental glomerulosclerosis. (A) Normal 
glomerulus with vascular and urinary poles. Smooth muscles, extra glomerular mesangial, and 
mesangial cells proper are hatched; podocytes are shown in blue, parietal epithelial cells in red. The 
GBM is shown in black, the parietal basement membrane in yellow, tubular epithelia are shown in 
white. (B) A dilated and podocyte-denuded capillary is attached to Bowman’s capsule. The 
attachment is accomplished by the affixation of parietal cells to the naked GBM. Thereby a gap in the 
parietal epithelium has come into existence, permitting filtration/exudation towards the cortical 
interstitium (arrow). (C) The adhesion has spread to neighboring capillaries resulting in either the 
collapse or in hyalinosis (shown in a dark grey pattern) of the involved capillaries. Podocytes at the 
flanks of the adhesion degenerate. The parietal epithelium may either appose those podocytes 
(arrowhead) or attach directly to the GBM at the flanks of the adhesion. Fluid leakage from perfused 
capillaries inside the adhesion has created a paraglomerular space (shown in yellow) that contains the 
sclerotic tuft remnants (that is, collapsed or hyalinized GBM formations). Towards the cortical 
interstitium this paraglomerular space has become separated by a layer of sheet-like fibroblast 
processes (shown in green). (D) Via the vascular pole the sclerotic process has reached a further 
lobule. A small “intact” tuft remnant protrudes into the urinary space still covered by the parietal 
epithelium. The sclerotic tuft remnants are located outside the parietal epithelium in the 
paraglomerular space that is separated from the cortical interstitium by a complete layer of cortical 
fibroblasts. Even in those late stages of injury perfused capillaries are regularly found within the 
sclerotic regions, probably accounting for the further expansion of the paraglomerular space that may 
extend onto the proximal tubule. In even later stages fibroblasts will invade the sclerotic area, 
resulting in fibrous organization. (Source: adapted from Kriz et al.; Kidney Int. 1998, 54:687-697. 
[Kriz et al., 1998]) 
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1.2.4.  Model systems for the study of glomerular kidney disease 
 
Podocyte cell culture 
 
Podocytes have taken center stage in renal research as important regulators of 
glomerular filtration, and podocytopathy has been shown to be an important 
determinant of glomerular kidney disease [Shankland, 2006]. A major breakthrough 
for the research on podocytes occured around a decade ago when the first reports 
described the primary culture of podocytes in a way that these cells resembled 
structurally and functionally glomerular podocytes in vivo [Mundel et al., 1996]. 
Soon afterwards, another milestone was achieved by generating conditionally 
immortalized differentiated podocytes cell lines, which can be maintained and studied 
in a straightforward and reproducible manner [Mundel et al., 1997]. 
 
Primary cultures of podocyte are derived from glomeruli isolated from kidney cortex. 
The isolation of glomeruli can be carried out by a sieving technique under sterile 
conditions, passing kidney homogenates through a set of consecutive sieves with 
decreasing pore sizes, which eventually yields a glomerular preparation with minor 
contaminations of tubular cells and pariethal epithelium [Mundel et al., 1997]. For 
higher purity of the glomerular preparation, an additional Ficoll-gradient 
centrifugation can be performed [Norgaard, 1976]. Ideally, cell culture is then started 
from manually selected glomeruli that have been decapsulated, i.e. glomeruli that are 
devoid of Bowman’s capsule, thereby minimizing the presence of cell types other 
than podocytes. 
 
A considerable pitfall of the early primary cultures of podocytes was that these cells 
very rapidly began to lose the cell type-specific properties of differentiated 
podocytes, including the characteristic cytoskeletal architecture and morphology and 
the expression of proteins normally found in differentiated podocytes, e.g. 
synaptopodin. The resulting phenotype was a cell exhibiting a cobblestone-like 
morphology, resembling undifferentiated podocyte precursor cells during early 
glomerular development [Mundel et al., 1996]. 
 
Therefore, in the mid 1990s, novel studies addressed the improvement the cell culture 
of podocytes, aiming at generating a cell culture model of podocytes that would 
resemble more the in vivo phenotype – in particular with regard to the expression of 
the important podocyte marker synaptopodin. Among the many tested modifications 
in the cell culture protocol, the measure of simply avoiding a repeated subcultivation 
proved promising; this led to the conversion of many cells with the cobblestone-like 
appearance into cells with a characteristic arborized phenotype, very much 
resembling the morphology of podocytes in vivo, and in contrast to the cobblestone-
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like precursor cells, these differentiated podocytes expressed synapopodin [Mundel et 
al., 1996]. However, differentiation in these cells was correlated to growth arrest in 
these cells, rendering this model not suitable for a routine laboratory practice due to 
limited capability of propagation.  
 
The solution to this problem came with the development of conditionally 
immortalized podocyte cell lines [Mundel et al., 1997]. For the generation of these 
cell lines, podocytes were obtained from the Immortomouse [Jat et al., 1991], a       
H-2Kb-tsA58 transgenic mouse carrying the thermolabile mutant of the proliferation-
promoting SV40 large T antigen under the control of an interferon-? (IFN-?)–
inducible promoter. Podocytes derived from the Immortomouse express functional T 
antigens and therefore grow continuously under permissive conditions at 33 °C in the 
presence of IFN-?, and stop dividing when the activity and expression of the tumor 
antigen is suppressed by restrictive conditions without IFN-? at 37 °C. Temperature 
shift from 33 °C to 37 °C renders the SV40 large T antigen inactive and induces 
growth arrest and differentiation of podocytes.  
 
The most prominent phenotypic change during differentiation of immortalized 
podocytes is a dramatic rearrangement of the podocyte actin cytoskeletin inclucing an 
extension of actin stress fibers and microtubules into cellular processes reminiscent of 
podocyte major processes in vivo. As the case for the arborized, differentiated cells 
observed in modified podocytes primary culture, also in conditionally immortalized 
podocytes differentiation is accompanied by an onset of synaptopodin expression. 
Notably, these cells even form slit diaphragm-like cell-cell contacts and – when 
properly cultured – display virtually all proteins identified in podocytes in vivo 
including, among others, nephrin, podocin and CD2AP [Shankland et al., 2007]. 
 
Nowadays, rat, mouse and human cultured podocytes are widely used throughout the 
world to study virtually all aspects of podocyte biology in health and disease 
including the podocyte actin cytoskeleton, cell cycle, signaling, cell-cell contacts, and 
matrix interaction. The availability of conditionally immortalized differentiated 
podocytes in culture has developed into an indispensable tool for the mechanistic 
analysis of podocyte function. In combination with animal models and human studies 
to confirm the in vitro results, the study of podocytes in culture is a valid and 
invaluable model system that will continue providing novel insight into the function 
of these unique cells in health and disease. 
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Models of podocyte damage and proteinuria 
 
Studying glomerular disease is a challenging task due to heterogeneity of glomerular 
disorders; for example, glomerular kidney diseases can be genetic or non-genetic, 
acute or chronic, primary or secondary, and can occur as (in early stages) clinically 
undetectable or overt conditions. Furthermore, as is the case for almost all human 
diseases, exploring glomerular disease directly in human subjects is limited by factors 
such as limited patient number, heterogeneity of the patient population, and ethical 
considerations. Therefore, the use of experimental models involving cultured cell 
lines and animals is indispensable to investigate the pathogenesis of glomerular 
disease in vitro and in vivo. Indeed, the availability of experimental tools such as 
conditionally immortalized differentiated podocyte cell lines or genetically modified 
mice has significantly advanced our understanding of many aspects of glomerular 
kidney disease. 
 
In this study, among others, two well-established experimental models of podocyte 
damage and proteinuria were used to study the role of TRPC6 in kidney podocytes: 
the puromycin aminonucleoside (PAN) model and the lipopolysaccharide (LPS) 
model.  
 
Puromycin aminonucleoside (PAN) is an analogue of the antibiotic puromycin, a 
substance that causes premature chain termination during translation. In contrast to 
puromycin, puromycin aminonucleoside does not inhibit protein synthesis or induce 
apoptosis, but acts as a glomerular epithelial cell toxin, which can be used to induce 
nephropathy in rats [Trachtman et al., 1995]. Progressive renal damage in the PAN 
model is partly mediated by excessive production of oxidant species. In puromycin 
aminonucleoside (PAN)-treated rats, podocyte foot process effacement and heavy 
proteinuria commence on day 4 after injection of PAN [Kim et al., 2001]. On day 8, 
proteinuria peaks, and on day 30, rats have recovered with largely restored podocyte 
foot process structure and resolution of proteinuria. The PAN rat is a very well 
established model of chronic glomerular injury and focal segmental 
glomerulosclerosis (FSGS) and has already been used in more than 100 peer-
reviewed publications. 
 
In contrast to the PAN model, the lipopolysaccharide (LPS) model is a more acute 
murine model of podocyte damage and transient nephrotic syndrome [Reiser et al., 
2004]. Lipopolysaccharides are found in the cell walls of Gram-negative bacteria. 
LPS is an endotoxin, which induces a strong response from normal animal immune 
systems. The mechanism behind this response involves binding of LPS to the 
CD14/TLR4/MD2 receptor complex, which promotes the secretion of pro-
inflammatory cytokines in many cell types, but especially in macrophages. It has 
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been found in podocytes that LPS induces expression of the B-cell costimulatory 
molecule B7-1 and a cytosolic form of the protease cathepsin L through CD14/TLR4-
mediated signaling. Both receptors, TLR-4 and CD14, are constitutively expressed in 
podocytes. It has further been reported that injection of 200 ?g LPS intraperitoneally 
in mice leads to foot process effacement and severe proteinuria within 24 h [Reiser & 
Mundel, 2004]. In animals that were analyzed for a prolonged time period, foot 
process effacement and proteinuria returned to baseline levels after 72 h. Notably, the 
effects of LPS-treatment are abrogated in B7-1-/- and cathepsin L-/- mice, implicating 
that B7-1 induction is necessary for the development of LPS-induced proteinuria. The 
LPS model has become a useful alternative to the other currently used models of 
podocyte injury, in particular because of its acute-onset nature and the reversibility of 
podocyte injury and proteinuria. An increasing number of laboratories worldwide 
have been utilizing the LPS model to study glomerular disease, a trend that is 
reflected by the increasing number of published reports featuring this model. A most 
recent example thereof is the combination of the LPS model with a transient gene 
delivery approach to elucidate the function of the GTPase dynamin in podocytes 
[Sever et al., 2007] (appendix). 
 
Finally, an important advantage of the PAN- and LPS models is that they can both be 
applied also in vitro on cultured podocytes. Whereas the administration of LPS to 
cultured podocytes has a similar time course as podocyte injury in vivo, including a 
peak phase of stress after 24 h and recovery after 72 h, the exposure of podocytes to 
PAN has a more prolonged course with the onset of structural changes occurring after 
24-48 h. Podocyte damage in cell culture as a result of LPS administration is 
reversible, whereas higher doses of PAN result in more severe podocyte injury that is 
usually not reversible. 
 
I.3.  Transient Receptor Potential (TRP) channels 
 
TRP channels were first identified in the fruit fly. Phototransduction in Drosophila 
melanogaster involves activation of membrane cation channels in photoreceptor cells 
leading to a sustained depolarizing current. The ionic basis for this sustained receptor 
potential is influx of calcium from the extracellular space. Cosens and Manning 
reported in 1969 that in one group of mutant flies this sustained receptor potential 
was compromised; these flies merely showed a transient receptor potential, and the 
mutant fly strain was named trp with the mutated gene being unknown [Cosens & 
Manning, 1969]. The trp gene was cloned in 1989 [Montell & Rubin, 1989] and 
subsequently shown to encode a calcium-permeable cation channel [Hardie & Minke, 
1992]. Since the discovery of the original TRP protein in the fly, more than 80 other 
TRP-like proteins were identified in several organisms. TRP homologs are expressed 
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in the fruit fly, the zebrafish Danio rerio, the worm Caenorhabditis elegans, and in 
several mammalian species including mice and humans [Venkatachalam & Montell, 
2007]. Together they represent the TRP superfamily of ion channel-forming proteins. 
 
TRP subunits form voltage-independent cation-permeable ion channels in most 
mammalian cells, and based on similar structural motifs and amino acid homology, 
mammalian TRP proteins have been classified into TRPC (Canonical), TRPV 
(Vanilloid), TRPM (Melastatin), TRPP (Polycystin), TRPA (Ankyrin), and TRPML 
(Mucolipin) subfamilies [Ramsey et al., 2006] (Fig. I.6.). Each TRP channel subunit 
consists of six putative transmembrane spanning segments (S1-6), a channel pore-
forming loop between S5 and S6, and intracellularly located amino- and carboxy-
termini. TRPC, TRPV, and TRPM channels share a highly conserved 25-amino acid 
motif termed the “TRP domain“ [Montell, 2005]. 
 
A functional TRP ion channel is formed by homo- or heterooligomerization of four 
channel subunits, and the subunit composition is thought to be a major determinant of 
channel function, subcellular localization, and biophysical properties [Schaefer, 
2005]. Oligomerization is thought to occur predominantly between closely related 
channel subunits of the same subfamily [Amiri et al., 2003]. Yet, there also a few 
examples of channels that consist of unrelated subunits, or subunits from different 
subfamilies [Schaefer, 2005]. 
 
 
 
 
 
 
 
 
 
 
All TRP channels characterized thus far are permeable to calcium with the exception 
of TRPM4 and TRPM5, which are only permeable to monovalent cations. Most 
calcium-permeable TRP channels are only poorly selective for calcium, with a 
permeability ratio relative to sodium (PCa/PNa) in the range between 0.3 and 10. 
Exceptions are TRPV5 and TRPV6, two highly calcium-selective TRP channels with 
PCa/PNa > 100 [Owsianik et al., 2006]. 
 
 
 
Fig. I.6. The TRP superfamily. A, ankyrin repeats; cc, coiled-coil domain; P, pore loop. (Source: 
adapted from Venkatachalam & Montell; Annu Rev Biochem. 2007, 76:387-417. [Venkatachalam & 
Montell, 2007].) 
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TRP channels are widespreadly expressed and serve very diverse functions ranging 
from thermal, tactile, taste, and osmolar sensing to fluid flow sensing [Clapham, 
2003]. Functional diversity can even be seen within a single subfamily, indicating 
that structural similarity does not necessarily correspond to similar function. 
 
As various as their functional properties are the modes of activation of TRP channels. 
TRP channels are gated by diverse stimuli that include the binding of intracellular and 
extracellular messengers, changes in temperature, and chemical and/or mechanical 
(osmotic) stress. In addition, some TRP channels appear to be constitutively open, 
whereas others seem to become activated upon depletion of intracellular calcium 
stores, although the latter mechanism, referred to as store-operated calcium entry 
(SOCE), remains an issue of intensive discussion [Clapham, 2003; Nilius, 2004]. 
Remarkably, the same channel can often be activated by more than one stimulus, 
illustrating the complexity of physiological roles played by TRP channels. 
 
Recent studies of TRP channels indicate that they are involved in numerous 
fundamental cell functions and are considered to play an important role in the 
pathophysiology of many diseases [Nilius et al., 2007]. Many TRP channels are 
expressed in the kidney along different parts of the nephron and growing evidence 
suggest that these channels are involved in hereditary as well as acquired kidney 
disorders [Hsu et al., 2007]. For example, TRPM6 has been implicated in 
hypomagnesemia with secondary hypocalcemia, a rare autosomal-recessive disorder 
[Chubanov et al., 2004], and mutations in PKD1 (encoding the TRPP1 channel) and 
PKD2 (encoding TRPP2), respectively, occur at a high frequency in individuals with 
polycystic kidney disease (PKD) [Wu & Somlo, 2000]. In addition, the highly 
calcium-selective channel TRPV5 contributes to several acquired mineral 
(dys)regulation diseases, such as diabetes mellitus, acid-base disorders, and vitamin D 
analogues-associated calcium imbalance, whereas TRPV4 may function as an 
osmoreceptor in kidney and participate in the (dys)regulation of sodium and water 
balance [Topala et al., 2007; Hsu et al., 2007]. 
 
Several studies highlight the potential of TRP channels as pharmaceutical targets 
[Wissenbach et al., 2004; Hicks, 2006]. TRPC6 expressed in leukocytes is for 
example one of the most promising target molecules for potential anti-inflammatory 
drugs fighting diseases including chronic obstructive pulmonary disease and asthma 
[Gosling et al., 2005]. 
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I.3.1.  The TRPC subfamily of ion channels 
 
The Transient Receptor Potential Canonical (TRPC) subfamily is composed of 
proteins that are most highly related to the Drosophila TRP. It consists of seven 
mammalian members, TRPC1-7 [Venkatachalam & Montell, 2007]. 
 
In the human, the TRPC subfamily can be divided into three subgroups on the basis 
of amino acid homology: i) TRPC1, ii) TRPC4/5, and iii) TRPC3/6/7. TRPC2 is a 
pseudogene in the human but seems to encode an expressed protein in rat and mouse. 
 
Whereas TRPC3, 6, and 7 share a number of similar features, e.g. with regard to their 
current-voltage relationships, they seem to have different basal activites [Dietrich et 
al., 2003], and TRPC6 currents were shown to be enhanced by the cation channel 
blocker flufenamate, whereas TRPC3 and 7 were not [Inoue et al., 2001]. The 
difference between the three channel types may indeed lie in their ion selectivity in 
that TRPC6 is somewhat calcium-selective (PCa/PNa = 5), while TRPC3 and 7 are not. 
 
Members of the TRPC subfamily are highly expressed in the central nervous system 
and to lesser degrees in many peripheral tissues, including kidney [Goel et al., 2005; 
Ambudkar et al., 2007]. 
 
TRPC channels contain three to four ankyrin repeats and a potential coiled-coil 
domain in the N-terminus. A proline-rich motif (LPXPFXXXPSPK) downstream of 
the EWKFAR motif is conserved in all members of the TRPC family and is thought 
to be responsible for interaction with Homer (for TRPC1) and/or immunophilins 
[Yuan et al., 2003; Sinkins et al., 2004]. 
 
A systematic analysis of the predicted pore region of TRPC family members has not 
been carried out yet. However, several studies have examined the effect of point 
mutations within the predicted pore region and extracellular loops bordering the pore.  
The change of a conserved LFW motif in the predicted pore helix of TRPC5 and 
TRPC6 to AAA resulted in dominant negative mutants [Hofmann et al., 2002; 
Strubing et al., 2003]. 
 
A number of studies aimed to elucidate the ability of TPRC proteins to form 
oligomers in the past years. Yet, the results show considerable inconsistence with 
regard to the suggested composition of native TRPC channels. Studies involving a 
systematic FRET approach to test possible combinations of TRPC channel complexes 
imply that TRPC channels exclusively form heteromers with members of their own 
subgroup (TRPC1, 4, 5 or TRPC3, 6, 7, respectively) [Hofmann et al., 2002; Amiri et 
al., 2003]. This is supported by findings that TRPC1 coimmunoprecipitated with 
TRPC4 and 5 but not with TRPC3, 6, and 7, and that – vice versa – TRPC3 
coimmunoprecipitated with TRPC6 and 7 but not with TRPC1, 4, and 5 when 
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heterologously expressed in Sf9 insect cells or when tested endogenously from 
isolated rat brain preparations [Goel et al., 2002]. Follow-up studies utilized TRPC 
isoform-specific antibodies to identify heterotypic TRPC interactions in rat and 
mammalian brain and revealed the presence of complexes containing either TRPC3 
or 6, or TRPC1, 4 or 5 [Strubing et al., 2001; Strubing et al., 2003]. While these data 
point towards a subgroup-restricted oligomerization of TRPC channels, there are a 
number of studies demonstrating that oligomerization can also occur between 
members of different subgroups – and even beyond TRP channel subfamily borders.  
For example, it was shown that the PKD2 gene product polycystin-2, which belongs 
to the TRPP subfamily, specifically associates with TRPC1 [Tsiokas et al., 1999].  
Consequently, the present evidence does currently not allow drafting a general model 
for TRPC oligomerization, and it still remains elusive how native TRPC channels are 
composed in the majority of cell types and tissues. 
 
A common feature of all TRPC channels is that they all can function as receptor-
operated channels downstream of G protein-coupled receptors via the phospholipase 
C pathway [Clapham, 2003]. Upon activation of the GPCR, stimulation of 
phospholipase C leads to the conversion of phosphatidylinositol-4,5-biphosphate 
(PIP2) into inositol-1,4,5-trisphosophate (IP3) and diacyl-glycerol (DAG). How the 
stimulation of phospholipase C translates into activation of the channel, is still under 
investigation, and multiple different mechanisms seem to be involved for each TRPC 
subunit. For example, TRPC2, 3, 6, and 7 can be directly activated by DAG or ist 
analogue 1-oleoyl-2-acetyl-sn-glycerol (OAG), whereas TRPC1, 4, and 5 are DAG-
insensitive [Dietrich et al., 2005]. 
 
Although the TRPC members of the mammalian transient receptor potential TRP 
cation channel family were the first to be described in 1995, the depth of knowledge 
of TRPC channels has fallen behind that of their counterparts in the TRPV and 
TRPM subfamilies in the intervening years. The complexities and controversies of 
TRPC channel composition and regulation have hindered their progress as therapeutic 
targets in the drug discovery environment to date, however embracing these 
challenges as opportunities may bring TRPC channels to the forefront of the 
discovery of novel therapies for many diseases. 
 
I.3.2.  Transient Receptor Potential Canonical 6 (TRPC6) 
 
TRPC6 is expressed in multiple organs including brain, placenta and ovary, with the 
highest levels of transcript detected in lungs [Boulay et al., 1997]. TRPC6 channels 
are believed to play an important role in pulmonary and vascular smooth muscle 
cells; the current evidence suggests that TRPC6 is activated downstream of the ?1-
adrenergic receptor [Inoue et al., 2001] and the vasopressin receptor [Jung et at., 
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2002], and mediates the regulation vascular and airway tone [Dietrich et al., 2006]. In 
line with an important role of TRPC6 in these cell types, TRPC6 has been found to be 
upregulated in pulmonary artery smooth muscle cells in primary pulmonary 
hypertension and in response to hypoxia [Lin et al., 2004; Yu et al., 2004]. In the 
kidney, TRPC6 expression has been reported in glomeruli and tubules [Facemire et 
al., 2004; Goel et al., 2006; Sours et al., 2006], where it is expressed in conjunction 
with several other TRPC members. 
 
Like TRPC3 and 7, TRPC6 appears to form nonselective cation channels that show 
both inward and outward rectification, at negative and positive voltages, respectively 
[Trebak et al., 2003]. The I-V relationships for these TRPCs demonstrate a far greater 
outward current (at positive voltages) than inward current (at negative voltages) with 
a reversal potential at around 0 mV. The single channel conductance of TRPC6 is 35 
pS, with no second conductance state observed [Hofmann et al., 1999]. 
 
With regard to the mode of activation, TRPC6 appears to function as a receptor-
regulated, but not a store-regulated cation channel: Hofmann et al. showed that 
neither thapsigargin, ionomycin, PIP2 nor IP3 activated TRPC6, and it was therefore 
concluded that TPRC6 operates independently from extracellular stores [Hofmann et 
al., 1999]. Furthermore, the phospholipase C inhibitor U73122 blocked agonist 
activation of TRPC6 leading the authors to conclude that TRPC6 is activated through 
PLC production of DAG, not by IP3 or the IP3-receptor, and not directly by G 
proteins. Another report describing a native TRPC6-like calcium channel in rabbit 
portal vein myocytes showed that those TRPC6-like channels could not be activated 
by IP3; however, it was shown that IP3 appears to synergize with DAG to produce 
greater TRPC6-like channel activation [Albert & Large, 2003]. It is important to 
mention that currently there is no known agonist or antagonist that is specific for 
TRPC6. However, when compared to the closely related subfamily members TRPC3 
and 7, TRPC6 exhibited a distinct response: when expressed in HEK293 cells, 
TRPC6 currents were enhanced by the cation channel blocker flufenamate while 
TRPC3 and 7 currents were not [Inoue et al., 2001]. 
 
Relatively little is known about proteins that interact with and regulate the trafficking 
and activity of TRPC6, although TRPC6 has been shown to bind to cytoskeletal 
proteins such as ?-actinin, actin, and drebrin [Goel et al., 2005] and endocytic 
vesicle-associated proteins such as dynamin, clathrin, and MxA [Goel et al., 2005] 
and the plasmalemmal Na+/K+ ATPase pump [Goel et al., 2005]. While cytoskeletal 
proteins can potentially exert an effect on channel trafficking, the role of these 
proteins in TRPC6 trafficking has not been directly demonstrated. Another 
determinant that may affect TRPC6 trafficking and activity is TRPC6 
oligomerization: both, TRPC3 and TRPC6 are regulated by PIP2 hydrolysis and 
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undergo translocation to the plasma membrane in response to agonist stimulation. 
Furthermore, TRPC6 has been shown to coimmunoprecipitate with TRPC3 and 7 
[Hofmann et al., 2002]. However, any direct impact of TRPC multimerization on 
TRPC6 trafficking remains elusive. In addition, it is also not clear whether trafficking 
of homomeric channels differs from that of heteromeric channels. 
 
Despite the existence of multiple potential phosphorylation sites in the sequence of all 
TRPCs, few studies have specifically addressed the role of kinases in TRPC6 channel 
activity. Phorbol-12-myristoyl-13-acetate (PMA)-induced activation of protein kinase 
C has been shown to block OAG-induced activation of ectopically expressed mouse 
TRPC7 [Okada et al., 1999] and rat TRPC6 [Zhang & Saffen, 2001], but 
unexpectedly had no effect on human TRPC6 [Estacion et al., 2004]. In 32P-labeled 
platelets, TRPC6 was significantly phosphorylated by protein kinase A and associated 
with other unidentified phosphoproteins; in this study, channel phosphorylation did 
not appear to affect either thrombin- or OAG-induced TRPC6 activity [Hassock et 
al., 2002]. Recently, the possibility that tyrosine kinases might play a role in 
regulation of TRPC6 has received some attention. A recent report implicates the Src 
family kinase Fyn in epidermal growth factor (EGF)-dependent regulation of human 
TRPC6 [Hisatsune et al., 2004]. In COS-7 cells overexpressing both Fyn and TRPC6, 
the channel was tyrosine phosphorylated following EGF-treatment, and Fyn 
phosphorylated TRPC6 in an in vitro kinase assay. Furthermore, Fyn and TRPC6 
were shown to interact through the SH2 domain of Fyn and the channel N-terminal 
domain of TRPC6. In inside-out patches excised from TRPC6-expressing HEK293 
cells, Fyn-dependent phosphorylation of TRPC6 increased OAG-induced channel 
activity. 
 
In 2005, Gudermann et al. published the first report on constitutive TRPC6-/- mice.  
The authors found that these mice were viable [Dietrich et al., 2005]. Fertility and 
litter sizes were comparable to those of wildtype mice. However, TRPC6-/- mice 
showed an elevated blood pressure and enhanced agonist-induced contractility of 
aortic rings as well as cerebral arteries. Furthermore, smooth muscle cells of TRPC6-
deficient mice had higher basal cation entry, increased TRPC-carried cation currents, 
and more depolarized membrane potentials. When the authors knocked down 
expression of TRPC3 with siRNA in these cells, the higher basal cation entry was 
abolished; the same thing happened when they expressed exogenous TRPC6, 
suggesting that TRPC3 channels, which have a higher basal activity than TRPC6 
channels [Dietrich et al., 2003], were induced in TRPC6-deficient cells. Recently, the 
same group proposed TRPC6 as a key regulator of hypoxic pulmonary 
vasoconstriction, since this vitally important mechanism was absent in TRPC6-
deficient mice challenged with hypoxic ventilation [Weissmann et al., 2006]. Thus 
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far no study has addressed the renal phenotype of TRPC6-deficient mice. According 
to our current knowledge, young TRPC6-/- mice did not present with an overt kidney 
disease phenotype, and aged or experimentally challenged mice have not been studied 
yet (Dr. Thomas Gudermann, personal communication, TRP Meeting in Leuven, 
Belgium).  
 
I.4.  Specific aims 
 
In 2004, Dr. Michelle Winn reported a mutation in the gene encoding the cation-
permeable channel TRPC6. This mutation was genetically linked to the development 
of familial focal segmental glomerulosclerosis (FSGS) in a large family from New 
Zealand (Winn et al., public presentation, 5th International Podocyte Conference, 
Seattle, Washington, United States, June 18-20, 2004) [Winn et al., 2004]. 
 
Based on this preliminary finding, indicating that genetic defects in an ion channel 
are associated with progressive kidney disease, and the notion that all previously 
described genes mutated in FSGS and nephrotic syndrome are highly expressed in the 
glomerular podocyte, the following hypothesis was developed: 
 
The ion channel-forming protein TRPC6 is expressed in podocytes, and TRPC6-
mediated Ca
2+
 signaling contributes to the regulation of the podocyte actin 
cytoskeleton. Malfunction of TRPC6 leads to a disruption of podocyte cytoskeletal 
organization, podocyte foot process effacement, glomerular dysfunction, and 
proteinuric kidney disease. 
 
The studies outlined in this thesis were designed to test the aforementioned 
hypothesis with a focus on the following three specific aims: 
 
• Explore TRPC6 mutations in genetic forms of proteinuric kidney disease 
(FSGS) 
 
• Investigate the association of TRPC6 with the glomerular filtration barrier 
 
• Explore TRPC6 expression in acquired forms of proteinuric kidney disease 
 
• Investigate the molecular basis of TRPC6 contribution to the pathophysiology 
of proteinuric kidney disease 
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Moller, C. C., Pollak, M. R., & Reiser, J. (2006). The genetic basis of human 
glomerular disease. Adv Chronic Kidney Dis, 13(2), 166-173. 
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harged sialoproteins and proteoglycans (gly-
ocalyx). Although the negative charge of the
lycocalyx constitutes a potential barrier re-
arding anionic macromolecules, there is no
vidence so far for such a role of the endothe-
ial glycocalyx. The second structure is the
lomerular basement membrane (GBM), a
hin sheet of specialized extracellular matrix
omposed of 4 major components: laminin,
ype IV collagen, nidogen/entactin, and pro-
eoglycans. During glomerulogenesis, the
BM is built up in a combined effort of the
nderlying endothelial and overlying visceral
pithelial cells (podocytes). As is the case for
he fenestrated endothelium, it is thought that
hat the presence of negatively charged mole-
ules within the GBM serves as a barrier re-
arding anionic macromolecules. The third
tructure consists of podocytes and the inter-
osed glomerular slit diaphragm (SD). Podo-
ytes are nonreplicating polarized epithelial
ells that originate from precursor mesenchy-
al cells. During nephrogenesis, these cells
ndergo modification from a classic epithelial
ell phenotype to a highly specialized octo-
us-shaped cell. Podocytes cover the external
urface of adjacent capillaries and interact
ith the GBM through finger-shaped exten-
ions called pedicels or foot processes (FP).
he basal surface of podocyte FP is anchored
n the GBM via 3-/1-integrins and -/-
ystroglycans. Podocyte FP interdigitate in a
omplex manner forming an intricate network
urrounding the glomerular capillaries. Adja-
ent FP bridge their narrow 300 to 400 ang-
trom wide gaps by an electron-dense mem-
rane-like structure, the SD (Fig 1). The SD is
thin porous membrane composed of a num-
er of proteins. The SD multiprotein complex
s thought to form the major determinant of
he size permselectivity of the glomerular fil-
ration barrier. It allows for the passage of
ater and solutes from the blood into the
idney ultrafiltrate while inhibiting the loss ofarger plasma molecules. codocyte Injury and Proteinuria
lomerular proteinuria is a hallmark of glo-
erular disease and results from an increased
ermeability of the glomerular filtration bar-
ier. Normally, proteins larger than albumin
o not enter the urinary space, whereas lower
olecular weight proteins are filtered and
artially reabsorbed in the proximal tubule.
ormal excretion levels of protein into the
rine vary between 0 and 150 mg/d. Protein-
ria is clinically characterized by a protein
oss into the urine of more than 150 mg/d.
evels of 3 (or 3.5) g of urinary protein per day
re generally used to define “nephrotic-
ange” proteinuria. In many forms of glomer-
lar diseases, proteinuria is correlated with
odocyte injury. The complexity of interac-
ions among podocyte proteins provides sev-
ral targets for podocytopathy and disruption
f the glomerular filtration barrier.1 Loss of
he integrity of the intricate structures of the
odocyte can be seen in patients with NS, who
linically present with hypertension, protein-
ria, and progressive kidney disease. Electron
icroscopic examination of kidney biopsy
pecimens reveals the loss of normal podocyte
P structure, resulting in a flattened podocyte
henotype, where FP forms an epithelial
onolayer lacking functional SD (FP efface-
ent). If early structural changes of podocytes
re not reversed, severe and progressive glo-
erular damage is likely to develop. This
nvolves podocyte vacuolization, pseudocyst
ormation, and detachment of podocytes from
he GBM. Because the highly differentiated
odocytes are unable to proliferate, the dam-
ge and loss of single podocytes lead to podo-
yte depletion over time, which is a major
eterminant in the development of glomeru-
osclerosis and chronic kidney failure.
BM-Associated Genetic
odocytopathies
asement membranes have been shown to
nfluence cell proliferation, migration, and dif-
erentiation. Also in the kidney, an intact
BM is necessary for proper adhesion and
unction of the underlying endothelial cells
nd podocytes.2 Inherited disruptions of 2
omponents of the GBM, type IV collagen and
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168 Möller et alaminin-2, have so far been shown to lead to
lomerular disease.
Type IV collagen-related diseases, includ-
ng Alport syndromes and thin basement
embrane nephropathy (TBMN), originate
rom defects in the genes encoding the
-chains of type IV collagen.3 In 4 of the 6
dentified -chain genes so far, mutations
ave been associated with progressive hered-
tary nephritis. With the exception of TBMN,
ll these gene defects lead to a thickened GBM
nd progressive hematuric glomerular dis-
ase, resulting in renal insufficiency and
SRD. In constrast, patients with TBMN
resent with a thinnened GBM and asymp-
omatic microscopic hematuria. Kidney func-
ion usually remains normal in these individ-
als. It is speculated that, in type IV collagen-
elated diseases, an increased mechanical
ragility of the GBM accounts for pathogene-
is.
The rare Nail-Patella syndrome (NPS) is
haracterized by loss-of-function mutations in
MX1B encoding a transcription factor regu-
ating the expression of COL4A3 (type IV col-
agen 3 chain), COL4A4 (type IV collagen 4
hain), NPHS1 (nephrin), NPHS2 (podocin),
nd CD2AP. In most patients with NPS, the
BM has a characteristic moth-eaten appear-
nce and contains fibrillar collagen deposits.
hereas some individuals do not present
ith any clinical nephropathy, proteinuria oc-
urs in 30% to 40% of patients and in 5% to
0% of patients the disease leads to progres-
ive kidney failure. Although the phenotype
f NPS seems to be primarily confined to the
BM, it is likely that transcriptional dysregu-
ation of SD proteins contributes to the patho-
iology of the disease.
Gene defects in LAMB2 encoding the lami-
in-2 chain lead to the rare Pierson syn-
rome. Laminin-2 is abundantly expressed
n the GBM where it is present in the adult
BM laminin-11 isoform (5:2:1). Lami-
in-11 plays a key role in anchoring and dif-
erentiation of podocyte FP. Laminin-11 mal-
unction, because of a lack of of functional
aminin-2, is thought to be the cause for the
isease, which leads to the onset of nephrosis
oon after birth, rapid progression to ESRD,
nd death in the first year. oytoskeleton-Associated Genetic
odocytopathies
he major function of the podocyte FP is to
reate the outer portion of the glomerular
ltration barrier. Because the glomerular cap-
llary wall undergoes cyclic distensions, a
unctional adaptive cytoskeleton, providing
oth mechanical strength and flexibility, is
equired for maintaining podocyte structural
ntegrity. To match this unique challenge,
odocytes have developed a highly dynamic
ytoskeletal architecture involving microtu-
ules, intermediate filaments, and actin mi-
rofilaments. Whereas the podocyte cell body
nd primary processes are predominantly
omposed of microtubules and intermediate
laments, podocyte FP contain an actin-based
ontractile cytoskeletal network. A group of
ytoskeleton-associated proteins, including
alin, paxillin, and vinculin, link actin fila-
ents to the cell membrane-associated inte-
rins at the GBM. Parts of the actin cytoskel-
ton are also linked to the SD via catenins and
O-1, or via CD2AP. Under normal condi-
ions, a dynamic actin cytoskeleton is part of
he adaptive responses of the podocyte to
hanges in its microenvironment. Under dis-
ase conditions, the prolonged reorganization
f actin bundles underlies the structural hall-
ark seen in FP effacement.
Mutations in ACTN4 encoding -actinin-4
re associated with the development of famil-
al FSGS.4 The disease is characterized by on-
et in adolescence or early adulthood, slow
rogression, nonnephrotic proteinuria, and
enal insufficiency. -Actinin-4 is expressed in
odocytes, where it cross-links F-actin fila-
ents in FP. The disease-causing mechanism
ppears to be linked to accelerated degrada-
ion of mutant -actinin-4 by the proteasome.
t is also thought that an increased affinity of
utant -actinin-4 to F-actin may result in a
ysregulation of actin filament formation in
odocytes. Interestingly, -actinin-4 is ex-
ressed throughout the body, but the human
henotype associated with ACTN4 mutations
s apparent only in the kidney. This suggests
hat either a podocyte-specific protein-protein
nteraction is altered by human disease-asso-
iated mutations or that the unique structure
f the podocyte makes it particularly suscep-
t
a
m
e
I
M
s
a
s
d
m
s
s
i
t
c
c
m
m
t
m
t
O
P
O
o
i
n
p
m
t
p
A
M
m
d
a
v
i
s
m
T
t
i
f
b
c
t
t
a
g
m
o
l
t
c
i
k
m
w
o
t
c
m
s
d
t
t
t
(
t
v
d
t
i
d
u
e
S
P
T
m
s
w
n
p
t
t
c
i
t
p
1
o
a
s
i
169Human Glomerular Diseaseible even to subtle changes in its cytoskeletal
rchitecture.
Another group of cytoskeleton-associated
utations lead to podocyte injury by interfer-
nce with the nonmuscle myosin heavy chain
IA (NMMHC-IIA) encoded by MYH9.5
YH9-related diseases include the Epstein
yndrome, Fechtner syndrome, May-Hegglin
nomaly, and Sebastian syndrome. It has been
uggested that these 4 sydromes are in fact not
istinct entities but rather derive from a com-
on single disorder with a continuous clinical
pectrum characterized by a varying expres-
ivity. Class II myosins play a well-character-
zed role in the contraction and force produc-
ion in muscles and are required for
ytokinesis, cell mobility, cell polarity, and
ell architecture. In podocytes, nonmuscle
yosin heavy chain IIA is thought to be a
ajor component of the actin-myosin contrac-
ile apparatus in FP. The disease-causing
echanism leading to the glomerular pheno-
ype of MYH9-related disease remains elusive.
rganelle-Associated Genetic
odocytopathies
ne podocyte organelle shown to be a target
f genetic defects causing glomerular disease
s the mitochondrion. The mitochondrial ge-
ome is a set of extrachromosomal genes
resent in a circular genome. Expression of
itochondrial gene mutations follows a pat-
ern of maternal inheritance. A typical exam-
le of a mitochondrial cytopathy is the
3243G transition in the mitochondrial gene
TTL1 encoding for the tRNALeu(URR). This
utation leads to a defect in the mitochon-
rial respiratory chain and has been associ-
ted with podocyte abnormalities and the de-
elopment of FSGS. Most recently, an
ndividual with steroid-resistant nephrotic
yndrome, FSGS, and evidence of abnormal
itochodria in the podocyte was presented.6
he pathogenic impact of the A3243G muta-
ion is not clearly understood. One hypothesis
s that because podocytes are terminally dif-
erentiated cells, they may be more suscepti-
le to the effects of mitochondrial dysfunction
ompared with neural and muscle cells. With
he accumulation of abnormal mitochondria,
he synthesis of mitochondrial proteins and pppropriate oxidadive phosphorylation to
enerate energy for proper podocyte function
ay be absent. Most recently, another disease
f potentially genetic origin was added to the
ist of mitochondria-associated podocytopa-
hies: a mitochondrial respiratory chain defi-
iency was reported in 1 patient with congen-
tal NS and 2 siblings with severe congenital
idney disease and probable NS.7 In all cases,
utations in the gene NPHS1 (nephrin),
hich are the classic cause for congenital NS
f the Finnish type, were excluded. The au-
hors suggest genetic deficiency in respiratory
hain genes as a putative disease-causing
echanism. However, the genetic locus of
uch mutations remains elusive.
Another organelle associated to glomerular
isease is the podocyte lysosome. The sys-
emic Fabry disease, a defect in galA encoding
he lysosomal enzyme -galactosidase A leads
o the formation of globotriaosylceramide
GL-3) deposits in nearly all glomerular cell
ypes. Even though this mainly affects the
ascular endothelium, there are particularly
ense accumulations in podocytes and distal
ubular epithelial cells.8 The clinical outcome
s azotemia, proteinuria, and chronic kidney
isease. In contrast to the majority of glomer-
lar diseases, a promising therapeutic strat-
gy exists with enzyme replacement therapy.
lit Diaphragm-Associated
odocytopathies
he SD appears early in nephrogenesis. It is a
odified adherens junction with a zipperlike
tructure composed of a number of proteins
ith large extracellular domains including
ephrin; neph 1, 2, and 3; P-cadherin; and the
rotocadherin FAT.9 Four distinct functions of
he SD have been described.10 These are func-
ion as molecular sieve, function as cell-cell
ontact between podocytes, function as signal-
ng platform, and function as organizing cen-
er regulating podocyte actin dynamics. In
articular, nephrin and its homologues neph
, 2, and 3 have entered the stage serving not
nly as important scaffolding molecules but
lso as key players in mediating extracellular
ignals into the podocyte cell body, a process
n which tyrosine phosphorylation appears to
lay a crucial role. The molecules composing
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170 Möller et alhe SD are linked to the podocyte intracellular
pace via a number of transmembrane and
ytoplasmic podocyte proteins located close
o the SD site. Among them are various adap-
or proteins including podocin, ZO-1, CD2AP,
nd catenins. Furthermore, it has been shown
hat the -actinin-4-binding protein densin-
80 and the src family protein tyrosine kinase
yn are located at the SD site. Most recently,
he calcium-permeable ion channel TRPC6
as been discovered as a part of the SD com-
lex.11 The complex interplay of SD proteins
s thought to be a major determinant for the
aintenance of the glomerular filtration bar-
ier. So far, several protein-protein interac-
ions have been shown at the SD site (eg,
ephrin interacts with neph 1, podocin,
D2AP, and TRPC6; podocin itself interacts
ith CD2AP and TRPC6; and both nephrin
nd TRPC6 are phosphorylated by Fyn). Be-
ause of the intricate organization of the SD, it
s no surprise that genetic defects in the asso-
iated proteins lead to podocyte injury. A
umber of genes associated with glomerular
iseases have been identified in the past years,
nd the respective clinical outcomes are well
haracterized.4 Among these diseases are the
ongenital NS of the Finnish type caused by
utations in NPHS1 encoding nephrin and
he steroid-resistant nephrotic syndrome of
he podocin type caused by mutations in the
PHS2 gene encoding podocin.
The Frasier syndrome and Denys-Drash
yndrome are overlapping syndromes caused
y mutations in WT1 encoding the Wilms’
umor protein (WT1). WT1 is a transcription
actor regulating a number of podocyte genes
ncluding NPHS1 (nephrin) and NPHS2
podocin). Both syndromes are characterized
y glomerular disease; whereas the Frasier
yndrome shows a FSGS pattern in kidney
iopsies, the Denys-Drash syndrome is de-
ned by diffuse mesangial sclerosis. A recent
tudy describes a patient with FSGS and slow
rogressive nephropathy carrying an F392L
utation in WT1.12 Another report revealed
he association between specific noncoding
T1 single-nucleotide polymorphisms and
SGS in the black population.13
In 2 patients with primary FSGS, a nucleo-
ide variant leading to CD2AP haploinsuffi-
iency was detected.14 The higher susceptibil- gty of individuals carrying this mutation for
lomerular disease shows the pathogenic role
f altered CD2AP expression levels. CD2AP is
ot only thought to be an important adaptor
rotein in podocytes, coupling the slit dia-
hragm to the actin cytoskeleton, but also
mplicated in endocytosis and lysosomal sort-
ng. This and the observation that in
D2AP/ mice immunoglobulins accumu-
ate in the GBM led the authors to speculate
hat, in addition to its possible structural role,
D2AP may also be involved in targeting
roteins to the degradative pathway. Immu-
oglobulin deposits in CD2AP/ mice may
eflect the impaired ability of the podocyte to
lear plasma proteins from the GBM, suggest-
ng a possible diesease-causing mechanism in
ffected patients with CD2AP haploinsuffi-
iency.
Most recently, mutations in the TRPC6
ene encoding for the transient receptor po-
ential canonical 6 (TRPC6) have been added
o the list of glomerular disease-associated
enes.11,15 TRPC6 forms a calcium-permeable
on channel located at the SD site. In 6 fami-
ies, mutations in TRPC6 were associated with
he development of FSGS. The disease pre-
ented in between 17 and 57 years of age and,
n several patients, progressed to ESRD. Three
utations were shown to cause biologically
ain-of-function effects, suggesting that an in-
reased calcium influx at the SD site may
ontribute to the pathogenesis in affected in-
ividuals. How an increased calcium influx
ay lead to the disease phenotype and what
he disease-causing mechanisms look like for
he other 3 identified mutations remains elu-
ive.
onclusion and Outlook
odocyte injury plays a key role in proteinuric
lomerular diseases. The identification of a
rowing number of disease-associated genes
nvolved in podocyte structure and function
Table 1) is in line with this paradigm. Recent
ears have brought substantial contributions
o a better understanding of the podocyte and
he SD. The observation that many of the
ecently identified genes are widely expressed
ut cause specific effects in the podocyte sug-
ests that the related glomerular phenotypes
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171Human Glomerular Diseaseay be the consequence of their particular
oles in the unique organization of the glo-
erular filtration barrier and the increased
usceptibility of podocytes even to subtle
hanges in certain pathways. Besides -acti-
in-4, another good example thereof is
D2AP. Although being widespreadly ex-
ressed, it was possible to rescue CD2AP/
ethality in mice with podocyte-targeted ex-
ression of CD2AP, highlighting the particu-
ar role of CD2AP in podocytes.16
In fact, the disease-causing mechanisms
emain elusive for the majority of glomeru-
ar diseases, in particular those with late
nset. Several factors hamper the efforts to
lucidate the respective pathogenic mecha-
able 1. Summary of the Most Important GBM-, C
nd Secondary Genetic Glomerular Diseases Withisms. First, podocytes are characterized by ahigh degree of instrinsic adaptability to
xternal challenges because they have to be
ble to flexibly respond to changes in their
icroenvironment such as altered hemody-
amics. In line with this notion is the obser-
ation that FP effacement itself is a revers-
ble process and occurs, albeit rarely and
artially, in every healthy individual. Podo-
ytes may be able to temporarily overcome
ubtle pathophysiologic changes, which
onsequenly result in glomerular damage
nly over time. For example, in the cases of
D2AP haploinsufficiency and TRPC6 dys-
unction, compensatory mechanisms medi-
ted by homologous proteins (Cin85 or
ther TRP channels, respectively) may be
eleton-, Organelle-, and SD-Associated Primary
ytopathic Phenotypeytosk
Podocble to retard the course of the disease.
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172 Möller et alecond, the use of mouse models is limited
or many diseases of glomerular origin be-
ause the murine phenotypes often signifi-
antly differ from the manifestation in man.
nockout models are not always sufficient
o simulate the intricate effects of the char-
cterized gene defects, which may in fact be
ore subtle. Third, as proposed for ACTN4
utations, the disease manifestation may be
ependent on a “second physiological hit”
n some cases (eg, variations in glomerular
apillary pressure or metabolic distur-
ances). Fourth, the manifold reasons for
odocyte damage, deriving from distinct
omains such as the SD, the GBM, or the
ctin cytoskeleton, can be difficult to emu-
ate in vitro.
Albeit the given limitations, the clinical
ignificance of proteinuria and the currently
vailable experimental tools will continue to
rive progress in the genetic and biologic
nderstanding of glomerular diseases. Be-
ides the genetic glomerulopathies de-
cribed previously (Table 1), it will be inter-
sting to see what we can learn from a
umber of other diseases whose glomerular
henotypes still require further character-
zation (Table 2). New genetic tools such as
nducible podocyte-specific promoter ele-
ents that enable the conditional expression
f transgenes exclusively in the glomerulus
able 2. Genetic Glomerular Diseases With Rare I
escribed Glomerular Phenotypeave become available.17 They will help to wvercome some of the limitations of murine
nockout models and to better define the
idney phenotypes of systemic diseases.
he establishment of conditionally immor-
alized podocyte cell lines and the develop-
ent of experimental models of podocyte
amage such as the puromycin amino-
ucleoside model and the lipopolysaccha-
ide model have been invaluable achieve-
ents to study podocyte biology because
hey allow the investigation of the complex
elationships between the components of
he glomerular filtration barrier under vari-
us experimental conditions. The existing
odocyte cell lines may be applied to study
hich SD-based protein interactions are dis-
upted in experimental podocyte injury,
esting the hypothesis that perturbated pro-
ein interactions at the SD site are a major
ause for podocytopathy. Of particular in-
erest will also be to use the genetic findings
or a better understanding of acquired forms
f glomerular disease. For example, the de-
ection of the calcium-permeable channel
RPC6 at the SD site and its implication in
amilial FSGS serve as a starting point to
tudy the role of this channel in acquired
orms of FSGS as well, adding the concept of
alcium signaling at the SD site to the pool
f potentially relevant pathogenic path-
ce, Unknown Genetic Cause, or Poorlyncidenays.
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II. TRPC6 MUTATIONS IN GENETIC FORMS 
OF PROTEINURIC KIDNEY DISEASE 
 
II.1.  Rationale 
 
Based on the preliminary data by Winn et al. it remained unclear whether the 
identified mutation in TRPC6 represented a singular phenomenon in the isolated 
population of New Zealand, or does in fact represent a more widespread genetic 
cause for FSGS. Furthermore, nothing was known about the consequences of the 
identified mutation on TRPC6 function, for example whether the mutation leads to 
TRPC6 loss-of-function, or hyperactive TRPC6 channels, respectively.  
 
Therefore, to investigate the abundance of mutations in the TRPC6 gene across 
different ethnical backgrounds, 71 ethnically diverse families affected by familial 
focal segmental glomerulosclerosis (FSGS) were tested for the presence of mutations 
in the TRPC6 gene in collaboration with the laboratory of Prof. Dr. Martin Pollak at 
the Brigham and Women’s Hospital in Boston, Massachusetts, United States. In 
addition, to address the functional consequences of mutations in TRPC6, a patch-
clamp setup enabling the electrophysiological characterization of wildtype and 
mutant TRPC6 channel currents was established in collaboration with Prof. Dr. David 
Clapham at the Children’s Hospital in Boston, Massachusetts, United States. 
 
II.2.  Materials and Methods 
 
II.2.1.  Patient families 
 
Blood was obtained from members of families with familial focal segmental 
glomerulosclerosis (FSGS) after informed consent was given in accordance with a 
protocol approved by the Institutional Review Board at the Brigham and Women’s 
Hospital in Boston, Massachusetts, United States. In these families, the clinical 
history and pedigree information was obtained. DNA from FSGS-affected probands 
from 71 families was analyzed for mutations in the TRPC6 gene using bidirectional 
sequencing. Sequence analysis was performed using PCR-amplified genomic DNA. 
High-throughput capillary sequencing instrumentation and Sanger dideoxy DNA 
sequencing [Sanger, 1981] was used for mutation detection. Verification of sequence 
alterations in probands, family members, and control subjects was done using 
MALDI-TOF mass spectrometry-based singe nucleotide polymorphism (SNP) 
genotyping at the Harvard-Partners Core Genotyping Facility. 
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Family FG-BN 
 
Family FG-BN is a two generation Colombian family. Clinical history was obtained 
in all twelve of the members and four were considered affected. Eight of the twelve 
members agreed to participate in the study. The mother was given a clinical diagnosis 
of nephrotic syndrome at age 52 and was still living in 2005. One daughter was 
diagnosed with FSGS at the age of 22 and confirmed by biopsy. She was never 
treated with steroids and has not been started on dialysis. Two brothers were 
diagnosed at the age 20 with renal disease. Neither was biopsied. One died at the age 
of 21 from end-stage renal disease (ESRD) and the other started dialysis 3 months 
after presenting with proteinuric renal disease. The father and six of the children are 
not affected. No clinical information could be obtained regarding the degree of 
proteinuria at the time of diagnosis in any of the affected members. None were 
treated with steroids and none have been transplanted. Two siblings, one boy and one 
girl, carry the S270T mutation, but have no clinical evidence of disease. At the time 
of screening, their ages and spot urine protein/Creatinine ratio were age 16 and         
17 mg/gCr and age 27 and 3 mg/gCr, respectively. 
 
Family FG-EA 
 
Family FG-EA is a four generation African American family from the midwestern 
United States. Clinical history was obtained from 36 members. Of these, seven 
members were considered affected and two of these agreed to participate in the study. 
One was diagnosed at the age of 27 and presented with hypertension and proteinuria. 
A biopsy done at the time of presentation revealed FSGS. This individual was started 
on dialysis at the age of 30 and received a kidney transplant soon thereafter. The 
transplant failed after 11 years for unknown reasons. The brother of this individual 
was diagnosed with kidney disease at the age of 37. No biopsy was obtained and the 
patient was started on dialysis at age 39. Neither patient received corticosteroid 
therapy. None of the clinically unaffected members agreed to participate in the study. 
 
Family FG-FQ 
 
Family FG-FQ is a four generation family from Mexico. Clinical history was 
obtained from 25 members and nine were considered affected. A total of eleven 
members of the 25 agreed to participate in the study, 3 of whom are clinically 
affected. The proband was diagnosed with FSGS by biopsy at the age of 35 and 
developed end-stage renal disease (ESRD) at the age of 45. He is awaiting a 
transplant and was never treated with corticosteroids. Two of his brothers are 
affected. One brother was diagnosed at the age of 40 with biopsy showing FSGS. He 
developed ESRD and then received a kidney transplant. He has no evidence of 
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recurrence of FSGS in the transplanted kidney after six years of follow-up. His son 
was diagnosed with FSGS by biopsy at the age of 18. He has been treated with 
angiotensin converting enzyme inhibitors and has not needed renal replacement 
therapy after 6 years of follow-up. The second brother presented with ESRD at the 
age of 31 and was transplanted soon thereafter. He has had no evidence of recurrence 
of FSGS after 9 years of follow-up. The other affected members were considered 
affected based on clinical history of ESRD. 
 
Family FS-XR 
 
Family FS-XR is a four generation family of Irish/German descent from the 
northeastern United States. Clinical information was obtained from all twelve 
members of the family, of which two are affected. Four members agreed to 
participate in the study. One proband (affected female in the second generation of the 
pedigree) developed what was described as preeclampsia during her third pregnancy 
at the age of 24. The proteinuria resolved after delivery. During the fourth pregnancy 
at the age of 29, proteinuria developed again but persisted after delivery. No 
treatment or biopsy was pursued at that time. At the age of 49, the patient presented 
with uremic symptoms, a biopsy revealed FSGS and she was started on dialysis 
shortly thereafter. She was transplanted with a kidney from her son at the age of 50 
and there is no evidence of recurrence in the transplanted kidney or development of 
kidney disease in the son. A biopsy of the transplant confirms absence of focal 
sclerosis or podocyte foot process effacement. Her daughter at the age of 27 
developed proteinuria during her third pregnancy with persistent proteinuria after 
delivery. She reached end-stage renal disease (ESRD) within 8 years and is awaiting 
transplant. No biopsy was obtained. The third daughter developed preeclampsia 
which resolved after delivery. When genotyped, the third daughter carries the 
mutation (generation 3; fifth individual). At the time of her screening, she was 32 
years old and her spot urine protein/Creatinine ratio was 145 mg/gCr (normal <150 
mg/gCr) and has no clinical evidence of kidney disease. 
 
Family FS-Z 
 
Family FS-Z is a five generation family of western European descent. Clinical 
information was obtained from 53 members and twelve were considered affected. A 
total of 28 members agreed to participate, of which 6 were affected. Six of the total 
twelve affected individuals died of end-stage renal disease (ESRD). One of these 
developed hypertension and progressive renal failure prior to kidney biopsy which 
showed FSGS at the age of 55. Of the six affected individuals who participated in the 
study, one brother and his sister had kidney biopsy-confirmed FSGS. The sister 
TRPC6 MUTATIONS IN GENETIC PROTEINURIC DISEASE  30 
 
developed kidney disease after donating a kidney to her brother. The brother lost the 
first renal allograft as a result of FSGS in the transplanted kidney, a second cadaveric 
allograft due to acute rejection, and is currently awaiting a third transplant. Another 
of the six has reached ESRD and is on hemodialysis. One developed nephrotic 
syndrome at age 57 and then was transplanted and has been without evidence of 
recurrent disease in the transplanted kidney. Two have proteinuric renal disease (1.6 
g/gCr and 2.7 g/gCr) and neither has progressed to ESRD as of 2005. Of these two, 
one developed kidney disease after donating a kidney to his affected father. In this 
family, there are nine individuals who carry the K874Stop mutation but do not have 
clinical evidence of kidney disease. Generation IV of this family includes four such 
individuals (3 women, 1 man) with age ranges between 37 and 44. Of these members, 
three of them provided urine specimens to estimate albumin excretion. The range of 
urinary albumin excretion in these individuals was between 5.6 mg/gCr and 28.3 
mg/gCr. In generation V, there are five individuals with K874Stop mutations without 
clinical disease (2 women, 3 men) with age ranges between 13 and 18. The range of 
urinary albumin excretion was between 5.9 mg/gCr and 64.4 mg/gCr. 
 
II.2.2.  Sequence alignment 
 
Sequence alignments were performed using the T-Coffee algorithm [Notredame et 
al., 2000] comparing human TRPC6 protein sequences to other human TRPC 
channels (TRPC1; TRPC3-7) and TRPC6 protein sequences in fly (Drosophila 
melanogaster), rat (Rattus norvegicus), mouse (Mus musculus), Guinea pig (Cavia 
porcellus), and chimpanzee (Pan troglodyte). Protein sequence data was obtained 
from the National Center for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov). 
 
II.2.3.  Site-directed mutagenesis 
 
Site-directed mutagenesis was performed to insert the variants identified into a full-
length human TRPC6 cDNA clone (pcDNA3.1-TRPC6). Two mutagenic 
oligonucleotide primers were designed containing the desired mutation, flanked by 
unmodified nucleotide sequence. Mutagenesis was performed with an amplification 
reaction using the human TRPC6 cDNA template, mutagenic primers, and Pfu DNA 
polymerase (Stratagene, LaJolla, California, United States). Clones were then 
selected and sequenced to identify and verify mutants. 
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II.2.4.  Patch-clamp electrophysiology 
 
35 mm dishes of HEK293-M1 cells (human embryonic kidney cells stably transfected 
with the M1 muscarinic receptor) were transiently transfected with 2 μg of wild-type 
eGFP-TRPC6 or mutant eGFP-TRPC6 cDNA and 0.25 μg of eGFP cDNA (control) 
using Lipofectamine 2000 (Invitrogen, Carlsbad, California, United States). After 
transfection, cells were plated on glass coverslips at low density. Recordings were 
obtained from cells 24-72 hours after transfection. Cells were maintained at 37 °C in 
DMEM/Ham’s F-12 (1:1), 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL 
streptomycin and 100 μg/mL G-418 in 5% CO2. eGFP-positive cells were visualized 
with a fluorescence microscope (Olympus, Center Valley, Pennsylvania, United 
States). Currents were recorded using an Axopatch 200B amplifier and pClamp8 
software (Molecular Devices, Sunnyvale, California, United States). Voltage ramps 
from –100 mV to 100 mV over 150 ms were applied every 3.45 s from a holding 
potential of 0 mV. During voltage ramps, currents were sampled at 10 kHz and the 
recordings were filtered at 2 kHz. Current amplitude was normalized for cell 
capacitance. In each experiment the membrane potential was held either at –60 mV or 
0 mV, and no differences were noted between experiments performed at a holding 
potential of –60 mV and 0 mV. Borosilicate glass pipettes with resistances of 2-4 M? 
were used for recording. The bath solution contained 135 mM NaCl, 5 mM CsCl, 2 
mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 10 mM Glucose, pH 7.4. The pipette 
solution contained 135 mM CsMES, 10 CsCl, 3 mM MgATP, 0.2 mM NaGTP, 0.2 
mM EGTA, 0.13 mM CaCl2, 10 mM HEPES, pH 7.3. The free calcium concentration 
in the pipette solution was approximately 100 nM as calculated by MaxChelator 2004 
software [Patton et al., 2004]. The average current amplitudes at –100 mV and 100 
mV were compared with Student’s t test. To determine the time to a 50%-decay of 
inward Ca
2+
 currents of wildtype and mutant TRPC6 channels, inward currents were 
recorded at –60 mV, and the time was measured starting when the inward current 
reached a maximum and ending when the current decayed to 50% of the peak 
amplitude. 
 
II.3.  Results 
 
II.3.1. Families with TRPC6-related FSGS 
 
To explore the role of TRPC6 gene variation in kidney disease, probands of 71 
pedigrees with familial FSGS were screened for alterations in the TRPC6 gene by 
DNA sequence analysis. Of the 71 families screened, 43 showed evidence of disease 
in members of multiple generations, and 28 showed evidence of disease in 2 or more 
members of a single generation (Fig. II.1.). Probands of 49% of the families were of 
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western European ancestry, 5% of African ancestry, and 27% described themselves 
as Hispanic. The phenotype in affected members of largest of these families (FS-Z) 
showed cosegregation only with chromosome 11q markers (with 2 point lod score 
examining linkage of affected individuals with the disease-associated haplotype equal 
to 1.8 at ?=0). Different heterozygous sequence variants were identified in five 
unrelated families with adult onset disease, all of which predicted changes in the 
encoded gene product: N143S, S270T, K874Stop, R895C and E897K (Table II.1.). 
Other available family members were also genotyped for the relevant variants; in all 
families, patterns of TRPC6 variant and disease inheritance followed a pattern of 
cosegregation with less than complete penetrance. In each family, inheritance was 
consistent with an autosomal-dominant pattern. 180 control individuals were also 
genotyped for the disease-associated variants. None of these disease associated 
variants were identified in the controls. In addition, none of these substitutions were 
found in the public SNP databases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family Ethnicity Mutation Exon 
Age range at disease 
presentation (years) 
Number of 
family members 
with ESRD 
FG-EA African-American N143S 2 27-39 5 of 36 
FG-BN Colombian S270T 2 17-52 3 of 12 
FG-Z Polish K874Stop 12 27-57 9 of 53 
FG-FQ Mexican R895C 13 18-46 6 of 25 
FS-XR Irish/German E897K 13 24-35 2 of 12 
 
 
 
 
 
Figure II.1. Pedigrees of families with inherited FSGS. TRPC6 variants segregating in each family 
are indicated. Genotyped individuals are indicated as carrying (+) or not carrying (-) the variant 
identified in each family. ESRD, end-stage renal disease. (Data generated in collaboration with Prof. 
Dr. Martin Pollak, Brigham and Women’s Hospital, Boston, Massachusetts, United States.) 
Table II.1. Clinical manifestation of TRPC6-related FSGS. 
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II.3.2.  Localization of mutations in the TRPC6 sequence 
 
Each of the observed amino acid substitutions occurred in evolutionarily conserved 
residues (Fig. II.2.). Two mutations predict amino-acid substitutions in the N-terminal 
intracellular domain of TRPC6 (N143S, S270T), two predict amino-acid substitutions 
in the C-terminal intracellular domain (R895C, E897K), and one encodes a premature 
stop codon near the C terminus (K874Stop). Among the four missense mutations, 
three lead to conservative amino acid substitutions, substituting a hydrophilic-neutral 
amino acid with another hydrophilic-neutral one (N143S, S270T), or an hydrophilic-
charged amino acid with another hydrophilic-charged one, respectively (E897K). In 
contrast, R895C is a non-conservative substitution, exchanging an hydrophilic-
charged amino acid to a hydrophobic residue. 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. II.2. Localization of mutations in the TRPC6 sequence. (Left) Sequence alignments (using T-
COFFEE) showing evolutionary conservation of mutated TRPC6 residues. All four missense 
mutations occur in conserved residues. (Right) Localization of mutations within the predicted TRPC6 
protein structure. The amino-terminal cytoplasmic sequence contains several ankyrin repeats and a 
potential coiled-coil region. The carboxy-terminal cytoplasmic domain contains a conserved 
sequence found in TRPC, TRPV and TRPM proteins, termed the TRP box, and a potential coiled-coil 
sequence. The location and identity of mutations associated with familial forms of FSGS are 
indicated. ANK1–4, ankyrin repeats 1–4; CC-N, N-terminal potential coiled coil region; LFW, amino 
acid motif conserved in the putative pore region of all TRPC channels; CIRB, calmodulin/IP3R 
binding region;. CC-C, C-terminal potential coiled coil region. (Source: adapted from Vazquez et al. 
(2004) Biochim Biophys Acta. 1742:21-36. [Vazquez et al., 2004]) 
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II.3.3.  Electrophysiological analysis of mutant TRPC6 channels 
 
To study whether mutations in TRPC6 affect calcium channel function, wild-type 
TRPC6 and the five mutant TRPC6 channels were expressed in HEK293 cells stably 
transfected with the G?q-coupled M1 muscarinic receptor. TRPC6 currents were 
recorded before and after activation of M1 receptors by carbachol. Currents from the 
N143S, S270T and K874Stop TRPC6 channels did not differ noticeably from wild 
type TRPC6 currents (data not shown). In contrast, currents from R895C and E897K 
mutant channels were significantly larger than wild type TRPC6 currents (Fig. II.3.). 
Notably, the non-conservative amino acid substitution R895C produced the most 
significant changes in current amplitude. Subtle differences in the rectification of the 
current-voltage relationship of these two mutants were also noted. However, the 
changes in rectification most likely result from the increased current density rather 
than directly from structurally related changes in channel gating or permeation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. II.3. Inreased current amplitudes of mutant TRPC6 channels. 
Representative whole-cell currents measured from HEK293-M1 cells transiently 
transfected with cDNA encoding wild-type (WT) TRPC6 (a) or R895C (b) or 
E897K (c) mutant TRPC6. Current traces were recorded as cells were perfused with 
control bath solution (gray traces) or 100 ?M carbachol (CCH, black traces). (d) 
Average normalized current amplitude measured at –100 mV (dark bars) and 100 
mV (light bars) from cells expressing wild-type (WT) TRPC6 or R895C or E897K 
mutants. Current amplitudes from cells expressing R895C and E897K mutants 
were significantly higher at both –100 mV and 100 mV than those from cells 
expressing wild-type channels (P < 0.01). The number of experiments is shown in 
parentheses, and the error bars show the S.E.M. for each measurement. (Data 
generated in collaboration with Prof. Dr. David Clapham, Children’s Hospital, 
Boston, Massachusetts, United States.) 
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The time to a 50%-decay of inward Ca
2+
 currents of wildtype and mutant TRPC6 was 
also studied. Inward currents were recorded at –60 mV, and the time was measured 
starting when the inward current reached a maximum and ending when the current 
decayed to 50% of the peak amplitude. Preliminary results suggest that the time to 
50%-decay was prolonged in all of the tested TRPC6 mutants (Fig. II.4.). The mean 
values differed from the wildtype in a range from +54% (20 s for N143S vs. 13 s for 
wild-type) to +246% (45 s for E897K vs. 13 s for wild-type). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. II.4. Prolonged time to 50%-decay for mutant TRPC6 channels. (A) Inward currents through 
wild-type TRPC6 (WT; upper panel) and mutant TRPC6 (R895C shown representatively; lower 
panel) channels were recorded at –60 mV following stimulation with carbachol. (B) The time to 
50%-decay of the inward current appeared to be prolonged in all of the evaluated TRPC6 mutants. 
The number of experiments is shown in parentheses, and the error bars show the S.E.M. for each 
measurement. (Data generated in collaboration with Prof. Dr. David Clapham, Children’s Hospital, 
Boston, Massachusetts, United States.) 
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II.4. Discussion 
 
II.4.1.  Clinical presentation of TRPC6-related FSGS 
 
Mutations in several podocyte genes have been identified as culprits for progressive 
renal failure or increased glomerular disease susceptibility [Pollak et al., 2002]. The 
presence of TRPC6 mutations cosegregating with kidney disease, the changes in  
channel current amplitude observed in two mutants, and the observed prolonged time 
to 50% decay suggest that TRPC6 channel function plays a role in normal renal 
ultrafiltration and the pathogenesis of glomerular disease. 
 
The work presented suggests that TRPC6-related FSGS is not restricted to certain 
ethnic groups as TRPC6 mutations were found to cosegregate with kidney disease in 
families of African-American, Colombian, Polish, Mexican, and Irish/German 
descent alike. Second, TRPC6 mutations appear to account for a significant number 
of inherited FSGS cases. Given that among 71 tested families, five were positive for 
TRPC6 mutations, this relates to a relative frequency of TRPC6-related FSGS of 
about 7% among all cases of familial FSGS. Third, the age range at disease 
presentation was broad, ranging from 17-57 years. This classifies TRPC6-related 
FSGS as a disease with a rather late onset, in contrast to other genetic 
glomerulopathies that manifest in infancy such as congenital nephrotic syndrome of 
the Finnish type, steroid-resistant nephrotic syndrome of the podocin type, or Wilms’ 
tumor protein 1 (WT1)-related diseases including Denys-Drash syndrome and Frasier 
syndrome. While in these diseases the early onset is most likely due to the severe 
damage that is inflicted on the molecular architecture of the slit diaphragm and the 
process of glomerular filtation as a result of nephrin or podocin disruption, the 
question remains why the onset of kidney disease in patients with TRPC6 mutations 
occurs at a relatively advanced age. One possible explanation is that mutations in 
TRPC6 may produce subtle changes in intracellular function that lead to irreversibly 
altered cell behavior only after time and in the presence of other renal insults 
[Pavenstadt et al., 2002]. This would be similar to the adult onset and dominantly 
inherited form of FSGS due to mutations in the widely expressed protein ?-actinin-4 
[Kaplan et al., 2000]. In addition, podocytes express several TRPC channel subunits 
other than TRPC6, and partial functional redundancy may also help account for the 
late onset of glomerular disease. Indeed, the ability of TRPC6 to form heteromers 
with other TRPC channels suggests a complex cellular regulation of calcium 
homeostasis [Schaefer et al., 2005]. A similar explanation was also suggested for the 
late onset of disease in CD2AP haploinsufficiency, an autosomal-dominant genetic 
disorder [Kim et al., 2003]. In this case the CD2AP-homolog Cin85 may partially be 
able compensate for decreased CD2AP levels [Tossidou et al., 2007]. 
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Finally, individuals with TRPC6-related FSGS did not present with any other 
pathological phenotype. TRPC6 is widely expressed in smooth muscle cells, where it 
is thought to contribute to the regulation of important physiological aspects such as 
airway resistance and vascular tone. However, TRPC6 mutations appear to exhibit 
their deleterious effect mainly in the kidney in absence of any other overt organ 
dysfunction. This suggests that the glomerular phenotype is the consequence of a 
unique role of TRPC6 in the organization of the glomerular filtration barrier and the 
increased susceptibility of this structure even to subtle changes in its 
microenvironment. Therefore, TRPC6 belongs to the same category of genes such as 
?-actinin-4 and CD2AP. Mutations in both genes foremostly lead to glomerular 
kidney disease while being widely expressed and associated with a plethora of 
different cellular functions in many cells throughout the body [Shih et al., 1999; 
Kaplan et al., 2000]. For example, in the case of CD2AP it was possible to rescue 
CD2AP
-/-
 lethality in mice with podocyte-targeted expression of CD2AP, 
highlighting the particular role of CD2AP in podocytes [Grunkemeyer et al., 2005]. 
 
II.4.2.   Nature of TRPC6 mutations 
 
Of the five TRPC6 mutations that were identified, all are located either at the            
N-terminal (N143S; S270T) or C-terminal (K874Stop; R895C ;E897K) intracellular 
tail of TRPC6. The two mutations at the N-terminus are both located within the 
sequence region spanning four ankyrin repeats. Ankyrin repeats fold into a helix-
loop-helix-beta-hairpin/loop structure with several repeats stacked against one 
another to form a single domain with a protein-binding interface [Mosavi et al., 
2004]. In TRPC channels, the first ankyrin-like repeat is the minimum indispensable 
key structure for functional assembly of homo- and heteromeric TRPC4/TRPC5 
channels [Schindl et al., 2007]. Mutations in this region may therefore compromise 
the ability of TRPC6 to oligomerize with other TRPC subunits, or to interact with 
other binding partners. Ankyrin repeats have also been shown to be important 
determinants of proper plasma membrane targeting of TRPC channels [Wedel et al., 
2003; Smyth et al., 2006]. Whereas not all ankyrin repeats seem to be crucial for the 
functional assembly of TRPC channels, a truncated variant of TRPC3 lacking all of 
the N-terminal ankyrin repeats no longer mediated agonist-induced Ca
2+-
entry in 
HEK293 cells [Wedel et al., 2003]. Finally, mutations within the ankyrin repeats of 
TRPC6 may prevent the channel from being correctly inserted into the plasma 
membrane. This is supported by findings of Cayouette et al. suggesting that TRPC6 
levels at the plasma membrane are regulated by targeted membrane insertion 
[Cayouette et al., 2004].  
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Notably, no changes in current amplitude were detected for the N-terminal N143S 
and S270T mutations and for the K874Stop non-sense mutation. Nevertheless, these 
mutations are likely to be disease-causing because of the nature of the changes 
(substitutions in very highly conserved residues), cosegregation with the disease 
phenotype, the absence of these changes from control individuals. Yet, this result 
suggests that an abnormality other than increased current amplitude is the cause of 
disease in the individuals with these mutations. The observed prolonged time to 50% 
decay may serve as a possible explanation. However, other factors may be involved 
as well, including altered channel regulation (despite normal current amplitude), 
altered interaction with slit diaphragm proteins, or altered protein turnover. Another 
possibility is that these mutations may exhibit altered current amplitudes only in the 
physiological context, e.g. when assembled into the proper heteromeric composition. 
Therefore, the effect of the studied mutations may not be visible when only the 
mutated TRPC6 subunits are expressed as monomeric channels in HEK293 cells. 
 
Among the three mutations at the C-terminus, two (R895C; E897K) are located very 
close to each other in a putative coiled-coil domain. The coiled-coil is an ubiquitous 
protein motif that is commonly used for oligomerization. There is one potential 
coiled-coil motif in each of the cytosolic N- and C-termini of TRPCs. While no study 
has specifically investigated the importance of the C-terminal coiled-coil motif in 
TRPC channel,  a recent study suggests that the C-terminal tail of TRPC4 and TRPC6 
participates in channel oligomerization [Lepage et al., 2006]. Importantly, the R895C 
and E897K mutations both resulted in TRPC6 channels with higher current 
amplitudes (Fig. II.3.) suggesting that disruption of the C-terminal putative coiled-
coil motif in TRPC6 has a direct consequence on channel activity. Whether this is 
indeed due to an interference with the ability of TRPC6 to oligomerize with other 
channel subunits, will have to be addressed in future studies.  
 
As is the case for the N143S and S270T mutations, also the mutation identified by 
Winn et al. in a large family from New Zealand (P112Q) is located at the N-terminal 
intracellular tail in the sequence region spanning the four ankyrin repeats [Winn et 
al., 2005]. Similar to the increased channel activity that we observed for the R895C 
and E897K mutations, Winn et al. found the current amplitude increased for the 
TRPC6 P112Q channel [Winn et al., 2005], indicating that interference with both,    
N- and C-terminal domains of TRPC6 can give rise to hyperactive channels. Winn et 
al. provide in their study a possible explanation for the increased current amplitude 
caused by the P112Q mutation: by carrying out surface biotinylation studies it was 
shown that mutant TRPC6 channels were more abundant in the plasma membrane 
when expressed heterologously in HEK293 cells than their wild-type counterparts. 
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II.4.3.  TRPC
-/-
 mice – a suitable model for TRPC-related FSGS? 
 
To study the pathogenic mechanisms behind many inherited human diseases, 
important insights may be drawn from the study of genetic animal models. TRPC6-
deficient mice have recently been characterized [Dietrich et al., 2005]. As mentioned 
above, young TRPC6
-/- 
mice appear to lack an overt renal phenotype. However, one 
has to take into account that thus far no study has explicitly addressed the renal 
phenotype of TRPC6-deficient mice. Moreover, given the late onset of the TRPC6-
related human disease, in particular also aged mice would have to be considered. 
 
One explanation is provided by the so-called second-hit hypothesis [Kriz, 2005]. For 
example, in the context of mutations in ?-actinin leading to FSGS [Yao et al., 2004], 
it has been suggested that, besides the presence of mutations, a second physiological 
hit such as a metabolic disturbance is required for the clinical manifestation of the 
disease. A similar mechanism may account for the absence of a disease phenotype in 
TRPC6
-/-
 mice, which have not been experimentally challenged yet. Furthermore, as 
decribed above, a genetic second hit in the form of mutations in genes other than 
TRPC6 may be required for the disease onset as it was seen in bigenic mouse models 
of FSGS involving the pairwise interaction of CD2AP, synaptopodin, and Fyn [Huber 
et al., 2006]. 
 
Also, the role of TRPC6 in the kidney may be different in the human and the mouse, 
and the findings in the animal model may not be applicable to the human disease 
phenotype. A recent example comes from a study indicating a key role of sialic acid 
in kidney development and function in mice [Galeano et al., 2007]. Mice carrying a 
mutation in ManNAc kinase, a key enzyme in the sialic acid biosynthesis pathway die 
within 72 h after birth from severe glomerular disease including podocyte foot 
process effacement, structural damages in the glomerular basement membrane, 
hematuria and proteinuria. This is due to the disruption of sialic acid production. In 
contrast, disruption of the same enzyme does not cause any kidney damage in 
humans, where the disease mainly affects muscle function. This finding illustrates 
that there may be considerable differences in the organization of cellular functions 
between humans and widely applied animal models such as mice or rats, and one has 
to apply caution when trying to adapt experimental observations made in animal 
models to a human disease. 
 
Finally, while TRPC6-deficient mice may reveal themselves as a suitable model to 
study the physiological role of TRPC6 in the kidney under an appropriate study 
design, they may not be suitable for studying the pathogenesis of TRPC6-related 
FSGS given that TRPC6 mutants appear to lead to increased channel function. 
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II.4.4.   Consequences for the diagnosis of FSGS 
 
The finding that mutations in the TRPC6 gene are associated with familial forms of 
FSGS may be used for genotyping of candidate individuals in the future. 
Polymorphisms of TRPC6 may act as susceptibility or initiation factors for renal 
disease and may help determine which patients would benefit from early, aggressive 
therapy. Two examples of how genotyping may be applied to patients with 
glomerular disease can be found in nephrin and podocin mutations. In 1998, genetic 
mutations in the NPHS1 gene encoding nephrin were shown to be associated with 
congenital nephrotic syndrome of the Finnish type [Kestila et al., 1998]. Nephrin can 
be found in podocytes as an essential component of the slit diaphragm. In 2000, 
genetic mutations in another important podocyte protein, podocin, were shown to be 
associated with steroid-resistant nephrotic syndrome [Boute et al., 2000]. Patients 
with this condition do not respond to standard treatment with the steroid prednisone. 
Consequently, the long-term prognosis for this steroid-resistant subgroup is poor 
because no satisfactory treatment exists. Like nephrin, podocin plays an important 
role in regulating kidney filtration at the slit diaphragm.  
 
A genotyping assay has been developed that can be used to screen patients for the 
presence of nephrin or podocin mutations. This genetic test is now commercially 
available. The test results can detect the presence of the currently known mutations in 
either nephrin or podocin and therefore provide clarity about the cause of the disease 
and diagnostic clues for adequate treatment of patients. A similar approach to test for 
the presence of TRPC6 mutations in individuals with a family background of 
inherited FSGS will become available in the near future. Given the late onset of 
TRPC6-related glomerular disease, knowledge about genetic defects in the TRPC6 
gene may enable an earlier therapeutic intervention. It may also prompt the affected 
individuals to adopt a lifestyle aiming to preserve kidney function as long as possible, 
e.g. adhere to a low-salt diet. Whereas there are currently no therapies available that 
can specifically target TRPC6-related FSGS, this may still help improve the situation 
for the affected individuals. 
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III. TRPC6 ASSOCIATION WITH THE 
GLOMERULAR FILTRATION BARRIER 
 
III.1.  Rationale 
 
The observation that mutations in TRPC6 are associated with a severe kidney 
phenotype  in the absence of other overt organ dysfunction,  points to a pivotal role of 
TRP6 channels in the kidney. However, the mechanism of TRPC6 involvement in 
kidney disease, and the role of TRPC6 in normal kidney function remain unclear. In 
an effort to understand the molecular mode of TRPC6 function for TRPC6 in the 
kidney, several key questions must be answered. Firstly, is TRPC6 expressed in 
podocytes? If so, what is the subcellular localization of TRPC6 in podocytes; in 
particular, is TRPC6 associated with the slit diaphragm, the key membranous 
structure often disrupted in focal segmental glomerulosclerosis? In an effort to reveal 
a possible link between TRPC6 and the glomerular filter, the expression of TRPC6 in 
podocytes and its association with the slit diaphragm were studied. 
 
III.2.  Materials and Methods 
 
III.2.1. Cell culture 
 
Conditionally immortalized mouse podocytes were cultured as described [Mundel et 
al., 1997]. A GFP-TRPC6 construct, which included the complete mouse TRPC6 
cDNA, was kindly provided by Mike Zhu (Ohio State University, Columbus, Ohio, 
United States). Cultured podocytes were transfected using Lipofectamine 2000 
(Invitrogen, Carlsbad, California, United States) according to standard protocols. 
 
III.2.2. Immunohistochemistry and Immunocytochemistry 
 
Female adult Sprague-Dawley rats with a body weight of 200 g were perfused via the 
abdominal aorta with 2% paraformaldehyde in PBS for 3 min at 220 mmHg followed 
by cryoprotectant sucrose-PBS solution (800 mOsmol) for 5 min at 220 mmHg. For 
immunofluorescent labeling, sections were washed once with PBS and incubated 
with blocking solution (2% fetal calf serum, 2% bovine serum albumin, 0.2% fish 
gelatin) for 30 min at room temperature before incubation with the primary antibody 
for 1 h at room temperature. For double labeling, a second primary antibody was 
applied for 1 h. Antigen-antibody complexes were visualized with secondary 
antibodies conjugated with fluorochromes. Specimens were analyzed using a 
confocal microscope (Zeiss, Oberkochen, Germany). The following antibodies were 
used: mouse G1 monoclonal antibody to synaptopodin [Mundel et al., 1997] and 
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rabbit polyclonal antiserum to TRPC6 (Alomone Labs, Jerusalem, Israel; 1:50 
dilution) and polyclonal antibodies against CD2AP (gift from Dr. Andrew Shaw, 
Washington University, Saint Louis, Missouri, United States), nephrin and podocin 
(all in 1:200 dilution). As a control, the primary antibodies were either omitted or, in 
the case of TRPC6 staining, the primary antibody was pre-incubated with a TRPC6 
control peptide for 1 h before use in the immunolabeling. Specimens were analyzed 
using a confocal microscope (Zeiss, Oberkochen, Germany). For immunofluorescent 
labeling of cultured podocytes, cells were processed as decribed before [Mundel et 
al., 1997]. Mouse kidneys (wild-type and nephrin
?/?
; kindly provided by Dr. 
Raghuram Kalluri, Beth Israel Deaconess Medical Center, Boston, Massachussets, 
United States) were harvested, snap-frozen and fixed with 4% formaldehyde after 
sectioning in ice-cold acetone for 10 min [Hamano et al., 2002]. Sections were 
washed once with PBS and incubated with blocking solution (2% fetal calf serum, 
2% bovine serum albumin, 0.2% fish gelatin) for 30 min at room temperature before 
incubation with the primary antibody for 1 h. For double labeling, a second primary 
antibody was applied for 1 h. Antigen-antibody complexes were visualized with 
secondary antibodies conjugated to fluorochromes. Specimens were analyzed using a 
confocal microscope (Zeiss, Oberkochen, Germany). 
 
III.2.3. RT-PCR 
 
Total RNA was isolated from murine cultured differentiated podocytes using Trizol 
reagent (Invitrogen, Carlsbad, California, United States) according to the 
manufacturer’s instructions. cDNA synthesis was performed with SuperScript II 
Reverse Transcriptase (Invitrogen, Carlsbad, California, United States) using 
Oligo(dT)12-18 oligonucleotide primers according to the manufacturer's instructions. 
 
III.2.4. Immunogold and Transmission Electron Microscopy 
 
Immunogold labeling of ultrathin frozen sections of perfusion-fixed mouse kidney 
were incubated with the rabbit anti-TRPC6 antibody (Chemicon, Temecular, 
California, United States), followed by gold-labeled anti-rabbit secondary antibody. 
Images were obtained using a Philips CM10 electron microscope (Philips, 
Eindhoven, Netherlands). 
 
III.2.5. Coimmunoprecipitation 
 
Recombinant mouse GFP-TRPC6 was coexpressed with FLAG-tagged mouse 
CD2AP, nephrin and podocin, respectively, in HEK293 cells. FLAG-fusion proteins 
from cell lysates were immunoprecipitated using anti-FLAG-M2 beads and eluates 
were analyzed by Western blotting using anti-FLAG and anti-GFP antibodies (Sigma, 
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Saint Louis, Missouri, United States). For endogenous coimmunoprecipitation 
studies, whole cell extracts from cultured differentiated podocytes were prepared and 
incubated with anti-TRPC6 antibody overnight. The reaction was then incubated with 
protein G-coupled beads (Sigma, Saint Louis, Missouri, United States) for 2 h. 
Coimmunoprecipitated protein complexes were visualized by Western blotting using 
antibodies against TRPC6 (1:300 dilution), CD2AP (1:2,000), nephrin (1:300) and 
podocin (1:1,500). As a negative control, protein G-coupled beads without antibody 
were used. 
 
III.3.  Results 
 
III.3.1. TRPC6 expression pattern in the kidney glomerulus 
 
Confocal microscopy of adult rat kidney sections revealed widespread expression of 
TRPC6 throughout the kidney tubules and glomeruli (Fig. III.1.). Most TRPC6 
expression within the glomerulus was confined to podocytes as shown by 
immunofluorescent double labeling with the podocyte marker synaptopodin resulting 
in a yellow staining pattern [Mundel et al., 1997]. In addition, a signal was also 
detected in glomerular endothelial cells. Pre-incubation of TRPC6 antibody with a 
TRPC6 control peptide resulted in a negative signal.  
 
 
 
 
 
 
 
 
 
 
Next, the expression of TRPC1-6 mRNAs in isolated glomeruli and cultured mouse 
podocytes was determined by RT-PCR (Fig. III.2., left). While expression of  
TRPC1-6 mRNAs was detected in isolated glomeruli, only TRPC1, 2, 5 and 6 
mRNAs were detectably expressed in cultured podocytes. These data are consistent 
with other reports detecting TRPC6 mRNA in glomeruli [Winn et al., 2005; Facemire 
et al., 2004]. A TRPC6-specific antibody detected TRPC6 protein expression in 
cultured mouse podocytes in the nucleus as well as at the plasma membrane          
(Fig. III.2., right). 
 
 
Fig. III.1. TRPC6 protein expression in the rat kidney glomerulus. (a) Confocal microscopy 
shows TRPC6 expression (red) in the glomerulus. TRPC6 colocalizes with the podocyte marker 
synaptopodin (green; overlap shown by yellow staining). (b) Compared with TRPC6 antibody 
labeling (green), preabsorption of TRPC6 antibody with control peptide results in negative staining. 
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To determine the precise subcellular localization of TRPC6, immunogold labeling of 
ultrathin frozen sections from adult kidney cortex was performed. Gold particles were 
found in the cell body of podocytes and in primary processes (Fig. III.3., upper panel, 
white arrowheads). Clusters of gold particles were observed, indicating the presence 
of TRPC6-containing vesicles. In podocyte foot processes, gold particles labeled 
areas in close vicinity to the slit diaphragm region (Fig. III.3, upper panel, black 
arrowheads). TRPC6 expression was sometimes also detected in glomerular 
endothelial cells. The high power view of a section through the slit diaphragm area 
revealed the close association of TRPC6 with the slit diaphragm (Fig. III.3., lower 
panel, black arrowheads). The expression of TRPC6 near the slit diaphragm is 
consistent with a role for this channel in regulation of the glomerular filtration barrier. 
 
 
 
 
 
 
 
 
 
 
 
III.3.2. TRPC6 association with the glomerular slit diaphragm 
 
Given the central role of slit diaphragm disruption in kidney pathologies, the pattern 
of TRPC6 localization was further examined with respect to the disease-associated 
slit diaphragm proteins nephrin, podocin and CD2AP. Nephrin serves a molecular 
Fig. III.3. TRPC6 immunogold labeling. (Left) Immunogold labeling shows TRPC6 localization in 
podocyte major processes (white arrowheads) and foot processes. TRPC6 in podocyte foot processes 
is located in close vicinity to the slit diaphragm (black arrowheads). (Right) High-power view of slit 
diaphragm areas (arrowheads) displays heavy TRPC6 immunogold labeling. 
Fig. III.2. TRPC6 expression in cultured podocytes. (Left) Analysis of TRPC1-TRPC6 mRNA 
expression in cultured podocytes by RT-PCR. TRPC1, 2 5, and 6 mRNAs are detected in total 
podocyte RNA (podo). TRPC3 and 4 mRNAs are detected in total glomerular RNA (glom) but not in 
total podocyte RNA. (Right) TRPC6 protein expression in cultured podocytes. TRPC6 localizes to 
the cell membrane in cultured differentiated podocytes (arrowheads) as shown by immunostaining. 
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scaffold and is involved in mediating extracellular signals into the podocyte cell body 
[Benzing, 2004]. Podocin is a stomatin protein family member with a predicted 
hairpin-like structure localizing to the insertion site of the slit diaphragm of podocytes 
[Boute et al., 2000], where it is thought to recruit other proteins into nephrin-
containing lipid raft signaling microdomains at the slit diaphragm [Schwarz et al., 
2001]. CD2AP is an important adapter protein, connecting the slit diaphragm 
complex to the podocyte actin cytoskeleton [Welsch et al., 2005]. 
 
Since available antibodies against TRPC6 and slit diaphragm proteins are all rabbit-
polyclonal, cultured podocytes were transfected with GFP-tagged TRPC6. Confocal 
microscopy of GFP-TRPC6-transfected podocytes stained with antibodies against 
nephrin, podocin and CD2AP revealed expression of GFP-TRPC6 at the podocyte 
cell membrane partially colocalizing with nephrin, podocin and CD2AP (Fig. III.4.). 
This further supported the notion that TRPC6 is associated with the slit diaphragm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. III.4. TRPC6 colocalizes with slit diaphragm proteins. GFP-TRPC6 colocalizes with 
CD2AP, nephrin and podocin at the cell membrane of cultured podocytes, as shown by confocal 
microscopy (arrowheads). 
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The colocalization of TRPC6 with nephrin, podocin and CD2AP raised the intriguing 
possibility that TRPC6 can interact with one or more of these key players at the slit 
diaphragm. To test this, coimmunoprecipitation studies were performed (Fig III.5.). 
Recombinant mouse GFP-TRPC6 was coexpressed with FLAG-tagged mouse 
nephrin, podocin, and CD2AP, respectively, in HEK293 cells. FLAG-fusion proteins 
from cell lysates were immunoprecipitated using anti-FLAG-M2 beads and eluates 
were analyzed by immunoblotting using anti-FLAG and anti-GFP antibodies. To 
detect the interaction of GFP-TRPC6 with FLAG-tagged nephrin, podocin or 
CD2AP, eluates were analyzed with anti-GFP antibody. GFP-TRPC6 was absent in 
eluates derived from cells cotransfected with FLAG-CD2AP. In contrast, GFP-
TRPC6 was present in eluates derived from cells cotransfected with FLAG-nephrin 
and FLAG-podocin, indicating that TRPC6 can associate with nephrin and podocin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Next, endogenous coimmunoprecipitation of TRPC6 with nephrin, podocin and 
CD2AP from cultured differentiated podocytes was carried out. Consistent with the 
overexpression data, TRPC6 coimmunoprecipitated with nephrin and podocin but not 
with CD2AP (Fig. III.6.). The association of TRPC6 with nephrin and podocin, key 
regulators of the the slit diaphragm points to an essential role of TRPC6 channels in 
the slit diaphragm protein complex. 
Fig. III.5. TRPC6 interacts with slit diaphragm proteins. 
GFP-TRPC6 associates with FLAG-tagged nephrin and podocin 
but not CD2AP in cotransfected HEK293 cells. GFP-TRPC6 was 
detected in total cell lysate bz Western blotting using an antibody 
to GFP (upper panel). FLAG-tagged fusion proteins were 
immunoprecipitated, eluted and visualized with an antibody to 
FLAG (middle panel). Coimmunoprecipitated GFP-TRPC6 was 
detected in eluate fractions (lower panel). FLAG-myopodin 
served as a negative control for TRPC6 binding. Apparent 
molecular weight is shown to the left in kDa. 
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TRPC6 expression in glomeruli of nephrin
-/-
-mice 
 
Nephrin is a central component of the slit diaphragm and mice deficient in nephrin 
suffer from proteinuria and partial foot process effacement [Putaala et al., 2001; 
Hamano et al., 2002]. Given that nephrin interacts with TRPC6 in podocytes        
(Fig. III.6), the effect of nephrin deficiency on the localization of TRPC6 in the 
glomerulus was studied (Fig. III.7.). Neonatal wild-type mice displayed a barely 
detectable expression of glomerular TRPC6. In contrast, a strong signal in podocytes 
from nephrin knock-out mice pointed to an induction of podocyte TRPC6 expression. 
Actual levels of TRPC6 protein remain to be determined as immunofluorescence is 
not a quantitative technique. Immunofluorescence double labeling with the podocyte 
marker synaptopodin showed that TRPC6 was expressed in podocytes, resulting in a 
partial yellow overlap. Notably, nephrin
-/-
 podocytes exhibited focal accumulation of 
TRPC6 protein. In summary, this suggests that lack of nephrin is correlated with 
altered subcellular localization of TRPC6, and possibly contributes to an induction of 
TRPC6 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig, III.6. Endogenous coimmunoprecipitation of TRPC6 with 
slit diaphragm proteins from cultured podocytes. TRPC6 
interacts with nephrin and podocin but not with CD2AP. Proteins 
were immunoprecipitated with antibody to TRPC6. 
Fig. III.7. TRPC6 expression in neonatal wild-type and nephrin
-/-
 mice. Weak 
TRPC6 expression was detected in glomeruli of 2 d old wild-type mice (upper 
panels). TRPC6 appeared to be induced in glomeruli of 2 d old nephrin-deficient 
mice (lower panels). TRPC6 formed aggregates in the glomerulus (white arrows). 
Double labeling of TRPC6 with the podocyte marker synaptopodin confirmed the 
localization of TRPC6 in kidney podocytes, resulting in a yellow overlap. 
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III.4.  Discussion 
 
III.4.1. Implications of the localization of TRPC6 in the glomerulus 
 
TRPC6 is a novel podocyte protein involved in FSGS 
 
Studies of familial nephrotic syndromes have delineated the importance of the 
podocyte in normal glomerular function [Kriz et al., 1998]. Indeed, all previously 
described genes mutated in focal segmental glomerulosclerosis (FSGS) and nephrotic 
syndrome are highly expressed in the glomerular podocyte [Moller et al., 2006]. The 
present data show that TRPC6 can potentially be added to the list of podocyte 
proteins involved in podocyte injury and FSGS development. Like other proteins 
shown be associated with podocytopathy, e.g. nephrin, podocin, ?-actinin-4, or 
CD2AP, TRPC6 expression was detected in podocyte foot processes in close 
proximity to the slit diaphragm. TRPC6 is the first calcium-permeable channel 
detected at this site, suggesting that calcium signaling plays a role in regulation of the 
slit diaphragm. 
 
TRPC6 expression in endothelial cells 
 
TRPC6 expression in glomeruli was not exclusively limited to podocytes, but was 
also detected in glomerular endothelial cells. Given the interdependence of the 
constituents of the glomerular filtration barrier – the GBM is built and maintained in 
a combined effort by the underyling endothelial cells and overlying podocytes – this 
raises the possibility that TRPC6 mutation elicits its pathological effects in part 
through endothelial cells, and that podocytopathy may be a secondary effect of 
endothelial cell malfunction. 
 
A possible pathogenic mechanism in endothelial cells may involve the vascular 
endothelial growth factor (VEGF), an important signaling protein involved in both 
vasculogenesis and angiogenesis. VEGF has recently been shown to play a critical 
role in maintaining the structure and function of the glomerulus [Eremina & Quaggin, 
2004]. Loss of only one VEGF-A allele in podocytes leads to glomerular capillary 
endothelial cell dysfunction and proteinuria [Eremina et al., 2003]. In vitro, VEGF-A 
and -C appear to enhance podocyte survival [Foster et al., 2006; Guan et al., 2006]. 
Notably, VEGF is also a potential activator of TRPC channels; TRPC channels have 
been implicated in mediating the calcium influx into endothelial cells, and changes in 
vascular permeability are seen in response to VEGF. TRPC6 and TRPC3 are capable 
of inducing calcium influx downstream of VEGFR2 when coexpressed in tissue 
culture [Pocock et al., 2004; Cheng et al., 2006]. In endothelial cells, increased 
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intracellular calcium leads to the activation of PKC-? and the Ca2+/calmodulin-
dependent myosin light chain kinase. These in turn enhance endothelial cell 
contraction and mediate disassembly of VE-cadherin cell–cell junctions, together 
allowing for increased fluid flow between cells [Tiruppathi et al., 2002]. 
 
However, none of the known proteins associated with familial FSGS have thus far 
been shown to have a role in glomerular endothelial cells. In contrast, all appear to 
have important roles in podocytes. Therefore, it seems more likely that FSGS-
associated TRPC6 mutations primarily affect podocytes, and that TRPC6 expression 
in glomerular endothelial cells plays a minor role. This is supported by the 
observation that TRPC6 mutations do not cause any detectable phenotype in the 
endothelial cells of other tissues. However, it is important to rule out this possibility 
by a suitable experimental approach, e.g. by cell type-specific knock-ins of one of the 
FSGS-assciated TRPC6 mutations in podocytes and endothelial cells, respectively. 
 
III.4.2. Implications of the interaction of TRPC6 with podocin, nephrin 
 
Two key questions arise from the findings that TRPC6 is expressed in podocyte foot 
processes near the slit diaphragm and interacts with the integral slit diaphragm 
proteins nephrin and podocin: first, what is the physiological role of these interactions 
in podocytes? Second, what is the molecular mechanism of TRPC6 malfunction 
leading to the development of FSGS? Addressing these questions is a challenging 
task given the current lack of understanding of FSGS pathogenesis and physiological 
TRPC6 channel function. However, a number of recent advances provide useful hints 
for the development of appropriate hypotheses: 
 
TRPC6 forms a mechanosensor complex together with podocin 
 
A recent report illustrates that podocin and the podocin homologue mec-2, which is 
known to function in mechanosensation in Caenorhabditis elegans [Huang et al., 
1995; O’Hagan et al., 2005], regulate the activity of TRPC6 in a cholesterol-
dependent manner [Huber et al., 2006]. The authors of this study speculate that 
podocin, like mec-2 in the worm, participates in mechanosensation at the glomerular 
filtration barrier in a multiprotein complex containing the transmembrane proteins 
neph1, neph2, nephrin, the cytoplasmic adaptor protein CD2AP, and TRPC6, 
monitoring glomerular pressure or filtration rate. Such a concept would fit well with 
findings derived from the human genetics; as is the case for TRPC6, mutations in the 
NPHS2 gene encoding podocin cause hereditary nephrotic syndrome in humans 
[Boute et al., 2000]. Although TRPC6-associated disease displays a later onset of 
kidney failure and milder symptomps than the podocin disease, the similarity of the 
defects supports the notion that podocin modulates TRPC6 function. 
TRPC6 ASSOCIATION WITH THE GLOMERULAR FILTER  50 
 
Based on the observation that podocin colocalizes with TRPC6, one possibility is that 
podocin may  regulate TRPC6 subcellular localization by acting to recruit TRPC6 to 
the slit diaphragm. The present data shows that TRPC6 was not only detected in 
podocyte foot processes but also in the cell body of podocytes. This is consistent with 
dynamic localization of TRPC6 in podocytes, which can be targeted for membrane 
insertion in a regulated manner. Similar regulatory mechanisms have been described 
for other TRPC channels. For example, TRPC3 insertion into the plasma membrane 
is regulated by VAMP2-dependent exocytosis [Singh et al., 2004]; TRPC5 in 
hippocampal neurons has been shown to be translocated and rapidly inserted into the 
plasma membrane following stimulation of the epidermal growth factor receptor 
(EGFR) [Bezzerides et al., 2004]. TRPC6 has been shown to be inserted into the 
plasma membrane upon G protein-coupled receptor activation in HEK293 cells 
[Cayouette et al., 2004]. According to this model, in order for TRPC6 to reach the slit 
diaphragm in podocyte foot processes, TRPC6 protein has to be transported from the 
cell body to the foot processes. Podocin is a candidate to target TRPC6 to its proper 
place in the plasma membrane. Podocin is present as high-order oligomers in 
erythrocyte lipid rafts where it may serve a scaffolding function, and in podocytes it 
is anchored to the plasma membrane at the insertion site of the slit diaphragm 
[Schwarz et al., 2001]. Moreover, mutations in NPHS2 encoding podocin have been 
shown to disrupt nephrin targeting to lipid raft microdomains [Huber et al., 2003]. 
 
Recent evidence substantiates the concept that TRPC6 and podocin may be part of a 
putative mechanosensor complex at the slit diaphragm. As discussed in more detail in 
Chapter IV, podocytes exhibit contractile responses and have been found to respond 
to both stretch [Endlich & Endlich, 2006] and shear stress [Friedrich et al., 2006]. 
Thus far it remains unclear how podocytes are able to sense mechanical stimuli. The 
idea of a mechanosensor near the slit diaphragm seems probable given that the slit 
diaphragm is subject to mechanical force in a vertical direction from fluid flow across 
the membrane and in a lateral direction from the contact between neighboring 
podocytes As described previously, the work of several groups has suggested that 
podocin participates in mechanosensation at the glomerular filtration barrier [Huang 
et al., 1995; O’Hagan et al., 2005]. Hence, TRPC may be part of this complex 
through its association with podocin. 
 
It has also been suggested that TRP channels can sense mechanical stretch directly, 
i.e. that the channel pore becomes permeable due to conformational changes induced 
by stretch of the plasma membrane [Lin & Corey, 2005; Dietrich et al., 2006]. 
Examples thereof are TRPM3 [Grimm et al., 2003], TRPM7 [Oancea et al., 2006], 
TRPP1 and TRPP2 [Nauli & Zhou, 2004; Praetorius & Spring, 2005], as well as 
TRPC1 [Maroto et al., 2005]. TRPC6 has been shown to respond to pressure stimuli 
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in patches even in the presence of phospholipase C blockers, arguing against second-
messenger activation and in favor of direct activation through membrane stretch 
[Spassova et al., 2006]. The authors of this study suggest a common molecular basis 
for lipid-mediated membrane stretch activation and the well-known activation of 
TRPC6 via diacyl-glycerol (DAG) in that in both cases the mechanism underlying 
channel activation is a conformational change rendering TRPC6 channels permeable. 
 
Future studies will have to address the mechanistic relevance of the podocin-TRPC6 
association by providing answers to the following questions: how does podocin 
modulate TRPC6 activity? Does TRPC6 act downstream of podocin as a 
mechanosensor? Can TRPC6 function as a mechanosensor by itself? Eventually, the 
elucidation of the podocin-TRPC6 interplay may help draft a model of the long-
sought mechanosensory complex at the slit diaphragm. 
 
TRPC6 is associated with nephrin-mediated signaling at the slit diaphragm 
 
A number of studies suggest that the slit diaphragm may serve as a platform 
mediating the signals required for sustained podocyte structure and function. The slit 
diaphragm protein nephrin was shown to associate with signaling microdomains, also 
known as lipid rafts [Benzing, 2004]. Nephrin itself appears to be a signaling 
molecule generating podocyte survival signals [Huber & Benzing, 2005], and its 
disruption from the slit diaphragm has been reported in secondary forms of FSGS 
[Schmid et al., 2003]. Tyrosine phosphorylation, a key event in signal transduction, 
has been shown to occur at the slit diaphragm site: the Src protein tyrosine kinase Fyn 
has been shown to bind and phosphorylate nephrin [Verma et al., 2003]. Nephrin 
phosphorylation then induces binding of Nck adapter proteins, which in turn 
reorganizes the actin cytoskeleton [Verma et al., 2006; Tanaka & Sabry, 1995]. Also 
TRPC6 has been shown to also be a target of phosphorylation by Fyn [Hisatsune, 
2004], and phosphorylation by Fyn has been shown to enhance TRPC6 channel 
activity [Shi et al., 2004]. Treatment of cultured podocytes with PAN induces 
structural changes leading to an increased tyrosine phosphorylation [Reiser et al., 
2000], and a recent study demonstrated that treatment of human podocyte cells with 
the plasma of nephrotic patients induced an alteration of intracellular Ca
2+
 signaling 
mediated by tyrosine phosphorylation [Coward et al., 2005].  
 
Given that TRPC6 interacts with nephrin in podocytes (Fig. III.6.), and nephrin 
deficiency has a profound effect on TRPC6 localization in glomeruli (Fig III.7.) this 
suggests that TRPC6 may be assembled in a complex together with nephrin and Fyn 
and that this complex is regulated by tyrosine phosphorylation of nephrin and/or 
TRPC6. TRPC6 as a component or downstream target of such a signaling platform 
could be involved in monitoring the integrity of the slit diaphragm in podocytes. 
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Progressive kidney failure is a genetically and clinically 
heterogeneous group of disorders. Podocyte foot processes 
and the interposed glomerular slit diaphragm are essential 
components of the permeability barrier in the kidney. Mutations 
in genes encoding structural proteins of the podocyte lead to 
the development of proteinuria, resulting in progressive kidney 
failure and focal segmental glomerulosclerosis. Here, we show 
that the canonical transient receptor potential 6 (TRPC6) ion 
channel is expressed in podocytes and is a component of the 
glomerular slit diaphragm. We identified five families with 
autosomal dominant focal segmental glomerulosclerosis in 
which disease segregated with mutations in the gene TRPC6 
on chromosome 11q. Two of the TRPC6 mutants had increased 
current amplitudes. These data show that TRPC6 channel 
activity at the slit diaphragm is essential for proper regulation of 
podocyte structure and function.
Proteinuria is a common feature of kidney dysfunction of glomerular 
origin and is itself a risk factor for both renal and extrarenal disease1. 
The glomerular podocyte is a central component of the renal filtration 
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Figure 1  TRPC6 expression in the kidney 
glomerulus. (a) Confocal microscopy shows 
TRPC6 expression (red) in the glomerulus. 
TRPC6 colocalizes with the podocyte marker 
synaptopodin (green; overlap shown by yellow 
staining). (b) Compared with the TRPC6 antibody 
labeling (green), preabsorption of TRPC6 antibody 
with the control peptide results in negative 
staining. (c) Analysis of TRPC1–TRPC6 mRNA 
expression (lanes 1–6, respectively) in cultured 
podocytes by RT-PCR. TRPC6, TRPC1, TRPC2 
and TRPC5 mRNAs are detected in total podocyte 
RNA (Podo). TRPC3 and TRPC4 mRNAs are 
detected in total glomerular RNA (Glom) but not 
in total podocyte RNA. (d) TRPC6 localizes to the 
cell membrane in cultured podocytes, as shown 
by immunostaining (green). (e) Immunogold 
labeling shows TRPC6 localization in podocyte 
major processes (MP, white arrows) and foot 
processes (FP). TRPC6 in podocyte foot processes 
is located in close vicinity to the slit diaphragm 
(black arrows). GBM, glomerular basement 
membrane. (f) High-power view of slit diaphragm 
areas (arrows) shows heavy TRPC6 immunogold 
labeling.
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barrier2. Podocytes (glomerular visceral epithelial cells) are located in 
the glomerulus. Their complex cytoarchitecture includes cellular exten-
sions (foot processes) that connect to the glomerular basement mem-
brane on the outer aspect of the glomerular capillaries. Together with 
the interposed slit diaphragm, a specialized multiprotein junction, they 
form a crucial component of the ultrafiltration barrier3. This explains 
why structural damage of the podocyte may lead to the development 
of proteinuria. Mutations in ACTN4 (α-actinin-4), NPHS1 (nephrin) 
and NPHS2 (podocin) lead to the development of proteinuric kid-
ney disease4. Winn and colleagues identified a family with autosomal 
dominant focal segmental glomerulosclerosis (FSGS) that segregated 
with a point mutation in the gene TRPC6 on chromosome 11q (ref. 5). 
This prompted us to examine the renal expression and interactions of 
TRPC6 as well as the spectrum and function of TRPC6 genetic variants 
in families with FSGS.
TRPC6 is a member of the transient receptor potential (TRP) 
superfamily of cation-selective ion channels. The TRPC subfamily 
(TRPC1–TRPC7) is a group of calcium-permeable cation channels 
that are important for the increase in intracellular Ca2+ concentra-
tion after the engagement of G protein–coupled receptors and receptor 
tyrosine kinases6. TRPCs form homo- and heterotetramers that can 
interact with a variety of other proteins7. Because all genes previously 
described to be mutated in FSGS and nephrotic syndrome are highly 
expressed in the glomerular podocyte, we examined the expression of 
TRPC6 in the kidney to define its localization. Confocal microscopy of 
adult rat kidney sections showed broad expression of TRPC6 through-
out the kidney in tubules and glomeruli (Fig. 1a). This observation is 
consistent with recent reports detecting TRPC6 mRNA in glomeruli5,8. 
Most TRPC6 expression in the glomerulus was confined to podocytes 
(Fig. 1a), as shown by immunofluorescent double labeling with the 
podocyte marker synaptopodin, resulting in a yellow staining pattern 
(Fig. 1a)9. TRPC6 was also expressed in glomerular endothelial cells. 
Whereas TRPC6 labeling with the antibody to TRPC6 produced strong 
glomerular staining and staining in tubules (Fig. 1b), preincubation of 
TRPC6 antibody with a TRPC6 control peptide resulted in a negative 
signal (Fig. 1b).
Next, we studied the expression of TRPC1–TRPC6 mRNAs in isolated 
glomeruli and cultured mouse podocytes by RT-PCR (Fig. 1c). Whereas 
TRPC1–TRPC6 were all expressed in the glomerulus, only TRPC1, 
TRPC2, TRPC5 and TRPC6 were expressed in cultured podocytes. We 
analyzed TRPC6 expression in a cultured mouse podocyte cell line10 
and detected labeling at the cell membrane (Fig. 1d). To determine the 
precise subcellular localization of TRPC6, we carried out immunogold 
labeling of ultrathin frozen sections from adult kidney cortex (Fig. 1e). 
Gold particles were found in the cell body of podocytes and in primary 
processes (Fig. 1e). In podocyte foot processes, gold particles labeled 
areas in close vicinity to the slit diaphragm region (Fig. 1e). We also 
detected TRPC6 expression in glomerular endothelial cells (Fig. 1e) and 
on a few mesangial cells (data not shown). In order for TRPC6 to reach 
the slit diaphragm in podocyte foot processes, it must be transported 
from the cell body through the major processes into the foot processes. 
Membrane proteins with high protein turnover can be found in various 
subcellular localizations. Similarly, podocalyxin, a major sialoprotein 
in podocytes, is detected intracellularly throughout the entire exocy-
totic pathway, consistent with a high rate of synthesis11. High-power 
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Figure 2  TRPC6 colocalizes and directly interacts 
with slit diaphragm proteins. (a) GFP-TRPC6 
colocalizes with CD2AP, nephrin and podocin 
at the cell membrane of cultured podocytes, as 
shown by confocal microscopy (arrows). (b) GFP-
TRPC6 associates with FLAG-tagged nephrin and 
podocin but not CD2AP in cotransfected HEK293 
cells. GFP-TRPC6 was detected in total cell 
lysate by immunoblotting using an antibody to 
GFP (upper panel). FLAG-tagged fusion proteins 
were immunoprecipitated, eluted and visualized 
with an antibody to FLAG (middle panel). 
Coimmunoprecipitated GFP-TRPC6 was detected 
in eluate fractions (lower panel). FLAG-myopodin 
served as a negative control for TRPC6 binding.  
Apparent molecular weight is shown to the left 
in kDa. (c) Endogenous coimmunoprecipitation 
of TRPC6 with slit diaphragm proteins from 
cultured podocytes. TRPC6 interacts with nephrin 
and podocin but not with CD2AP. Proteins were 
immunoprecipitated with antibody to TRPC6.
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Figure 3 TRPC6 is upregulated in glomeruli of 2-d-old nephrin-deficient 
mice, as shown by fluorescence microscopy. Weak TRPC6 expression was 
detected in glomeruli of 2-d-old wild-type mice (WT; upper panels). TRPC6 
was upregulated in glomeruli of 2-d-old nephrin-deficient mice (KO; lower 
panels). TRPC6 forms aggregates in the glomerulus. Double labeling of 
TRPC6 with the podocyte marker synaptopodin shows the localization of 
TRPC6 in kidney podocytes, resulting in yellow staining.
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magnification of a section through the slit diaphragm area showed that 
TRPC6 was closely associated with the slit diaphragm (Fig. 1f).
Next, we tested whether TRPC6 colocalizes with the human dis-
ease-associated slit diaphragm proteins nephrin, podocin and CD2AP. 
Because available antibodies against TRPC6 and slit diaphragm pro-
teins are all rabbit polyclonal, we transfected cultured podocytes with 
green fluorescent protein (GFP)-tagged TRPC6. Confocal microscopy 
of podocytes transfected with GFP-TRPC6 constructs and stained with 
antibodies against nephrin, podocin and CD2AP (Fig. 2a) showed that 
GFP-TRPC6 was expressed at the podocyte cell membrane and partially 
colocalized with endogenous nephrin, podocin and CD2AP12–14. These 
findings suggest that in podocytes, TRPC6 is at least in part associated 
with the slit diaphragm.
To test whether TRPC6 interacts with nephrin, podocin or CD2AP, 
we carried out coimmunoprecipitation studies (Fig. 2b). We coex-
pressed recombinant mouse GFP-TRPC6 with FLAG-tagged mouse 
nephrin, podocin or CD2AP in human embryonic kidney (HEK293) 
cells. We immunoprecipitated FLAG fusion proteins from cell lysates 
using anti-FLAG-M2 beads and analyzed eluates by immunoblotting 
using antibodies to FLAG and to GFP. To detect the interaction of 
Table 1  Characteristics of TRPC6 mutations
Family Ethnicity Mutation Exon Age at disease
presentation
Number of family members
with ESRD 
Change in
current amplitude
FG-EA African American N143S 2 27–39 5 of 36 No
FG-BN Colombian S270T 2 17–52 3 of 12 No
FS-Z Polish K874X 12 27–57 9 of 53 No
FG-FQ Mexican R895C 13 18–46 6 of 25 Yes
FS-XR Irish and German E897K 13 24–35 2 of 12 Yes
Summary of families and TRPC6 variants identified, including range of ages at disease presentation (in y), number of family members known to have end-stage renal disease 
(ESRD) and indication of whether the variant protein produced an altered current amplitude when expressed in HEK cells. Additional clinical details are given in Supplementary 
Note online.
Figure 4  Pedigrees of families with inherited FSGS. TRPC6 variants segregating in each family are indicated. Genotyped individuals are indicated as carrying 
(+) or not carrying (–) the variant identified in each family. ESRD, end-stage renal disease.
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GFP-TRPC6 with FLAG-tagged nephrin, podocin or CD2AP, we ana-
lyzed eluates with antibody to GFP. Immunoblotting showed that GFP-
TRPC6 was absent from the eluates derived from cells cotransfected 
with FLAG-CD2AP (Fig. 2b). In contrast, GFP-TRPC6 was present in 
eluates derived from cells cotransfected with FLAG-nephrin and FLAG-
podocin, indicating that TRPC6 had a direct biochemical interaction 
with nephrin and podocin but not with CD2AP. We also carried out the 
reverse coimmunoprecipitation, using FLAG-TRPC6 and GFP-tagged 
slit diaphragm fusion proteins (data not shown). These experiments 
yielded identical results. We also carried out endogenous coimmuno-
precipitation using whole cellular extracts from cultured differentiated 
podocytes known to express the vital slit diaphragm components neph-
rin, podocin and CD2AP15. The immunoprecipitation with antibody to 
TRPC6 antibody showed that TRPC6 had an interaction with nephrin 
and podocin but not with CD2AP (Fig. 2c).
Nephrin is a central component of the slit diaphragm, and mice 
deficient in nephrin suffer from proteinuria and partial foot-process 
effacement16,17. We therefore examined the effect of nephrin deficiency 
on the localization of TRPC6 in the glomerulus (Fig. 3). Neonatal wild-
type mice had low levels of expression of glomerular TRPC6 (Fig. 3). 
Some expression was detected in podocytes, as shown by immuno-
fluorescence double labeling with the podocyte marker synaptopodin, 
resulting in a partial yellow overlap (Fig. 3). The targeted deletion of 
nephrin led to an induction of podocyte TRPC6 expression and to 
focal accumulation of TRPC6 (Fig. 3). These data suggest that the lack 
of nephrin induces podocyte TRPC6 expression and leads to altered 
cellular localization of TRPC6.
To explore the role of TRPC6 gene variation in kidney disease, we 
screened probands of 71 pedigrees with familial FSGS for alterations 
in TRPC6 by DNA sequence analysis. Of these 71 families, 43 showed 
evidence of disease in members of multiple generations, and 28 showed 
evidence of disease in two or more members of a single generation. 
Probands of 49% of the families were of western European ancestry; 5% 
were of African ancestry, and 27% described themselves as Hispanic. The 
phenotype in affected members of the largest of these families (FS-Z) 
cosegregated only with chromosome 11q markers (two-point lod score 
examining linkage of affected individuals with the disease-associated 
haplotype equaled 1.8 at θ = 0). We identified different heterozygous 
sequence variants in five unrelated families with adult-onset disease, 
all of which predicted changes in the gene product: N143S, S270T, 
K874X, R895C and E897K (Table 1). We genotyped the relevant vari-
ants in other available family members. In all families, TRPC6 variant 
and disease inheritance followed a pattern of cosegregation (with less 
than complete penetrance). In each family, inheritance was consistent 
with an autosomal dominant pattern (Fig. 4 and Supplementary Note 
online). Each of the observed amino-acid substitutions occurred in evo-
lutionarily highly conserved residues (Supplementary Fig. 1 online). 
Two mutations predict amino-acid substitutions in the N-terminal 
intracellular domain of TRPC6; two predict amino-acid substitutions 
in the C-terminal intracellular domain; and one encodes a premature 
stop codon near the C terminus (Supplementary Fig. 1 online). We 
genotyped 180 control individuals for the disease-associated variants 
but found none of them. None of these substitutions were found in the 
public SNP databases either.
To study whether mutations in TRPC6 affect calcium channel func-
tion, we expressed wild-type or one of the five mutant TRPC6 channels 
in HEK293-M1 cells stably transfected with the Gαq-coupled M1 mus-
carinic receptor. We recorded TRPC6 currents before and after activa-
tion of M1 receptors by carbachol. Currents from N143S, S270T and 
K874X mutant TRPC6 channels did not differ noticeably from those 
from wild-type TRPC6 channels (data not shown). In contrast, currents 
from R895C and E897K mutant channels were significantly larger than 
those from wild-type TRPC6 channels (Fig. 5). Similarly, Winn and 
coworkers identified increased current amplitude with the disease-asso-
ciated TRPC6 P112Q channel5. We also noted subtle differences in the 
rectification of the current-voltage relationship of these two mutants. 
We believe that these changes in rectification result from the increased 
current density rather than directly from structure-related changes 
in channel gating or permeation. If the currents through R895C and 
E897K mutant TRPC6 channels are similarly increased in vivo, these 
mutations could lead to a gain-of-function alteration in activity and, 
thus, increased calcium influx.
Three of the TRPC6 mutations that we identified did not produce 
apparent changes in current amplitude. Nevertheless, we believe that 
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Figure 5  Electrophysiological analysis of mutant 
TRPC6 channels. Representative whole-cell 
currents measured from HEK293-M1 cells 
transiently transfected with cDNA encoding wild-
type (WT) TRPC6 (a) or R895C (b) or E897K (c) 
mutant TRPC6. Current traces were recorded as 
cells were perfused with control bath solution 
(gray traces) or 100 µM carbachol (CCh, black 
traces). Voltage ramps from –100 mV to 100 
mV over 150 ms were applied every 3.45 s from 
a holding potential of 0 mV. Current amplitude 
was normalized for cell capacitance. (d) Average 
normalized current amplitude measured at –100 
mV (dark bars) and 100 mV (light bars) from 
cells expressing wild-type (WT) TRPC6 or R895C 
or E897K mutant TRPC6. Current amplitudes 
from cells expressing R895C and E897K mutant 
channels were significantly higher at both –100 
mV and 100 mV than those from cells expressing 
wild-type channels (*P < 0.01). The number of 
experiments for each is shown in parentheses, 
and the error bars show the s.e.m. for each 
measurement.
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these mutations cause disease because of their nature (substitutions in 
very highly conserved residues or premature stop codon), their cosegre-
gation with the disease phenotype and their absence from control indi-
viduals. This suggests that an abnormality other than increased current 
amplitude is the cause of disease in individuals with these mutations. 
The several possibilities include altered channel regulation (despite nor-
mal amplitude), altered interaction with other slit-diaphragm proteins 
and altered protein turnover.
Mutations in several podocyte genes have been implicated in sus-
ceptibility to progressive renal failure or increased glomerular dis-
ease4. The presence of TRPC6 mutations cosegregating with kidney 
disease; the evolutionary conservation of the altered amino acids, 
slit-diaphragm localization and interactions; and the gain-of-func-
tion changes observed in two mutants suggest that TRPC6 channel 
function is essential for normal renal ultrafiltration. The question 
remains why the onset of kidney disease in individuals with TRPC6 
mutations occurs at a relatively advanced age. Like the adult onset 
and dominantly inherited form of FSGS caused by mutations of the 
widely expressed protein α-actinin-4, gain-of-function mutations of 
TRPC6 might produce subtle changes in intracellular function that 
lead to irreversible alterations of cell behavior only after time and in 
the presence of other renal insults18. In addition, podocytes express 
several other TRPC channels, including TRPC1, TRPC2 and TRPC5 
(Fig. 1b). Partial functional redundancy might also account for the late 
onset of glomerular disease. The ability of TRPC6 to form heterotet-
ramers with other TRPC channels is suggestive of a complex cellular 
regulation of calcium homeostasis.
Podocyte electrophysiology has been under investigation for many 
years19. Published work has been focused on measurements of the 
membrane potential and whole-cell conductance in rodent podocytes 
and their response to vasoactive agonists19. The location of podocytes 
within the glomerulus, surrounding the glomerular capillaries, exposes 
these cells to the transmural hydrostatic pressure driving ultrafiltra-
tion. Podocyte foot processes contain a contractile apparatus that may 
be regulated by slit diaphragm–derived calcium signaling20. Mature 
podocytes express several types of receptors and second messenger 
systems3. These include receptors for muscarine, angiotensin, prosta-
glandin E2 and atrial natriuretic peptide, all of which activate intracel-
lular Ca2+, phospholipase C, inositol 1,4,5-triphosphate, cAMP and 
cGMP signaling cascades. Thus, podocytes may use foot process– and 
slit diaphragm–derived intracellular signals to respond to their cellu-
lar environment. Nephrin itself is a signaling molecule that generates 
podocyte survival signals21. Fyn kinase is associated with nephrin22 and 
regulates TRPC6 channel opening by tyrosine phosphorylation23. The 
disruption of nephrin from the slit diaphragm, as has been reported 
in secondary forms of FSGS24, might mediate its effects on podocytes 
by modulating TRPC6-originated calcium flux. Changes in TRPC6 
calcium currents in podocyte foot processes seem to be central to the 
ability of the podocyte to regulate its intracellular and cytoskeletal 
behavior over its lifetime.
METHODS
Immunohistochemistry and immunoelectron microscopy. We perfused female 
adult Sprague-Dawley rats (body weight = 200 g) through the abdominal aorta 
with 2% paraformaldehyde in phosphate-buffered saline for 3 min at 220 mm 
Hg and then with cryoprotectant sucrose–phosphate-buffered saline solution 
(800 mOsmol) for 5 min at 220 mm Hg. We collected kidneys from wild-type 
and nephrin-deficient mice, snap-froze them in accordance with standard 
protocols, sectioned them in ice-cold acetone and then fixed them with 4% 
formaldehyde. For immunofluorescent labeling, we washed sections once with 
phosphate-buffered saline and incubated them with blocking solution (2% fetal 
calf serum, 2% bovine serum albumin and 0.2% fish gelatin) for 30 min at room 
temperature before further incubation with the primary antibody for 1 h at 
room temperature. For double labeling, we applied a second primary antibody 
for 1 h. We visualized antigen-antibody complexes with secondary antibodies 
conjugated with fluorochromes. We analyzed specimens using a confocal micro-
scope (Zeiss). We incubated immunogold-labeled ultrathin frozen sections of 
perfusion-fixed mouse kidney with the rabbit antibody to TRPC6 (Chemicon) 
and then with gold-labeled secondary antibody to rabbit. We obtained images 
using a Philips CM10 electron microscope.
We used the following antibodies: mouse monoclonal antibody G1 to syn-
aptopodin; rabbit polyclonal antisera to TRPC6 (Chemicon, Sigma, Alomone 
1:50 dilution); and polyclonal antibodies against CD2AP (gift from A. Shaw, 
Washington University), nephrin and podocin (all at 1:200 dilution). As a nega-
tive control, we either omitted the primary antibodies or, in the case of TRPC6 
staining, preincubated the primary antibody with a TRPC6 control peptide for 
1 h before immunolabeling. We analyzed specimens analyzed using a confocal 
microscope (Zeiss). For immunofluorescent labeling of cultured podocytes, we 
processed cells as described before10. We carried out immunofluorescent labeling 
of nephrin-deficient kidneys as described previously17.
Coimmunoprecipitation studies. We expressed recombinant mouse GFP-
TRPC6 with FLAG-tagged mouse CD2AP, nephrin or podocin in HEK293 
cells. We immunoprecipitated FLAG fusion proteins from cell lysates using anti-
FLAG-M2 beads and analyzed eluates by immunoblotting using antibodies to 
FLAG or to GFP (Sigma).
For endogenous coimmunoprecipitation studies, we prepared whole-cell 
extracts from cultured differentiated podocytes and incubated them with 
antibody to TRPC6 overnight. We then incubated the reaction with protein 
G–coupled beads (Sigma) for 2 h. We visualized coimmunoprecipitated protein 
complexes by western blotting using antibodies against TRPC6 (1:300 dilution), 
CD2AP (1:2,000), nephrin (1:300) or podocin (1:1,500). As a negative control, 
we used protein G–coupled beads without antibody.
Cell culture and transfection. We cultured wild-type mouse podocytes as 
described9,25. The GFP-TRPC6 construct, which included the complete mouse 
Trpc6 cDNA, was provided by M. Zhu (Ohio State University, Columbus, Ohio, 
USA). We transfected cultured podocytes using standard protocols.
RT-PCR. We isolated total RNA from cultured mouse podocytes using the Trizol 
reagent (Invitrogen) in accordance with the manufacturer’s instructions. We 
synthesized cDNA using SuperScript II Reverse Transcriptase (Invitrogen) and 
Oligo(dT)12-18 oligonucleotide primers in accordance with the manufacturer’s 
instructions.
Clinical recruitment. We obtained blood from members of families with familial 
FSGS after informed consent was given in accordance with a protocol approved 
by the Institutional Review Board at Brigham and Women’s Hospital. We also 
obtained clinical history and pedigree information for these families. We mea-
sured albumin excretion in urine using a DCA 2000 microalbumin/creatinine 
analyzer (Bayer). We isolated genomic DNA from peripheral blood leukocytes 
using Qiagen columns.
Genotyping. We analyzed DNA from probands from 71 families with familial 
FSGS for mutations in TRPC6 using bidirectional sequencing. We carried out 
sequence analysis using PCR-amplified genomic DNA. We used high-through-
put capillary sequencing instrumentation and Sanger dideoxy DNA sequencing 
to detect mutations. Sequence alterations in probands, family members and con-
trol subjects were verified using MALDI-TOF mass spectrometry (Sequenom)-
based SNP genotyping at the Harvard-Partners Core Genotyping Facility. Primer 
sequences are given in Supplementary Table 1 online.
Sequence alignment. We generated sequence alignments using the T-Coffee 
program comparing human TRPC6 protein sequences to sequences of other 
human TRPC channels (TRPC1 and TRPC3–TRPC7) and of TRPC6 proteins 
in fly (Drosophila melanogaster), rat (Rattus norvegicus), mouse (Mus musculus), 
guinea pig (Cavia porcellus) and chimpanzee (Pan troglodytes)26. We obtained 
protein sequence data from the National Center for Biotechnology Information 
database.
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Site-directed mutagenesis. We used site-directed mutagenesis to insert the 
variants identified into a full-length human TRPC6 cDNA clone (pcDNA3.1-
TRPC6). We designed two mutagenic oligonucleotide primers containing the 
desired mutation and flanked by unmodified nucleotide sequence. We car-
ried out mutagenesis with an amplification reaction using the TRPC6 cDNA 
template, mutagenic primers and Pfu DNA polymerase. We then selected and 
sequenced clones to identify and verify mutants.
Electrophysiological analysis of mutant and wild-type TRPC6. We transiently 
transfected 35-mm dishes of HEK293-M1 cells (human embryonic kidney cells 
stably transfected with the M1 muscarinic receptor) with 2 µg of wild-type or 
mutated TRPC6 cDNA and 0.25 µg of eGFP cDNA using Lipofectamine 2000 
(Invitrogen). We then plated transfected cells on glass coverslips at low density. 
We took recordings from cells 24–72 h after transfection. We maintained cells 
at 37 °C in Dulbecco’s modified Eagle medium and Ham’s F-12 medium (1:1), 
10% fetal bovine serum, 100 U ml–1 penicillin, 100 µg ml–1 streptomycin and 
100 µg ml–1 G-418 in 5% CO2.
We visualized eGFP-positive cells with a fluorescence microscope (Olympus) 
and recorded currents using an Axopatch 200B amplifier and pClamp8 software 
(Axon Instruments). During voltage ramps, we sampled currents at 10 kHz and 
filtered the recordings at 2 kHz. In each experiment, we held the membrane 
potential at either –60 mV or 0 mV (no differences were noted between these 
experiments). We used borosilicate glass pipettes with resistances of 2–4 MΩ 
for recording. The bath solution contained 135 mM NaCl, 5 mM CsCl, 2 mM 
CaCl2, 1 mM MgCl2, 10 mM HEPES buffer and 10 mM glucose (pH 7.4). The 
pipette solution contained 135 mM CsMES, 10 CsCl, 3 mM MgATP, 0.2 mM 
NaGTP, 0.2 mM EGTA, 0.13 mM CaCl2 and 10 HEPES buffer (pH 7.3). Free 
calcium concentration in the pipette solution was ∼100 nM as calculated by 
MaxChelator. We compared average current amplitudes at –100 mV and 100 
mV using the Student’s t-test.
Note: Supplementary information is available on the Nature Genetics website.
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IV. TRPC6 INDUCTION IN ACQUIRED FORMS  
OF PROTEINURIC KIDNEY DISEASE 
 
IV.1.  Rationale 
 
TRPC6 mutations provide important novel clues towards the understanding of 
hereditary forms of proteinuric glomerular disease. For example, the current evidence 
indicates that TRPC6 mutations lead to more active ion channels, indicating that the 
pathological effect of TRPC6 mutations is due to hyperactivity of the channel rather 
that TRPC6 loss-of-function. However, from a global healthcare perspective the 
small number of families with TRPC6 mutations limits the enthusiasm to develop 
TRPC6 antagonists specifically for this type of disease. On the other hand, the 
presence of TRPC6 at the slit diaphragm raises another key question: Is malfunction 
of wild-type TRPC6 a more general cause of glomerular disease – also occuring in 
the far more common acquired forms? Similar to increased channel function due to 
genetic mutation, altered TRPC6 activity may also be observed in acquired forms of 
proteinuric kidney disease and represent a common pathogenic feature in this 
clinically heterogenous class of disorders. Based on this notion, expression levels of 
TRPC6 were explored in human kidney biopsies and in experimental models of 
acquired glomerular failure. Furthermore, the potential consequences of increased 
TRPC6 levels were addressed in a set of mechanistic in vitro and in vivo studies. 
 
IV.2.  Materials and Methods 
 
IV.2.1.  Human kidney biopsies 
 
Glomerular total cDNA samples were obtained from human kidney biopsies and 
renal samples from a tumor-free part of a nephrectomy specimen in a multicenter 
study for renal gene expression analysis (the European Renal cDNA Consortium) 
[Cohen et al., 2002]. Informed consent was obtained according to the respective local 
ethical committee guidelines. Kidney microdissection, RNA quality control by 
microfluid electrophoresis, and reverse transcription were performed in accordance 
with the standard protocols of the European Renal cDNA Consortium. 
Microdissected glomeruli from 34 patients with proteinuric diseases and 8 control 
subjects were analyzed. Patients were stratified according to their histologic diagnosis 
into focal segmental glomerulosclerosis (FSGS; n = 9), minimal change disease 
(MCD; n = 13), and membranous glomerulonephritis (MGN; n = 28). For control 
biopsies, renal tissue was derived from healthy poles of tumor nephrectomies     
(CON; n = 9). 
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IV.2.2.  Quantitative real-time PCR 
 
TRPC6 mRNA levels in human glomerular diseases 
 
Quantitative real-time PCR on glomerular total cDNA samples obtained from human 
kidney biopsies was performed on a Applied Biosystems 7300 Real-Time PCR 
System using heat-activated Amplitaq Gold TaqDNA polymerase (Applied 
Biosystems, Foster City, California, United States). All real-time PCR reagents were 
supplied by Applied Biosystems (Foster City, California, United States). 
Predeveloped TaqMan assay reagent was used for TRPC6 and the internal standard 
18S ribosomal RNA. The primers for human TRPC6 were cDNA-specific and did not 
amplify genomic DNA. PCR conditions were as follows: 2 min at 50 °C, 10 min at 
95 °C, followed by 40 cycles of 15 s at 95 °C, 60 s at 60 °C. Quantification of the 
templates was performed using a standard curve [Giulietti et al., 2001]. Quantities of 
TRPC6 cDNA were normalized against the amount of 18S rRNA. All measurements 
were performed in duplicate, and controls that consisted of ddH2O were negative in 
all runs. Data were given as means ± SD. Statistical analysis was performed by using 
the unpaired t test with the significance level set to P < 0.05. 
 
TRPC6 mRNA levels in puromycine aminonucleoside (PAN)-treated rats 
 
For the assessment of glomerular TRPC6 mRNA levels in PAN-rats, rat glomeruli 
were isolated by standard differential sieve-technique [Shankland et al., 2007] and 
total mRNA was isolated using Trizol reagent (Invitrogen, Carlsbad, California, 
United States). cDNA synthesis was performed with SuperScript II Reverse 
Transcriptase (Invitrogen, Carlsbad, California, United States) using Oligo(dT)12-18 
oligonucleotide primers. Quantitative real-time PCR was performed essentially as 
described above with cDNA-specific primers for rat TRPC6 and rat GAPDH as 
endogenous control. Relative quantities of TRPC6 were normalized against the 
relative quantities of GAPDH. An untreated control sample was used as calibrator 
and its expression level was set to 100%. Fold-expression changes were calculated 
using the comparative threshold (CT) method for relative quantitation with the 
equation 2
-??CT [Livak & Schmittgen, 2001]. All measurements were performed in 
triplicate, and controls that consisted of ddH2O were negative in all runs. Data were 
given as means ± standard deviation (SD). Statistical analysis was performed by 
using the unpaired t test with the significance level set to P < 0.05. 
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IV.2.3.  Immunohistochemistry and Immunocytochemistry 
 
Human glomerular biopsies were fixed in cold acetone and stained with anti-TRPC6 
antibody (Abcam, Cambridge, Massachusetts, United States) and mouse G1 
monoclonal antibody to synaptopodin [Mundel et al., 1997] following standard 
protocols. Immunocytochemistry on cultured podocytes was done on cells that were 
grown on coverslips as described [Reiser et al., 2004]. The podocyte actin 
cytoskeleton was visualized with the Alexa Fluor 594 phalloidin conjugate 
(Molecular Probes, Eugene, Oregon, United States). Renal biopsies from passive 
Heymann nephritis (PHN) rats were fixed in methyl Carnoy’s solution and embedded 
in paraffin. Indirect immunoperoxidase staining [Pippin et al., 2003] was performed 
on 4 ?m sections using TRPC6 primary antibody (omitted in controls). Glomeruli 
were scored from 1 to 4 on the basis of the percentage of positively stained podocytes 
in each glomerulus (0 to 25% positive = 1; 26 to 50% positive = 2; 51 to 75% 
positive = 3; 76 to 100% positive = 4). Scoring values were statistically analyzed by 
one-way ANOVA, and Bonferroni multiple comparison test was performed. At all 
time points, the increase in TRPC6 expression was statistically significant. 
Immunogold and transmission electron microscopy were performed according to 
standard protocols as described previously [Reiser et al., 2005]. 
 
IV.2.4.  Podocyte cell culture 
 
Conditionally immortalized mouse podocyte cell lines were cultured as previously 
described [Mundel et al., 1997]. Podocytes were grown in 75 cm
2
 plastic tissue cell 
culture flasks (Becton Dickinson, Franklin Lakes, New Jersey, United States) in a 
humidified atmosphere and 5% CO2. Cells were maintained under permissive 
conditions at 33 °C in medium containing RPMI-1640, 10% fetal bovine serum,    
100 U/ml penicillin-streptomycin (all from Invitrogen, Carlsbad, California, United 
States), and supplemented with 100 U/ml ?-interferon (Cell Sciences, Canton, 
Massachusetts, United States). Cells were allowed to differentiate by shift to 37 °C 
for growth under non-permissive conditions in medium without ?-interferon. 
 
IV.2.5.  C5b-9 treatment 
 
To determine the expression of TRPC6 in podocytes stimulated with complement in 
vitro, conditionally immortalized mouse podocytes [Mundel et al., 1997] were used. 
All studies were performed between days 15 and 17 of growth-restrictive conditions 
at 37 °C. For induction of sublytic C5b-9 attack, mouse podocytes were stimulated 
with sheep anti-mouse podocyte IgG and complement as described previously [Pippin 
et al., 2003]. In group C6+, podocytes were sensitized with medium that contained 
0.5 mg/ml sheep anti-mouse podocyte IgG at 37 °C for 30 min. Sensitized podocytes 
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were then exposed to a sublytic amount of complement for 30 min, washed three 
times, and incubated in growth medium for 48 h. In group C6–, which served as 
control, podocytes were sensitized with sheep anti-mouse podocyte IgG and exposed 
to complement that lacked C6 for 30 min. Whole-cell lysates were isolated in RIPA 
buffer, and Western blotting analysis was performed according to standard 
procedures using anti-TRPC6 antibody and monoclonal anti-actin antibody (Sigma, 
Saint Louis, Missouri, United States) as a loading control. 
 
IV.2.6.  Induction of passive Heymann nephritis (PHN) 
 
The passive Heymann nephritis (PHN) model of membranous nephropathy was 
induced in male Sprague-Dawley rats (Simonsen Laboratories, Gilroy, California, 
United States) by intraperitoneal injection (5 ml/kg body weight) of sheep antibody to 
Fx1A [Perkinson et al., 1985]. Rats that received an injection of normal sheep serum 
(5 ml/kg body weight) served as controls for the anti-Fx1A antibody. Control and 
PHN rats were sacrificed at 5, 11, and 28 d (n = 5 for each time point) for renal 
biopsies and glomerular isolation. All animal studies were approved by the 
Subcommittee on Research Animal Care of the Massachusetts General Hospital. 
 
IV.2.7.  Induction of puromycin aminonucleoside (PAN) nephropathy 
 
Rats were obtained from male Sprague-Dawley rats (Simonsen Laboratories, Gilroy, 
California, United States). For studying TRPC6 protein expression in glomeruli, rats 
were given a single injection of puromycin aminonucleoside (PAN; Sigma, Saint 
Louis, Missouri, United States) (50 mg/kg body weight) at day 0. At days 0, 4, 8, and 
28, rats were killed and kidneys were collected. For assessment of TRPC6 mRNA 
levels and PAN-induced albuminuria, rats were given three consecutive injections of 
PAN (50 mg/kg body weight) at days 0, 10, and 20. At days 27 and 34, rats were 
killed and kidney were collected. All animal studies were approved by the 
Subcommittee on Research Animal Care of the Massachusetts General Hospital.  
 
IV.2.8.  Fluo-4 calcium imaging 
 
Cultured differentiated podocytes were treated for 24 h with 10 or 50 ?g/ml 
puromycin aminonucleoside (PAN). Cells then were loaded with the Fluo-4 calcium 
indicator (Invitrogen, Carlsbad, California, United States) in 0.1 mM Ca
2+
 for 1 h. 
Receptor-operated channels were activated by addition of 100 ?M 1-oleoyl-2-acetyl-
sn-glycerol (OAG), followed by changing the extracellular buffer to 2 mM Ca
2+ 
to 
distinguish membrane-associated channel-dependent changes in calcium. 
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IV.2.9.  Cytochalasin D treatment 
 
Cultured differentiated podocytes were treated with cytochalasin D (Sigma, Saint 
Louis, Missouri, United States) as described before [Reiser et al., 2000]. 60 min after 
addition of cytochalasin D, cells were washed twice with PBS. 
 
IV.2.10. GFP-TRPC6 overexpression in vitro 
 
Cultured differentiated podocytes were transiently transfected with GFP-TRPC6 
using Lipofectamine 2000 (Invitrogen, Carlsbad, California, United States). After 
48h, cells were fixed with paraformaldehyde and stained with phalloidin (Invitrogen, 
Carlsbad, California, United States) to visualize the actin-based cytoskeleton. 
IV.2.11. In vivo gene delivery 
 
FLAG-TRPC6 plasmids were introduced into C57BL6 mice (Bar Harbor, Maine, 
United States) using the TransIT In Vivo Gene Delivery System (Mirus Bio, 
Madison, Wisconsin, United States) [Herweijer & Wolff, 2007]. 15 ?g of plasmid 
DNA was mixed with 15 ?l of Mirus polymer solution and 170 ?l of endotoxin-free 
H2O. It then was topped with 1.8 ml of Mirus delivery solution before injection 
through tail vein. All animal studies were approved by the Subcommittee on 
Research Animal Care of the Massachusetts General Hospital. For measuring 
luciferase activity, mice were gene-delivered with 10 ?g of pGL3 luciferase reporter 
plasmid (Promega, Madison, Wisconsin, United States). Kidneys from 5 mice were 
harvested 12 h after gene delivery, and luciferase activity was assayed using the 
Luciferase Assay System (Promega, Madison, Wisconsin, United States). Kidneys 
from 7 uninjected control mice were also tested. Light intensity was measured on a 
SpectraMax M5 plate reader luminometer (Molecular Devices, Sunnyvale, 
California, United States). 
 
IV.2.12. Assessment of proteinuria and albuminuria  
 
For assessment of proteinuria in mice, spot urine samples were cleared by 
centrifugation at 3,000 rpm for 5 min at 4 °C. Total urinary protein was determined 
using the Bio-Rad Protein Assay (Bio-Rad, Hercules, California, United States) 
according to the method of Bradford [Bradford, 1976]. 2 ?L of pre-cleared urine was 
mixed with 200 ?L of 1x dye solution. After incubation at room temperature for        
5 min, the absorbance at a wavelength of 585 nm was measured using a SpectraMax 
M2
e
 plate reader spectrophotometer (Molecular Devices, Sunnyvale, California, 
United States). A standard curve was obtained by measuring serial dilutions of bovine 
serum albumin (Bio-Rad, Hercules, California, United States). Albuminuria in PAN-
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treated rats was assessed by collection of urine from each animal for 24 h in 
metabolic cages (Nalgene, Rochester, New York, United States) and measurement of 
the albumin concentration by ELISA using the Neph-Rat Kit (Exocell, Philadelphia, 
Pennsylvania, United States). For verification of efficiency of anti-Fx1A injection in 
passive Heymann nephritis (PHN) rats, urinary protein was determined using the 
sulfosalicylic acid method before control and PHN rats were killed [Shankland et al., 
1996] (data not shown). 
 
IV.3.  Results 
 
IV.3.1. TRPC6 induction in human acquired glomerular diseases 
 
Elevated TRPC6 mRNA expression in human acquired glomerular diseases 
 
TRPC6 mRNA expression was analyzed in isolated glomeruli from patients with 
focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and 
membranous glomerulonephritis (MGN) (Fig. IV.1.). Control samples were obtained 
from the healthy kidney poles of individuals who underwent tumor nephrectomies. 
By real-time quantitative PCR, the ratio of TRPC6 mRNA to 18S ribosomal RNA 
was determined. Levels of TRPC6 mRNA were significantly increased in patients 
with MCD (n = 13; P = 0.006) and MGN (n = 28; P = 0.024) as compared with 
control patients (n = 9). In patients with FSGS (n = 9), the increase in TRPC6 mRNA 
did not reach statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. IV.1. TRPC6 mRNA expression in 
human acquired glomerular diseases. The 
ratio of human TRPC6 mRNA versus 18S 
ribosomal RNA (18S rRNA) was determined by 
quantitative real-time PCR. Compared with 
control kidneys (CON; n = 9), TRPC6 mRNA 
was statistically significantly upregulated in 
kidneys from patients with minimal change 
disease (MCD; **P = 0.0063; n = 13) and with 
membranous glomerulonephritis (MGN; *P = 
0.0238; n = 28). In kidneys from patients with 
FSGS (n = 9), the increase in TRPC6 mRNA 
did not reach statistical significance. 
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TRPC6 protein expression in human acquired glomerular diseases 
 
To determine the spatial distribution of TRPC6 protein, immunostaining of TRPC6 
was performed on human kidney biopsies of normal tissue and of glomeruli from 
FSGS, MCD, and MGN kidneys (Fig. IV.2.). In control glomeruli, TRPC6 labeling 
was found throughout the glomerulus and in particular at the outer aspects of 
capillary loops; double labeling with synaptopodin showed that glomerular TRPC6 
was localized in podocytes represented by yellow overlap (Fig. IV.2., CON). In 
FSGS, TRPC6 staining appeared clustered and aggregated as well as segmentally 
more intense (Fig. IV.2., FSGS). TRPC6 staining in MCD displayed a similar pattern 
as FSGS but with less intensity (Fig. IV.2., MCD). In MGN, glomerular TRPC6 
expression was granular and particularly intense in podocytes (Fig. IV.2., MGN). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV.3.2. TRPC6 induction in the C5b-9 cell culture model of membranous 
disease 
 
The described TRPC6 mRNA and protein studies suggested that TRPC6 expression 
was highest in MGN. This is of particular significance given that membranous 
nephropathy is the most common cause of idiopathic nephrotic syndrome in white 
adults, accounting for about one fifth of cases [Ronco & Debiec, 2006]. In about 40% 
of patients, membranous nephropathy leads to end-stage renal disease (ESRD) after 
Fig. IV.2. TRPC6 protein expression in human acquired glomerular diseases. Kidneys were 
examined by indirect immunofluorescence using a primary antibody against TRPC6. Double labeling 
with the podocyte marker synaptopodin led to a yellow overlap (merge). In FSGS and MCD kidneys, 
TRPC6 staining was induced and appeared clustered. TRPC6 intensity was stronger in FSGS than in 
MCD. TRPC6 staining was strongest and appeared granulated in glomeruli during MGN. 
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10 years [Wasserstein, 1997; Glassock, 2004]. Eighty percent of cases are classified 
as idiopathic, which reflects the current lack of knowledge with respect to the 
pathogenic mechanisms behind membranous disease. There is currently no effective 
treatment option available, and the appropriate treatment of membranous disease 
remains a subject of continuing debate [Glassock, 2004]. In membranous 
nephropathy, subepithelial immune deposits form in situ as a result of circulating 
antibodies against one or several antigens that remain yet to be identified in the 
human [Imai et al., 1997]. Hand in hand with the formation of immune deposits goes 
activation of complement leading to assembly of C5b-9 membrane attack complexes 
on podocyte plasma membranes. This represents the main culprit for sublethal 
podocyte injury and the onset of proteinuria [Pippin et al., 2003]. It has also been 
reported that the damage of podocytes mediated by complement C5b-9 complex is 
associated with an activation of (the TRPC6-associated) phospholipase C, and an 
increase in intracellular calcium [Cybulsky et al., 1990]. 
 
Since immunfluorescence studies do not allow quantitative measurements of TRPC6 
protein in podocytes, TRPC6 expression was examined in a well-established in vitro 
model of membranous disease. In this model, cultured differentiated mouse 
podocytes were exposed to anti-podocyte antibody [Ronco & Debiec, 2006] and 
serum with or without complement as a model to mimic the effects of the 
complement system in membranous glomerular disease [Cybulsky et al., 2005]. 
Western blotting of TRPC6 in treated cells showed significantly increased TRPC6 
expression in cells that were stimulated with C6+ serum when compared to cells that 
were stimulated by C6– serum lacking functional complement (n = 3, P < 0.05;     
Fig. IV.3.). The finding that TRPC6 expression is elevated in the C5b-9 model is 
consistent with the in vivo data from human biopsies and establishes a useful in vitro 
model for studying TRPC6 in membranous disease. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. IV.3. TRPC6 levels are increased in the C5b-9 in vitro model of membranous disease. (Left) 
Cultured differentiated podocytes were stimulated with antipodocyte antibody and C6- or C6+ serum. 
Western blotting shows that the expression of TRPC6 increased in cells that were stimulated with 
C6+ serum when compared with cells that were stimulated by C6- serum. (Right) Densitometric 
analysis of three Western blots revealed a significant increase of TRPC6 in podocytes that were 
stimulated with C6+ serum compared with C6- serum (P < 0.05). 
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IV.3.3. TRPC6 induction in two animal models of acquired glomerular 
disease 
 
TRPC6 induction in the passive Heymann nephritis (PHN) rat 
 
To establish wheater glomerular injury by C5b-9 could also induce podocyte TRPC6 
expression in vivo, the passive Heymann nephritis (PHN) model of membranous 
nephropathy was used [Perkinson et al., 1985]. In the PHN model, rats are 
administered an injection of anti-Fx1A antibody, which induces the formation of 
subepithelial immune deposits. This in turn causes the activation of the C5b-9 
membrane attack complex of complement and the subsequent development of severe 
proteinuria. Sprague-Dawley rats that received an injection of normal sheep serum 
served as controls for anti-Fx1A. Control and PHN rats were sacrificed at 5, 11, and 
28 d (n = 5 for each time point) for immunohistochemical analysis of glomeruli. 
TRPC6 protein expression was strongly induced in glomeruli in rats with PHN    
(Fig. IV.4.). While induced TRPC6 staining was observed predominantly along 
capillary loops resembling a podocyte staining pattern, expression was also detected 
in glomerular endothelial cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRPC6 induction in rats treated with puromycin aminonucleoside (PAN) 
 
TRPC6 expression levels were also explored in the puromycin aminonucleoside 
(PAN) rat model of podocyte injury and nephrotic syndrome [Kim et al., 2001]. 
TRPC6 levels were significantly induced in the glomeruli of PAN-injected rats          
Fig. IV.4. TRPC6 levels are increased in the passive Heymann nephritis (PHN) in vivo model of 
membranous disease. (Left) Immunostaining for TRPC6 shows increased glomerular TRPC6 
expression levels at days 5, 11, and 28. While TRPC6 expression predominantly followed a podocyte 
staining pattern, few endothelial also were positively stained. (Right) Semiquantitative scoring of 
glomerular TRPC6 immunostaining (score from 1 to 4) of the percentage of positively stained 
podocytes. Scoring values were statistically analyzed by one-way ANOVA. At all time points, the 
increase in TRPC6 expression was statistically significant. 
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4 d after treatment at the peak of PAN-mediated injury (Fig. IV.5., a). Induced 
TRPC6 protein was detected mainly in podocytes as shown by double labeling with 
the podocyte marker synaptopodin. Eight days after PAN treatment, TRPC6 
expression levels were still elevated. Twenty-eight days after PAN treatment, which 
is the timepoint representing recovery from PAN-mediated injury, TRPC6 expression 
levels had returned to baseline. By quantitative real-time PCR, an upregulation of 
TRPC6 mRNA in rats was detected upon PAN-mediated injury (Fig. IV.5., b). This 
correlated with the development of albuminuria (Fig. IV.5., c). Consistent with a role 
of TRPC6 in the establishement or progression of acquired glomerular kidney 
disease, TRPC6 induction accompanied proteinuria in the PAN rat. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. IV.5. TRPC6 levels are induced in podocytes in vivo after treatment of rats with puromycin 
aminonucleoside (PAN). (a) Frozen rat kidney sections were immunostained using antibodies that 
were specific for TRPC6 and the podocyte marker synaptopodin. When primary antibodies were 
omitted in the staining procedure (2nd ab), a background signal for TRPC6 in tubules but no signal in 
glomeruli and no signal for synaptopodin was detected. In the glomeruli of untreated rats (PAN day 
0), TRPC6 was expressed predominantly in podocytes as shown by a partial overlap with 
synaptopodin. Four days after PAN treatment, in the peak phase of PAN-induced stress, TRPC6 
expression was induced dramatically in podocytes. Eight days after PAN treatment, TRPC6 levels 
still seemed to be elevated, and 28 d after PAN treatment (= recovery) TRPC6 expression returns to 
baseline levels. (b) Rats were injected with 3 consecutive doses of PAN. Two weeks after the third 
injection, TRPC6 mRNA levels were 4.9-fold elevated in glomeruli (P < 0.01). (c) One week after 
the third injection, albuminuria was determined to be 519 mg/24 h (P < 0.001). Two weeks after the 
third injection, the average amount was determined to be 2,009 mg/24 h (P < 0.001). 
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IV.3.4. OAG-induced Ca
2+ 
influx upon PAN-mediated podocyte injury 
 
In an effort to elucidate the consequence of elevated TRPC6 expression in injured 
podocytes, calcium influx in cultured podocytes after PAN-treatment was studied 
(Fig. IV.6.). Twenty-four hours after the application of PAN on cultured podocytes, 
receptor-operated calcium channels were activated by addition of the diacylglycerol 
analog 1-oleoyl-2-acetyl-sn-glycerol (OAG). In PAN-treated podocytes, an elevated 
calcium influx was observed compared to untreated control cells, suggesting that 
increased calcium influx is a component of PAN-mediated podocyte injury.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV.3.5.  Rapid-onset proteinuria after TRPC6 overexpression in vivo 
 
The data from the human biopsies and the experimental models suggested a link 
between TRPC6 expression level and glomerular injury. To determine if TRPC6 
overexpression is sufficient to cause disease, an in vivo hydrodynamic gene delivery 
approach was used to induce transient overexpression of TRPC6 in mice. Urinary 
protein excretion was measured as a marker for glomerular injury. 
 
In recent years hydrodynamic gene delivery via injection into the tail vein has been 
established as a novel method for transient gene transfer into small rodents such as 
mice and rats [Herweijer & Wolff, 2007]. Hydrodynamic delivery of plasmid DNA 
expression vectors allows for a broad range of in vivo experiments, including the 
testing of regulatory elements, antibody generation, evaluation of gene therapy 
approaches, basic biology, and disease model creation [Hodges & Scheule, 2003].   
 
Fig. IV.6. Increased Ca
2+
 levels in cultured podocytes after treatment with 
puromycin aminonucleoside (PAN). Cultured differentiated podocytes were 
treated for 24 h with 10 or 50 ?g/ml PAN. Cells then were loaded with Fluo-4 in 
0.1 mM Ca2+ for 1 h. Receptor-operated channels were activated by addition of 100 
?M OAG followed by changing the extracellular buffer to 2 mM Ca2+ to 
distinguish membrane-associated channel-dependent changes in calcium. 
Differences were statistically significant at the time points indicated (P < 0.05). 
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The current understanding of the mechanism of hydrodynamic gene delivery is that 
upon rapid injection of a solution into the tail vein, fluids enter the vena cava where 
the fluids back up, as the large volume cannot be pumped rapidly enough through the 
heart. This creates increased pressure in the vena cava and pushes the plasmid DNA 
solution into draining vasculature, in particular the large hepatic vein. There, the fluid 
is forced out of the capillaries into the tissue and the nucleic acids (or other 
compounds present in the solution) enter into the parenchymal cells. Although 
nucleic acid uptake and expression has been measured in all major organs, the 
majority (> 90%) is found in the liver. Two anatomic features account for this; first, 
the liver has larger access vessels to the vena cava than other organs, absorbing the 
bulk of the injected plasmid DNA solution; second, liver vessels contain a higher 
number of large pores allowing for easier fluid/plasmid DNA extravasation. 
 
It is conceivable that podocytes are particularly susceptible target cells for gene 
delivery by tail vein injection because of their exposed location in close contact to the 
glomerular blood vessels. For example, it was previosuly shown that gene delivery of 
a plasmid DNA encoding the calcium-dependend serine protease Furin lead to strong 
expression of Furin in podocytes  [Mayer et al., 2003]. 
 
To study the phenotype of mice after overexpression of wild-type TRPC6 in 
podocytes, wild-type FLAG-tagged TRPC6 was transiently overexpressed in mouse 
kidneys using a gene delivery approach. FLAG-TRPC6 was often detected in 
podocyte foot processes in close proximity to the slit diaphragm 12 h after injection 
(Fig. IV.7., a). When mice were administered an injection of the pGL3 luciferase 
reporter vector, luciferase activity was detected in whole-kidney homogenates 12 h 
after injection (Fig. IV.7., b). Mice that were administered an injection of FLAG-
TRPC6 displayed transient proteinuria 15 h after injection (Fig. IV.7., c). These data 
demonstrate that transient TRPC6 overexpression in mice was sufficient to cause 
proteinuria. 
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IV.3.6. Effects of TRPC6 overexpression on the podocyte actin 
cytoskeleton 
 
Podocytes possess a highly dynamic cytoskeletal architecture involving microtubules, 
intermediate filaments, and actin microfilaments [Ichimura et al., 2007]. This 
architecture provides the mechanical stability for podocytes to resist the high 
intraluminal hydrostatic pressure driving ultrafiltration. Perturbation of the 
cytoskeletal architecture plays a major role during podocyte injury and foot process 
effacement [Pavenstadt et al., 2003]. Therefore, it was hypothesized that TRPC6 may 
exert its biological effects in podocytes through a similar mechanism. This would be 
in line with reports suggesting a functional interplay between TRP channels and the 
actin cytoskeleton. [Arikawa et al., 1990; Smith et al., 1991; Monk et al., 1996; 
Montell, 1997; Wyszynski et al., 1997]. 
 
Effect of cytochalasin D on TRPC6 localization in podocytes 
 
It was tested whether disruption of the actin cytoskeleton in cultured podocytes with 
cytochalasin D affects the localization of TRPC6. Cytochalasin D disrupts actin 
filaments and inhibits actin polymerization [Schliwa, 1982]. After depolymerization 
of F-actin in cultured podocytes using cytochalasin D [Reiser et al., 2000], TRPC6 
Fig. IV.7. TRPC6 in vivo gene delivery leads to transient overexpression of exogenous TRPC6 
in podocytes and is associated with the development of proteinuria. (a) A construct coding for a 
FLAG-TRPC6 fusion protein was gene-delivered into mice via tail vein injection. Twelve hours after 
gene transfer, mouse kidneys were processed for immunogold analysis with anti-FLAG antibody. 
Immunogold labeling of FLAG-TRPC6 was detected in podocyte foot processes in close vicinity of 
the slit diaphragm. (b) Gene delivery of the pGL3 luciferase reporter vector led to the detection of 
luciferase activity in kidneys 12 h after gene transfer (P = 0.0158). (c) FLAG-TRPC6 was gene-
delivered into mice and proteinuria was assessed by Bradford assay. Before gene delivery, baseline 
urine protein excretion averaged to 0.23 mg/ml. Fifteen hours after gene delivery, mice developed 
proteinuria with an average urine protein excretion of 0.63 mg/ml (P = 0.0275). 
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appeared to be internalized and was closely associated with depolymerized clusters of 
actin (Fig. IV.8.). Upon removal of cytochalasin D, TRPC6 relocalized to the plasma 
membranel, indicating that TRPC6 subcellular distribution could be governed by the 
cytoskeleton. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRPC6 overexpression in vitro leads to disruption of the podocyte actin cytoskeleton 
 
To study whether TRPC6 overexpression affects the actin cytoskeleton directly, we 
transiently overexpressed green fluorescence protein (GFP)-tagged TRPC6 [Reiser et 
al., 2005] in cultured podocytes. Cells that expressed GFP-TRPC6 displayed a 
marked loss of actin stress fibers (Fig. IV.9.) when compared to untransfected control 
cells. Transfection of empty GFP vector had no effect on the podocyte actin 
cytoskeleton, nor did transfection of GFP-tagged TRPC5. These studies suggest that 
induction of TRPC6 channel could result in pathology by affecing cytoskeletal 
organization. 
 
 
 
 
 
 
 
Fig. IV.8. Effect of cytochalasin D treatment on TRPC6 
subcellular localization. Six hours after cytochalasin D 
incubation, TRPC6 localized with depolymerized actin clusters 
within the cell body (top right). Thirty minutes after washout of 
cytochalasin (partial recovery), TRPC6 started to redistribute 
within the cell (bottom left). Sixty minutes after washout (full 
recovery), most of TRPC6 was relocalized at the cell membrane 
(bottom right, arrows). 
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IV.4.  Discussion 
 
IV.4.1. Dual role for TRPC6 in genetic and acquired forms of proteinuric 
kidney disease 
 
The presented studies show that TRPC6 was induced in a subset of acquired human 
proteinuric kidney diseases. This was also the case in experimental in vitro and in 
vivo models of acquired glomerular disease. These results are consistent with 
hyperactivity of mutated TRPC6 channels in genetic FSGS. Taken together, these 
data indicate that TRPC6 plays a pivotal role in both, genetic and non-genetic forms 
of glomerular disease. TRPC6 is therefore the first known example of a protein 
involved in both, genetic and acquired forms of glomerular kidney disease. Whereas 
in TRPC6-related FSGS TRPC6 hyperactivity or misregulation is due to genetic 
mutation leading to podocyte damage, in acquired forms of proteinuric diseases 
perturbed podocyte function appears to be a consequence of wild-type TRPC6 protein 
induction, due to increased TRPC6 transcription or altered protein turn-over. Based 
on the data presented, a putative mechanism for TRPC6 regulation of podocytes 
could include modulation of calcium signaling and/or modification of the actin 
cytoskeleton. To test this hypothesis, TRPC6 loss-of-function studies in podocytes 
are the next step. These could involve TRPC6 knock-down in podocytes, or the use of 
a published dominant-negative variant of TRPC6 [Hofmann et al., 2002]. 
 
Of particular significance is the induction of TRPC6 in membranous disease. The 
presented data show that TRPC6 mRNA levels were significantly elevated in 
glomeruli from patients with membranous glomerulonephritis (MGN). The 
assessment of TRPC6 localization in glomeruli from patients with MGN by 
immunostaining revealed strong expression of TRPC6 in podocytes and the formation 
of aggregates. Furthermore, induction of TRPC6 was also observed in the passive 
Heymann nephritis (PHN) in vivo model and the C5b-9 in vitro model of 
membranous disease. These findings open a whole new series of possible 
Fig. IV.9. TRPC6 overexpression leads to the loss of stress fibers in podocytes. Cultured 
podocytes were transfected with a green fluorescence protein (GFP)-TRPC6 fusion protein (green) 
and stained with phalloidin to visualize actin stress fibers. Cells were analyzed by confocal 
microscopy. Cells that were transfected with GFP-TRPC6 show a significant loss of stress fibers and 
exhibit a more cortical actin cytoskeleton than untransfected control cells, or cells that were 
transfected with empty GFP vector. 
TRPC6 INDUCTION IN ACQUIRED PROTEINURIC DISEASE  68 
 
investigations. For example, it will be important to study the mechanism of TRPC6 
regulation by complement, and to investige the downstream effects of elevated 
TRPC6 activity in membranous disease. Notably, among the cellular mechanisms 
leading to proteinuria in membranous nephropathy are cytoskeletal changes similar to 
what is observed upon TRPC6 overexpression [Topham et al., 1999].  
 
IV.4.2. Possible role of TRPC6 in podocytes 
 
TRPC6 as a regulator of the podocyte contractile apparatus 
 
Disruption of the actin cytoskeleton in cultured podocytes led to the delocalization of 
TRPC6 from the plasma membrane and the association of TRPC6 with clusters of 
depolymerized actin. This suggests that TRPC6 channels are associated with the 
podocyte actin cytoskeleton (Fig. IV.8.). In addition, overexpression of a GFP-
TRPC6 fusion protein in cultured podocytes lead to a marked reduction of stress 
fibers and the development of a more cortical actin cytoskeleton (Fig. IV.9.), further 
supporting that there may be a functional link between TRPC6 and the podocyte actin 
cytoskeleton. Together this data point to a regulatory role for TRPC6 with regard to 
the actin cytoskeleton in podocytes. 
 
It has long been hypothesized that podocyte foot processes contain an actin-based 
contractile cytoskeletal network since they contain several proteins of the contractile 
apparatus normally found in muscle [Drenckhahn & Franke, 1988]. Experimental 
evidence that podocytes respond to mechanical stimuli by reorganization of their 
actin cytoskeleton comes from the work of several groups. Interestingly, Endlich et 
al. reported that mechanical stress induced a reversible reorganization of the podocyte 
actin cytoskeleton in a Ca
2+
- and Rho kinase-dependend manner [Endlich et al., 
2001]. These data provided a link between Ca
2+
-signaling and the actin cytoskeleton 
in podocytes. In 2004, it was discovered that human podocytes possess a stretch-
sensitive, calcium-activated K
+
 channel, which in vascular smooth muscle cells 
functions to moderate the degree of membrane depolarization [Kirber et al., 1992]. 
Electrophysiological studies of this channel revealed that its activity was increased 
when suction was applied to the patch pipette, indicating that the channel was stretch-
sensitive. Recently it was also shown that the podocyte actin cytoskeleton is 
reorganized in response to  fluid shear stress in vitro [Friedrich et al., 2006]. Finally, 
mature podocytes express several types of receptors for substances know to be 
involved in the contraction and relaxation of smooth muscle cells [Rebibou et al., 
1992; Mundel et al., 1995; Pavenstadt, 2000]. 
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The podocyte contractile apparatus has been proposed to  render the podocyte capable 
of reacting to changes in glomerular capillary tone and to adjust for the size of the 
filtration surface area [Kriz et al., 1994]. Podocyte hypertrophy has been suggested as 
a major consequence of podocyte (mal)adaption to mechanical strain [Shirato et al., 
1996]. According to this model, podocyte foot process effacement represents an 
adaptive change in cell shape resulting in increased surface area coverage by  
podocytes  [Kriz et al., 1994; Kretzler et al., 1994, Petermann et al., 2005]. 
 
The contractile cyoskeletal network could also equip podocytes to regulate the 
strength of the capillary wall [Kriz et al., 1995]. Such a system could underlie several 
possible regulatory functions. First, varying restoring forces at a given transmural 
pressure difference might result in changes of the filtration surface area. Second, if 
the hydraulic permeability of the GBM were a function of its elastic distension and/or 
compression, then an adjustable system influencing local distension of a large part of 
the GBM would serve to stabilize the hydraulic permeability in the face of changes in 
the wall stress of the glomerulus. 
 
Hints about the functional role of TRPC6 in podocytes may also be derived from 
smooth muscle cells, which share a number of structural and functional properties 
with podocytes, and for which important roles for TRPC6 have been described 
[Dietrich et al., 2006]. In smooth muscle cells, ion channels initiate and regulate 
contraction and tone; apart from voltage-gated calcium channels, non-selective cation 
channels have also been identified as important players in the regulation of vascular 
tone by mediating the entry of cations like calcium, sodium, and magnesium. Several 
studies point to a pivotal role of TRPC6 in vascular and pulmonary smooth muscle 
cells. TRPC6 appears to play a similar function as the ?1-adrenoceptor-activated non-
selective cation channel in vascular smooth muscle cells [Inoue et al., 2001], and the 
vasopressin-, 5-HT-, PDGF-activated cation channel in the aortic smooth muscle cell 
line A7r5 [Jung et al., 2002]. In addition, TRPC6 appears to play a critical role in the 
intravascular pressure-induced depolarization and constriction of small arteries and 
arterioles [Welsh et al., 2002] known as the Bayliss effect. Studies in TRPC6 knock-
out mice reveal a crucial role for TRPC6 in the control of airway and vascular smooth 
muscle contractility [Dietrich et al., 2005; Weissmann et al., 2006]. 
 
TRPC6 as a modulator of the podocyte transcriptional machinery 
 
Calcium responses can be subdivided into short-term, rapid responses that do not 
involve transcriptional changes, and long-term modifications that require changes in 
gene transcription [Berridge et al., 1998]. One or both of these mechanisms may 
occur downstream of TRPC6 activation. 
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It has been shown that sustained increased intracellular calcium can directly affect 
gene transcription. For example, the genes encoding AP-1 transcription factor 
components are calcium-sensitive, and elevation of calcium upregulates their 
transcription [Fantozzi et al., 2003]. AP-1 transcription factors modulate many 
cellular processes including proliferation, migration and apoptosis, and play an 
important regulatory role in podocytes. For example, nephrin signaling has been 
shown to activate AP-1 transcription factors [Huber et al., 2001], and increased AP-1 
binding activity to DNA has been suggested to underlie the induction of endothelin-1 
protein in podocytes in response to protein overload [Morigi et al., 2005].   
 
It was recently reported that TRPC6 is a key component of a Ca
2+
-dependent 
regulatory loop that drives pathologic cardiac remodeling via the calcineurin-NFAT 
pathway [Kuwahara et al., 2006]. Nuclear factor of activated T-cells (NFAT) 
transcription complexes are translocated into the nucleus upon dephosphorylation by 
the phosphatase calcineurin, which is itself activated by calcium signaling pathways. 
The authors demonstrated that calcineurin activation lead to TRPC6 upregulation. 
This is thought to result through direct regulation of the TRPC6 promoter by NFAT. 
Whereas it remains unclear what the implications of a putative NFAT-signaling 
pathway involving TRPC6 could be, an abstract presented at the ASN Renal Week 
2005 [Franz et al., 2005] suggests that calcineurin signaling may also be of 
importance in podocytes: cultured differentiated podocytes express calcineurin, and 
that treatment of podocytes with the calcineurin inhibitor cyclosporine A increased 
the expression of the cytoskeletal regulator synaptopodin [Asanuma et al., 2006]. 
 
Podocyte loss - the ultimate consequence of TRPC6 malfunction? 
 
Alterations in the intracellular calcium concentration may ultimately cause the 
irreversible damage and loss of podocytes (podocytopenia). Differentiated podocytes 
cannot proliferate and there is no known molecular mechanism of podocyte 
regeneration. Consequently, there appears to be no compensatory mechanism for 
podocyte loss. Podocyte depletion inevitably results in decreasing kidney function. 
This is believed to be one of the underlying causes for both disease and age-related 
deterioration of the kidneys [Pagtalunan et al., 1997; Kim et al., 2001; Mundel & 
Shankland, 2002]. Podocyte apoptosis and detachment from the GBM have been 
proposed as putative mechanisms leading to podocyte loss. 
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Firstly, a sustained increase in intracellular calcium has the potential to cause 
podocyte apoptosis due to calcium overload [Shankland, 2006]. This may be caused 
by an ability of TRPC6 to augment the deleterious effects of angiotensin II, an 
activator of G protein-coupled receptors upstream of TRPC6 [Pavenstadt et al., 
2003]. Angiotensin II induces apoptosis in cultured rat podocytes and perhaps TRPC6 
enhances this pathway of programmed cell death [Ding et al., 2002].  
 
Detachment is another mechanism of podocyte loss. Hara and colleagues have shown 
that cells obtained from the urine of patients with various glomerular diseases stained 
positive for the podocyte marker podocalyxin, indicating that podocytes detached 
from the GBM [Hara et al., 2001]. Similar results have been shown in a PAN model 
of podocyte injury in rats [Kim et al., 2001]. While the mechanisms of podocyte 
detachment remain unknown, they are likely to involve the abnormal function of 
integrins [Regele et al., 2000]. Since calcium is a known regulator of integrin 
function, an increase of intracellular calcium mediated by TRPC6 channels may 
interfere with the podocyte ability to adhere to the GBM. This could eventually lead 
to the detachment of podocytes from the GBM. 
 
IV.4.3. Potential of gene delivery to study TRPC6 function and as a 
therapeutic intervention 
 
The ectopic expression of TRPC6 in mice resulted in transient proteinuria, suggesting 
that TRPC6 can drive the manifestation of proteinuric kidney disease. Similar to 
endogenous TRPC6, gene-delivered TRPC6 was expressed in close proximity to the 
slit diaphragm, indicating that the exogenous protein was properly targeted. Whereas 
this observation illustrates the potential of the gene delivery approach to study 
TRPC6 function in vivo, the important question of tissue- or cell-specificity must be 
addressed since hydrodynamic tail vein delivery mainly results in expression in the 
liver and only lower levels of expression (100- to 1000-fold) are found in the spleen, 
heart, kidneys and lungs.  
 
It has been shown that by delivering the plasmid DNA solution directly into vessels 
supplying an organ, it is possible to direct a majority of the expression to that organ. 
For example, Maruyama et al. demonstrated that delivery into the renal vein resulted 
in high reporter gene expression levels in the kidneys [Maruyama et al., 2004; 
Kameda et al., 2004]. While such approaches allow for the testing of expression 
constructs in particular organs, the surgical nature of these delivery approaches 
prevents routine use. Another approach to achieve tissue- or cell type-specific 
expression of the delivered plasmid DNA is the use of target-specific promoters. For 
podocyte-specific gene delivery this option became available with cloning of the 
p2.5P podocin-promoter [Moeller et al., 2002]. Since podocin expression is almost 
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exclusively limited to podocytes, p2.5P enables podocyte-specific targeting [Gawlik 
& Quaggin, 2005]. Given that in the present work, gene delivery was carried out with 
plasmids encoding for TRPC6 under the control of the constitutive cytomegalovirus 
(CMV) promoter, which lead to overexpression of TRPC6 in podocytes but also in 
other cell types in the glomerulus and other organs, it will be important to validate the 
obtained findings by delivering TRPC6 in a podocyte-specific fashion under the 
control of the p2.5P podocin-promoter.  
 
The results of the gene delivery experiments illustrate the potential of the gene 
delivery technique to investigate TRPC6 function in podocytes. In contrast to genetic 
mouse models, whose generation is costly and time-consuming, hydrodynamic gene 
delivery can easily be carried out in high throughput. In addition, an advantage of this 
approach is the flexibility to overcome strain-specific and gene-dosage effects. The 
feasibility of gene-transfer allows to test protein overexpression in different rodent 
strains with the ability to gauge the level of protein expression by varying different 
concentrations of gene-transferred plasmid. It will be interesting to see the effects of 
gene delivery of the FSGS-associated variants of TRPC6, or simultaneous gene 
delivery of TRPC6 with other channel subunits in a podocyte-specific manner. 
 
Another popular application of hydrodynamic gene delivery is the evaluation of gene 
therapy approaches. Gene delivery has been used to test gene therapy approaches for 
genetic and acquired diseases including treatments for diabetic nephropathy [Dai et 
al., 2004] and crescentic glomerulonephritis [Higuchi et al., 2003]. Recent work on 
the GTPase dynamin illustrates the potential of hydrodynamic tail vein delivery as a 
therapeutic intervention [Sever et al., 2007] (appendix): During proteinuric kidney 
disease, induction of a cytoplasmic form of the lysosomal protease cathepsin L leads 
to cleavage of dynamin at an evolutionary conserved site, resulting in reorganization 
of the podocyte actin cytoskeleton and proteinuria. Dynamin mutants that lack the 
cathepsin L site, or render the cathepsin L site inaccessible through dynamin self-
assembly, are resistant to cathepsin L cleavage. When gene-delivered into mice, these 
mutants restored podocyte function and resolve proteinuria. With respect to TRPC6, a 
possible therapeutic approach lies in blocking the hyperactive channel. In light of the 
absence of small molecule inhibitors specifically targeting TRPC6, a gene delivery 
approach involving a dominant-negative TRPC6 pore mutant [Hofmann et al., 2002] 
could be an interesting alternative to block TRPC6 channel activity in vivo. 
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Induction of TRPC6 Channel in Acquired Forms of
Proteinuric Kidney Disease
Clemens C. Mo¨ller,* Changli Wei,* Mehmet M. Altintas,* Jing Li,* Anna Greka,*
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Injury to podocytes and their slit diaphragms typically leads to marked proteinuria. Mutations in the TRPC6 gene that codes
for a slit diaphragm–associated, cation-permeable ion channel have been shown recently to co-segregate with hereditary forms
of progressive kidney failure. Herein is shown that induced expression of wild-type TRPC6 is a common feature of human
proteinuric kidney diseases, with highest induction observed in membranous nephropathy. Cultured podocytes that are
exposed to complement upregulate TRPC6 protein. Stimulation of receptor-operated channels in puromycin aminonucle-
oside–treated podocytes leads to increased calcium influx in a time- and dosage-dependent manner. Mechanistically, it is
shown that TRPC6 is functionally connected to the podocyte actin cytoskeleton, which is rearranged upon overexpression of
TRPC6. Transient in vivo gene delivery of TRPC6 into mice leads to expression of TRPC6 protein at the slit diaphragm and
causes proteinuria. These studies suggest the involvement of TRPC6 in the pathology of nongenetic forms of proteinuric
disease.
J Am Soc Nephrol 18: 29–36, 2007. doi: 10.1681/ASN.2006091010
P odocytes are specialized cells that reside in the kidneyglomerulus and cover the outer surface of the filteringcapillaries (1). Their foot processes form a complex
interdigitating pattern with slits that are bridged by extracellu-
lar protein–protein contacts to form the slit diaphragm (2).
Podocyte foot processes and slit diaphragms contribute to the
formation of the glomerular filter, combining a seal to macro-
molecules with high hydraulic conductivity that is subject to
regulation. These two characteristics both are perturbed in most
glomerular kidney diseases, resulting in a leakage of proteins
into the urine, which may give rise to progressive damage and
decline in GFR (3). Mutations in genes that are specific for
podocyte development and function have taken center stage in
understanding glomerular kidney diseases that cause various
degrees of proteinuria and, potentially, the progression to
ESRD (4).
Recently, a mutation in the cation-permeable ion channel
TRPC6 was identified as a culprit for a familial form of FSGS
(5). Our group subsequently characterized TRPC6 as a compo-
nent of the slit diaphragm, suggesting that it functions as
critical regulator of normal renal function (6).
TRPC6 belongs to the TRP superfamily of ion channel-form-
ing proteins. TRP channel genes encode subunits that form ion
channels in many cell types (7,8). Members of the TRP super-
family have been identified on the basis of amino acid sequence
and structural similarity and are classified into seven subfam-
ilies (9). TRPC6 is a member of the TRPC subfamily and has
been reported to be Ca2 selective. Ca2 entry through other
TRPC channels has been shown to increase cytoplasmic Ca2,
allowing for phosphorylation of signal transduction proteins
and transcription factors or for the regulation of cytoskeletal
dynamics (10). Mutations of TRP proteins produce many renal
diseases, including Mg2 wasting, hypocalcemia, and polycys-
tic kidney diseases (11). The discovery of mutations in the
TRPC6 gene as cause for hereditary FSGS as well as the local-
ization of TRPC6 at the slit diaphragm open a whole series of
questions about the physiologic and pathophysiologic role of
this channel in podocytes. On the basis of our previous findings
in hereditary FSGS, we hypothesized that also in acquired
forms of kidney disease, TRPC6 expression levels and channel
function may contribute to glomerular disease pathogenesis via
a dysregulated Ca2 influx at the slit diaphragm site. In this
article, we provide evidence that, in addition to the effects of
gain-of-function mutations in the TRPC6 gene, elevated levels
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of wild-type TRPC6 protein in acquired glomerular diseases
lead to podocyte dysfunction. We discuss a role of elevated
TRPC6 levels in the reorganization of the podocyte actin cy-
toskeleton and the development of proteinuria.
Materials and Methods
Animals and Treatments
All animal studies were approved by the Subcommittee on Research
Animal Care of the Massachusetts General Hospital. C57BL6 mice were
obtained from Jackson Laboratory (Bar Harbor, ME). The passive Hey-
mann nephritis (PHN) model of experimental membranous nephrop-
athy was induced in male Sprague-Dawley rats (Simonsen Laborato-
ries, Gilroy, CA) by intraperitoneal injection (5 ml/kg body wt) of
sheep antibody to Fx1A (12). Rats that received an injection of normal
sheep serum (5 ml/kg body wt) served as controls for the anti-Fx1A
antibody. Control and PHN rats were killed at 5, 11, and 28 d (n  4 to
5 for each time point) for renal biopsies and glomerular isolation. For
verification of efficiency of anti-Fx1A injection, urine protein excretion
was determined using the sulfosalicylic acid method before control and
PHN rats were killed (13) (data not shown). For assessment of TRPC6
mRNA levels and puromycin aminonucleoside (PAN)-induced albu-
minuria, rats were given three consecutive injections of PAN (50
mg/kg body wt) at days 0, 10, and 20. At days 27 and 34, rats were
killed and kidneys were collected. Glomeruli were isolated using stan-
dard sieve technique. TRPC6 mRNA levels were analyzed by quanti-
tative real-time reverse transcriptase–PCR according to standard pro-
tocols. Albuminuria was assessed by collection of urine from each
animal for 24 h in metabolic cages (Nalgene, Rochester, NY) and
measurement of the albumin concentration by ELISA using the Neph-
Rat Kit (Exocell, Philadelphia, PA). For TRPC6 immunostainings, rats
were given a single injection of PAN (50 mg/kg body wt) at day 0. At
days 0, 4, 8, and 28, rats were killed and kidneys were collected.
Kidneys were processed for immunostaining as described before (6).
Patients
Human kidney biopsies, obtained in a multicenter study for renal
gene expression analysis (the European Renal cDNA Consortium),
were processed as described (14). Informed consent was obtained ac-
cording to the respective local ethical committee guidelines. Histologies
were stratified by the reference pathologists of the European Renal
cDNA Consortium. Predeveloped TaqMan assay reagent was used for
TRPC6 and the internal standard 18S rRNA. Quantification of the given
templates was performed according to the standard curve method. All
measurements were performed in duplicate; controls that consisted of
bi-distilled H2O were negative in all runs. Microdissected glomeruli
from 34 patients with proteinuric diseases and eight control subjects
were analyzed. Patients were stratified according to their histologic
diagnosis into FSGS (n  9), minimal-change disease (MCD; n  13),
and membranous glomerulonephritis (MGN; n  28). For control bi-
opsies, renal tissue was derived from healthy poles of tumor nephrec-
tomies (CON; n  9).
Cell Culture
To determine the expression of TRPC6 in podocytes that were stim-
ulated with complement in vitro, we used conditionally immortalized
mouse podocytes (15). All studies were performed between days 15
and 17 of growth-restrictive conditions. For induction of sublytic C5b-9
attack, mouse podocytes were stimulated with sheep anti-mouse podo-
cyte IgG and complement as described previously (16). In group C6,
podocytes were sensitized with medium that contained 0.5 mg/ml
sheep anti-mouse podocyte IgG at 37°C for 30 min. Sensitized podo-
cytes then were exposed to a sublytic amount of complement for 30
min, washed three times, and then incubated in growth medium for
48 h. In group C6, which served as control for C5b-9–attacked cells,
podocytes were sensitized with sheep anti-mouse podocyte IgG and
exposed to complement that lacked C6 for 30 min. Whole-cell lysates
were isolated in RIPA buffer, and Western blot analysis was performed
according to standard procedures using anti-TRPC6 antibody and anti-
actin antibody as a loading control.
Immunohistochemistry, Immunocytochemistry, and Electron
Microscopy
Human glomerular biopsies were fixed in cold acetone and stained
with anti-TRPC antibody (Abcam, Cambridge, MA) and monoclonal
anti-synaptopodin antibody (15) following standard protocols. Immu-
nocytochemistry on cultured podocytes was done on cells that were
grown on coverslips as described previously (6). Actin cytoskeleton
was visualized with the Alexa Fluor 594 phalloidin conjugate (Molec-
ular Probes, Eugene, OR). Renal biopsies from PHN rats were fixed in
methyl Carnoy’s solution and embedded in paraffin. Indirect immuno-
peroxidase staining (16) was performed on 4-m sections using TRPC6
primary antibody (omitted in controls). Glomeruli were scored from 1
to 4 on the basis of the percentage of positively stained podocytes in
each glomerulus (0 to 25% positive  1; 26 to 50% positive  2; 51 to
75% positive  3; 76 to 100% positive  4). Scoring values were
statistically analyzed by one-way ANOVA, and Bonferroni multiple
comparison test was performed. At all time points, the increase in
TRPC6 expression was statistically significant. Transmission electron
microscopy and immunoelectron microscopy were performed accord-
ing to standard protocols as described previously (6).
Calcium Flux Studies
Differentiated cultured podocytes were treated for 24 h with 10 or 50
g/ml PAN. Cells then were loaded with the Fluo-4 calcium indicator
in 0.1 mM Ca2 for 1 h. Receptor-operated channels were activated by
addition of 100 M 1-oleoyl-2-acetyl-sn-glycerol, followed by changing
the extracellular buffer to 2 mM Ca2 to distinguish membrane-asso-
ciated channel-dependent changes in calcium.
In Vivo Gene Delivery
FLAG-TRPC6 plasmids were introduced into C57BL6 mice using the
TransIT in vivo gene delivery system (Mirus Bio, Madison, WI). In brief,
15 g of plasmid DNAwas mixed with 15 l of Mirus polymer solution
and 170 l of endotoxin-free H2O. It then was topped with 1.8 ml of
Mirus delivery solution before injection through tail vein. Fifteen hours
after gene delivery, proteinuria was assessed by Bradford protein assay
(Bio-Rad, Hercules, CA). Mice that received an injection showed sig-
nificant proteinuria as compared with baseline urine protein excretion
(P  0.0275). For the luciferase activity assay, kidneys were harvested
from eight mice 12 h after gene delivery of 10 g of pGL3 luciferase
reporter plasmid, and luciferase activity was assayed using the Lucif-
erase Assay System (Promega, Madison, WI). We also tested kidneys
from eight control mice that did not receive an injection. Light intensity
was measured on a plate reader luminometer.
Statistical Analyses
Unless stated otherwise, statistical analyses were performed by using
the unpaired t test, and the null hypothesis was rejected at the 0.05
level. Values are presented as means  SD.
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Figure 1. TRPC6 mRNA and protein expression in human glomerular disease. (A) The ratio of human TRPC6 mRNA versus 18S
ribosomal RNA was determined by quantitative real-time reverse transcriptase–PCR. Compared with control kidneys (CON; n 
9), TRPC6 mRNA was statistically significantly upregulated in kidneys from patients with minimal-change disease (MCD;
**P  0.0063; n  13) and with membranous glomerulonephritis (MGN; *P  0.0238; n  28). In kidneys from patients with FSGS
(n  9), the increase in TRPC6 mRNA did not reach statistical significance. (B) Kidneys were examined by indirect immunoflu-
orescence using a primary antibody against TRPC6. Double labeling with the podocyte marker synaptopodin leads to a yellow
overlap (merge). In FSGS and MCD kidneys, TRPC6 staining was induced and appeared clustered. TRPC6 intensity was stronger
in FSGS than in MCD. TRPC6 staining was strongest and appeared granulated in glomeruli during MGN. TRPC6 levels are
increased in models of MGN. (C) Cultured podocytes were differentiated for 15 to 17 d and stimulated with antipodocyte antibody
and C6 or C6 serum. Western blot analysis shows that the expression of TRPC6 increased in cells that were stimulated with
C6 serum when compared with cells that were stimulated by C6 serum (left). Densitometric analysis of three Western blots
revealed a significant increase of TRPC6 in podocytes that were stimulated with C6 serum compared with C6 serum (right;
P  0.05). (D) Immunostaining for TRPC6 shows increased glomerular TRPC6 expression levels at days 5, 11, and 28 of passive
Heymann nephritis (top). Although TRPC6 expression predominantly followed a podocyte staining pattern, few endothelial also
were positively stained. Semiquantitative scoring of glomerular TRPC6 immunostaining (score from 1 to 4) of the percentage of
positively stained podocytes was performed (bottom). Scoring values were statistically analyzed by one-way ANOVA. At all time
points, the increase in TRPC6 expression was statistically significant.
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Figure 2. TRPC6 levels are induced in podocytes in vivo after treatment of rats with puromycin aminonucleoside (PAN). (A)
Frozen rat kidney sections were stained using antibodies that were specific for TRPC6 and the podocyte marker synaptopodin.
When primary antibodies were omitted in the staining procedure (second antibody), we could detect a high background signal
for TRPC6 in tubules but no signal in glomeruli and no signal for synaptopodin. In the glomeruli of untreated rats (PAN day 0),
TRPC6 is expressed predominantly in podocytes as shown by a partial overlap with synaptopodin. Four days after PAN
treatment, in the peak phase of PAN-induced stress, TRPC6 expression is induced dramatically in podocytes. Eight days after
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Results and Discussion
In this study, we first examined the expression of TRPC6 in
nongenetic forms of human proteinuric kidney diseases. We
analyzed TRPC6 mRNA expression in isolated glomeruli from
patients with FSGS, MCD, and MGN (Figure 1A). Control
samples were obtained from the healthy kidney poles of indi-
viduals who underwent tumor nephrectomies. By real-time
quantitative PCR, we determined the ratio of TRPC6 mRNA to
18S ribosomal RNA (17). We found significantly increased lev-
els of TRPC6 mRNA in patients with MCD (n  13, P  0.006)
andMGN (n 28, P 0.024) as compared with control patients
(n  9). In patients with FSGS (n  9), the increase in TRPC6
mRNA did not reach statistical significance. Immunostaining of
TRPC6 was performed on human kidney biopsies of normal
tissue and of glomeruli during FSGS, MCD, and MGN (Figure
1B). In control glomeruli, TRPC6 labeling was found through-
out the glomerulus and in particular at the outer aspects of
capillary loops (Figure 1B, CON). Double labeling with the
podocyte marker synaptopodin showed that glomerular
TRPC6 was localized in podocytes represented by a yellow
overlap (Figure 1B, CON). In FSGS, TRPC6 staining appeared
clustered and aggregated as well as segmentally more intense
(Figure 1B, FSGS). TRPC6 staining in MCD displayed a similar
pattern as FSGS but with less intensity (Figure 1B, MCD). In
MGN, glomerular TRPC6 expression was granular and dramat-
ically induced in podocytes (Figure 1B, MGN).
Given our observation that TRPC6 mRNA and protein were
strongest in MGN, we next exposed cultured differentiated
mouse podocytes to antipodocyte antibody and serum with or
without complement. Treatment of cultured podocytes with
sublytic amounts of C5b-9 mimics the effects of the complement
system as a potent mediator of glomerular injury in membra-
nous glomerular disease. Consequences of sublytic C5b-9 at-
tack include the release of calcium and the activation of signal-
ing pathways in the podocyte (16). Western blot analysis of
TRPC6 in treated cells showed significantly increased TRPC6
expression in cells that were stimulated with C6 serum when
compared with cells that were stimulated by C6 serum that
lacked functional complement (n  3, P  0.05; Figure 1C).
To test the hypothesis that C5b-9 induces podocyte TRPC6
expression in vivo, we used the PHN model of experimental
membranous nephropathy (12). In the PHN model, rats are
administered an injection of anti-Fx1A antibody, inducing for-
mation of subepithelial immune deposits, the activation of the
C5b-9 membrane attack complex of complement, and the de-
velopment of severe proteinuria. Sprague-Dawley rats that re-
ceived an injection of normal sheep serum served as controls
for the anti-Fx1A antibody. Control and PHN rats were killed at
5, 11, and 28 d (n  4 to 5 for each time point) for immunohis-
tochemical analysis of glomeruli. TRPC6 protein expression
was strongly induced in glomeruli in rats with PHN (Figure
1D). While induced TRPC6 staining was observed predomi-
nantly along capillary loops that resembled a podocyte staining
pattern, we also found noticeable expression in glomerular
endothelial cells.
Next, we explored TRPC6 expression levels in the PAN ex-
perimental model of podocyte injury and nephrotic syndrome
(18). TRPC6 levels were induced significantly in the glomeruli
of PAN-injected rats 4 d after treatment at the peak of PAN-
mediated injury (Figure 2A). Induced TRPC6 protein was de-
tected mainly in podocyte as shown by double labeling with the
podocyte marker synaptopodin (Figure 2A). Eight days after
PAN treatment, TRPC6 expression levels still were upregulated
slightly. Twenty-eight days after PAN treatment, which repre-
sents the recovery from PAN-mediated injury, TRPC6 expres-
sion levels returned to baseline (Figure 2A). By real-time quan-
titative PCR, we determined an upregulation of TRPC6 mRNA
levels in rats upon PAN-mediated injury (Figure 2B). The in-
crease in TRPC6 mRNA correlated with the development of
albuminuria in these rats (Figure 2C).
To understand better whether induction of wild-type TRPC6
is associated with changes in intracellular calcium, we exam-
ined the calcium influx in cultured podocytes after injury with
PAN (18) (Figure 2C). Twenty-four hours after the application
of PAN on cultured podocytes, receptor-operated calcium
channels were activated by addition of the diacylglycerol ana-
log 1-oleoyl-2-acetyl-sn-glycerol. We observed elevated calcium
influx in PAN-treated podocytes compared with untreated con-
trol cells, suggesting that increased influx of calcium is a com-
ponent of podocyte injury, possibly mediated by TRPC6 chan-
nels (Figure 2C).
In the next step, we focused on the molecular mechanisms
that may account for the pathogenic effect of induced TRPC6
protein. TRP channels are known to be associated with the actin
cytoskeleton (19), the proper organization of which is essential
for normal podocyte function (20). Therefore, we first tested
whether the disruption of the actin cytoskeleton in cultured
podocytes (15) would affect the localization of TRPC6. After
PAN treatment, TRPC6 levels still seem to be elevated, and 28 d after PAN treatment, which represents the recovery from
PAN-induced stress, TRPC6 expression returns to baseline levels. The upregulation of TRPC6 mRNA in isolated glomeruli
correlates with the development of albuminuria in PAN-treated rats. (B) Rats were administered injections of three consecutive
doses of PAN. Two weeks after the third injection, TRPC6 mRNA levels were 4.9-fold elevated in isolated glomeruli (P  0.01).
(C) Rats were administered injections of three consecutive doses of PAN. One week after the third injection, the average amount
of albumin in the urine was determined to e 519 mg/24 h (P  0.001). Two weeks after the third injection, the average amount
of albumin in the urine was determined to be 2009 mg/24 h (P 0.001). PAN treatment is correlated with increased calcium influx
in cultured podocytes. (D) Differentiated podocytes were treated for 24 h with 10 or 50 g/ml PAN. Cells then were loaded with
Fluo-4 in 0.1 mM Ca2 for 1 h. Receptor-operated channels were activated by addition of 100 M 1-oleoyl-2-acetyl-sn-glycerol,
followed by changing the extracellular buffer to 2 mM Ca2 to distinguish membrane-associated channel-dependent changes in
calcium. Differences in intracellular calcium concentration were statistically significant at the time points indicated. *P  0.05.
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Figure 3. TRPC6 is associated with the podocyte actin cytoskeleton. (A) Effect of cytochalasin D treatment on TRPC6 subcellular
localization. Six hours after cytochalasin D incubation, TRPC6 localizes with depolymerized actin clusters within the cell body (top
right). Thirty minutes after washout of cytochalasin (partial recovery), TRPC6 starts to redistribute within the cell (bottom left).
Sixty minutes after washout (full recovery), most of TRPC6 is re-localized at the cell membrane (bottom right, arrows). (B) TRPC6
overexpression leads to the loss of stress fibers in podocytes. Differentiated podocytes were transfected with a green fluorescence
protein (GFP)-TRPC6 fusion protein (green) and stained with phalloidin to visualize actin stress fibers. Cells were analyzed by
confocal microscopy. Cells that were transfected with GFP-TRPC6 (right) show a significant loss of stress fibers and exhibit a more
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depolymerization of F-actin in cultured podocytes using cy-
tochalasin D (18), we found TRPC6 closely associated with
depolymerized clusters of actin (Figure 3A, top right). The
removal of cytochalasin D allows the reorganization of the actin
cytoskeleton; consequently, TRPC6 started to redistribute to its
original localization at the cell membrane (Figure 3A, bottom).
To study whether TRPC6 overexpression affects the actin
cytoskeleton directly, we overexpressed green fluorescence
protein (GFP)-tagged TRPC6 (6) in cultured differentiated
podocytes (Figure 3B). Cells that expressed GFP-TRPC6 dis-
played loss of actin stress fibers (Figure 3B, right) that normally
are found in untransfected control cells (Figure 3B, left). Trans-
fection of the empty GFP vector had no effect on the podocyte
actin cytoskeleton (Figure 3B, middle). These studies suggest
that TRPC6 is functionally associated with the actin cytoskele-
ton in podocytes and that induction of TRPC6 channel directly
affects cytoskeletal organization in these cells.
If such a functional association of TRPC6 with podocyte actin
cytoskeleton were true, we wondered, then, whether we could
observe a phenotype in mice when overexpressing wild-type
TRPC6 in podocytes. Therefore, we used a transient gene de-
livery approach to deliver wild-type FLAG-tagged TRPC6 in
mouse kidneys (21). With this approach, we found gene-trans-
ferred FLAG-TRPC6 in podocyte foot processes often in close
vicinity to the slit diaphragm 12 h after gene injection (Figure
3C, arrows). When mice were administered an injection of the
pGL3 luciferase reporter vector, we were able to detect lucif-
erase activity in whole-kidney lysates 12 h after gene injection
(Figure 3D). Functionally, mice that were administered an in-
jection of FLAG-TRPC6 displayed transient proteinuria 15 h
after gene injection (Figure 3E).
The discovery that mutations in the TRPC6 gene cause he-
reditary FSGS together with the finding that TRPC6 is a com-
ponent of the slit diaphragm multiprotein complex raises ques-
tions regarding the mechanisms that are involved in the
physiologic and pathophysiologic role of this channel in podo-
cytes. In this study, we provide evidence that, in addition to the
effects of gain-in-function mutations in TRPC6, pathophysi-
ologically elevated expression levels of TRPC6 are detected in
acquired glomerular diseases. Our data in cultured podocytes
suggest that the consequences of elevated TRPC6 include reor-
ganization of the podocyte actin cytoskeleton and altered cal-
cium regulation. Importantly, overexpression of wild-type
TRPC6 seems to be sufficient to cause proteinuria in healthy
mice. Taken together, these data indicate that TRPC6 plays a
pivotal role in nongenetic forms of glomerular disease, suggest-
ing that functional TRPC6 blockade may provide an effective
treatment for genetic and acquired forms of proteinuric kidney
disease, in particular in MGN.
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Kidney	podocytes	and	their	foot	processes	maintain	the	ultrafiltration	barrier	and	prevent	urinary	protein	loss	
(proteinuria).	Here	we	show	that	the	GTPase	dynamin	is	essential	for	podocyte	function.	During	proteinuric	
kidney	disease,	induction	of	cytoplasmic	cathepsin	L	leads	to	cleavage	of	dynamin	at	an	evolutionary	con-
served	site,	resulting	in	reorganization	of	the	podocyte	actin	cytoskeleton	and	proteinuria.	Dynamin	mutants	
that	lack	the	cathepsin	L	site,	or	render	the	cathepsin	L	site	inaccessible	through	dynamin	self-assembly,	are	
resistant	to	cathepsin	L	cleavage.	When	delivered	into	mice,	these	mutants	restored	podocyte	function	and	
resolve	proteinuria.	Our	study	identifies	dynamin	as	a	critical	regulator	of	renal	permselectivity	that	is	specifi-
cally	targeted	by	proteolysis	under	pathological	conditions.
Introduction
In the US alone, kidney diseases affect some 20 million people, 
twice as many as it did 2 decades ago. Renal ultrafiltration occurs 
in glomeruli, specialized structures that ensure permselectivity of 
the kidney filter so that essential plasma proteins are retained in 
the blood. A sign of glomerular dysfunction is the loss of protein 
in the urine (termed proteinuria or nephrotic syndrome if pro-
tein loss exceeds 3.5 g/d). Proteinuria often leads to progressive 
renal failure, eventually requiring dialysis or kidney transplanta-
tion (1). Podocytes are specialized cells within the glomerulus that 
are essential for ultrafiltration (Supplemental Figure 1A; supple-
mental material available online with this article; doi:10.1172/
JCI32022DS1).  Podocytes  form  foot  processes  (FPs),  highly 
dynamic cellular extensions that are connected by slit diaphragms. 
Together with the glomerular basement membrane (GBM) and the 
glomerular endothelial cells, podocytes form a key component of 
the kidney permeability barrier. Most forms of proteinuria are 
characterized by a reduction of podocyte membrane extensions in 
number and size as well as transformation of podocyte FPs into a 
band of cytoplasm (referred to as FP effacement). Familial muta-
tions underlie only a small percentage of kidney diseases (2) and 
therefore do not readily explain the molecular mechanisms under-
lying the far more common acquired causes of FP effacement and 
proteinuria. In this study, we show that dynamin is essential to 
maintain the filtration barrier in kidneys due to a role in regulating 
actin dynamics in podocytes. We further demonstrate that CatL is 
responsible for FP effacement. CatL affects podocyte function by 
cleaving dynamin in the cytoplasm. The cleavage of dynamin by 
CatL is inhibited when dynamin is induced to self-assemble. Gene 
delivery of dynamin mutants that are prone to self-assemble into 
higher-order structures, or that contain a mutated CatL cleavage 
site, can prevent and reverse podocyte FP effacement and protein-
uria in a mouse model of proteinuria.
Results
Cathepsin L is necessary for podocyte FP effacement and proteinuria in 
a mouse model. Cathepsin L (CatL) belongs to a subclass of cyste-
ine proteases termed lysosomal cathepsins, which are involved 
primarily in protein breakdown within the lysosomal compart-
ment. Interestingly, CatL is strongly induced in rodent nephrotic 
podocytes (3). Moreover, earlier studies showed that inhibitors of 
cysteine proteases reduced proteinuria in rats, possibly by inhibit-
ing degradation of the GBM (4). Recently, Goulet and colleagues 
described a novel role for CatL in processing of the CDP/Cux tran-
scription factor in the nucleus during the S phase (5). Together, 
these findings raise many possibilities for the potential site of CatL 
action during the pathogenesis of proteinuria, including the cyto-
plasm. To explore the relevance of CatL in human kidney disease, 
we examined CatL mRNA levels using quantitative real-time PCR 
(rt-PCR) in microdissected glomeruli from patients with acquired 
proteinuric diseases (6). CatL mRNA levels were 2-fold or greater 
in biopsy samples from patients with 3 types of proteinuric kid-
ney diseases — membranous glomerulonephritis, focal segmental 
glomerulosclerosis, and diabetic nephropathy — compared with 
control samples (Figure 1A). Samples from patients with minimal 
change disease, which is characterized by reversible podocyte FP 
effacement, showed only a minor increase. There was also a signifi-
Nonstandard	abbreviations	used: CatL, cathepsin L; FP, foot process; PAN, puro-
mycin aminonucleoside.
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cant increase in staining for CatL in glomeruli of patients with dia-
betic nephropathy (in Figure 1, compare B and C). The glomerulus 
contains 4 major cell types: podocytes, endothelial cells, mesangial 
cells, and cells of the Bowman capsule. CatL was induced in the 
nuclei of glomerular cells, in line with its role in cleaving transcrip-
tion factors (5). There was also a strong increase in CatL within 
cells of the Bowman capsule (Figure 1C, arrowheads) and proxi-
mal tubular cells as shown before in proteinuric states (Figure 1C, 
asterisk; ref. 7). Finally, CatL staining was also elevated in the cyto-
plasm of podocytes (Figure 1C, red arrows).
We next examined whether a similar upregulation of CatL occurs 
in the LPS mouse model of proteinuria (3). Immunocytochemistry 
using anti-CatL antibodies (8, 9) detected weak CatL staining in nor-
mal glomeruli (Figure 1D, left). Glomerular CatL labeling increased 
within 24 hours after a single LPS injection (Figure 1D, middle) 
but not in mice lacking CatL (Figure 1D, right) (10). LPS treatment 
resulted in FP effacement in control mice (Figure 1E, left and middle) 
but not in the LPS-treated CatL–/– mice (Figure 1E, right). Finally, 
urinary protein increased from a baseline level of approximately 0.25 
mg/ml to 1.2 ± 0.15 mg/ml in control mice but remained unchanged 
in LPS-treated CatL–/– mice (0.25 ± 0.11 mg/ml) (Figure 1F). These 
data provide genetic evidence that CatL is essential for proteinuria.
LPS induces expression of cytoplasmic CatL. To investigate how CatL 
triggers proteinuria, we examined its subcellular activity before 
and after LPS treatment in cultured podocytes. Subcellular sites 
of CatL and CatB activity were visualized by a fluorogenic sub-
strate, CV-(FR)2, which emits light upon cleavage by CatL or CatB 
(3). In untreated podocytes, protease activities were restricted to 
lysosomes (Figure 2A, left column). LPS treatment dramatically 
increased protease activity, which now extended outside lysosomes 
into the cytoplasm (Figure 2A, middle column). The vast majority 
of cytoplasmic cathepsin activity after LPS administration could 
be attributed to CatL, since it was sensitive to the CatL inhibitor 
Z-FF-FMK, which does not inhibit CatB (Figure 2A, right col-
umn; notice only perinuclear red staining). In line with the CatL 
activity in the cytoplasm, CatL protein colocalized with the lyso-
some-associated membrane protein LAMP-2 in lysosomes of con-
trol cells (Figure 2B, left column). After LPS treatment, there was 
a dramatic increase in overall CatL staining, some of which was 
present in the cytosol as well as in the nucleus (Figure 2B, right 
column). In addition, induced CatL was detected in LAMP-2–posi-
tive vesicles extending in podocyte processes close to the plasma 
membrane, which likely represent vesicles targeted for secretion 
(Supplemental Figure 1B and ref. 9). The relocalization of CatL 
upon LPS treatment was specific, since other lysosomal proteases 
such as CatB (Figure 2C) and mannosidase α (Supplemental Fig-
ure 1C) colocalized exclusively with LAMP-2 before and after LPS 
treatment. Finally, the presence of CatL in the cytoplasm was not 
due to lysosomal leakage (Supplemental Figure 1D).
The mRNA for CatL contains several AUG codons (Figure 2D). 
After translation from the first AUG, CatL is processed to yield a 
30-kDa lysosomal form, called single-chain CatL (Figure 2D, black 
arrows). However, alternative translation initiation from a down-
stream AUG produces a CatL isoform devoid of the lysosomal 
targeting sequence (called short CatL), which localizes to the cyto-
plasm (Figure 2D, red arrow; ref. 5). To test whether LPS induces 
expression of short CatL, subcellular fractionation experiments 
using cultured podocytes were performed. The particulate fraction 
contains membranes, including lysosomes, whereas the soluble 
fraction represents cytoplasm. GAPDH was used as a marker for 
soluble cytosolic proteins and the efficiency of lysis. As expected, 
lysosomal single-chain CatL (30 kDa) was present in the particulate 
fraction, which also contained LAMP-2, CatB, and mannosidase α 
(Figure 2E, lane 2). LPS treatment for 24 hours led to strong induc-
tion of a 34-kDa short CatL, which was present exclusively in the 
Figure 1
CatL is essential for proteinuric kidney diseases. (A) Quantitative rt-
PCR of microdissected glomeruli from human biopsies of patients with 
acquired proteinuric diseases: minimal change disease (MCD; n = 7), 
membranous glomerulonephritis (MGN; n = 9), focal segmental glo-
merulosclerosis (FSGS; n = 7), and diabetic nephropathy (DN; n = 10). 
**P < 0.01. CON, control (n = 8). (B) CatL labeling of normal human 
kidney. (C) CatL labeling of human kidney with diabetic nephropathy, 
mildly reduced renal function, and nephrotic range proteinuria. (D) 
Immunocytochemistry of mouse glomeruli using monoclonal anti-CatL 
antibody. WT mice received either PBS (WT CON) or LPS (WT LPS). 
LPS was also injected into CatL–/– mice (CatL–/– LPS). Original magni-
fication, ×400 (C and D). (E) Electron micrographs of FPs. (F) Urinary 
protein levels determined using the standard Bradford protein assay. 
Urine was collected immediately before (Baseline) and 48 hours after 
addition of LPS. Each bar represents at least 8 animals.
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cytoplasm (Figure 2E, compare lanes 1 and 3). In contrast, there 
was no significant increase in the amount of the single-chain form, 
LAMP-2, or mannosidase α (Figure 2E, lanes 2 and 4). In addition, 
the soluble fractions were not contaminated with nuclear proteins 
such as the transcription factor Wilms tumor 1 (Supplemental 
Figure 1E), indicating that the soluble short form of CatL did 
not come from the nuclear compartment. Interestingly, addition 
of LPS also induced expression of the 39-kDa pro-CatL, which is 
known to be secreted (Figure 2E and Supplemental Figure 1B). 
The ability of CatL mRNA to allow downstream AUG translation 
and thus generate cytoplasmic CatL was confirmed by transfecting 
CatL–/– fibroblasts with a cDNA in which the first AUG codon had 
been mutagenized (Supplemental Figure 1, F and G; ref. 5).
Loss of dynamin staining in podocytes correlates with the proteinuria and 
is CatL dependent. We next attempted to identify a target of cyto-
plasmic CatL. The computer-based algorithm PEPS (Prediction of 
Endopeptidase Substrates; ref. 11) identified the GTPase dynamin 
as a potential CatL substrate (data not shown). Dynamin is a large 
GTPase essential for the formation of clathrin-coated vesicles at 
the plasma membrane (12), and it has also been implicated in the 
regulation of actin dynamics in certain cell types (13). We first 
examined dynamin distribution in podocytes using immunogold 
EM. Dynamin antigenic sites were detected within the center of 
podocyte FPs (Figure 3A, left, asterisk) and in electron-dense areas 
rich in cortical actin cytoskeleton (Figure 3A, left, a). In addition, 
a high-power view localized dynamin on the cytoplasmic side of 
vesicular structures, which are most likely clathrin-coated pits 
(Figure 3A, right, v). Next, we examined dynamin staining in mice 
before and after LPS treatment. As expected based on the EM data, 
immunocytochemistry in control mice detected dynamin staining 
in glomeruli (Figure 3B, left), in a pattern consistent with podo-
cyte expression. Twenty-four hours after a single LPS injection, 
dynamin labeling in the glomerulus appeared weaker and clus-
tered (Figure 3B, middle panel), but it remained unchanged in 
tubules (data not shown). A similar dynamin staining pattern was 
observed in a rat model for proteinuric kidney disease in which 
animals are  injected with puromycin aminonucleoside (PAN) 
(Supplemental Figure 2A; ref. 14), suggesting that changes in glo-
merular dynamin staining are associated with proteinuria. Impor-
tantly, dynamin staining was preserved in CatL–/– mice treated with 
Figure 2
Induction of cytoplasmic CatL protein and activity by LPS. (A) Cultured podocytes were stained using anti–LAMP-2 antibodies and the BIOMOL 
CV-CatL/B activity detection kit. Control cells, cells treated with 50 μg/ml of LPS for 24 hours, and cells treated with LPS and 1 μM of the selective 
CatL inhibitor Z-FF-FMK are shown. (B) Labeling of cultured podocytes using anti-CatL antibody, untreated or after treatment with 50 μg/ml of 
LPS for 24 hours. (C) Labeling of cultured podocytes using anti-CatB antibody, untreated or after treatment with 50 μg/ml of LPS for 24 hours. 
(D) Schematic of CatL mRNA and resulting proteins. (E) Subcellular fractionation of podocytes in isotonic sucrose prior to and 24 hours after 
LPS treatment. Total proteins from the soluble (S) and the particulate (P) fractions were analyzed by Western blotting.
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LPS (Figure 3B, right). We hypothesize that the alteration of dyna-
min staining in vivo is due to proteolysis by cytoplasmic CatL. To 
investigate this possibility, DNAs encoding for short-form CatL 
or pre-pro-CatL were injected in CatL–/– mice using transient gene 
delivery (15, 16). Both DNA constructs led to glomerular CatL 
expression (Figure 3C, top row). Strikingly, expression of the short 
CatL specifically altered dynamin staining in a manner similar to 
that seen with LPS (Figure 3C, bottom row). Together with the 
fact that dynamin is a substrate of CatL in vitro (see below), these 
data are consistent with dynamin being cleaved by CatL in kidney 
after LPS treatment. Because isolated glomeruli from animals also 
contain other resident cells, we quantified dynamin abundance 
before and after LPS treatment using cultured podocytes. West-
ern blotting of podocyte lysates revealed an approximately 30% 
decrease in the amount of endogenous dynamin after LPS treat-
ment (Figure 3, D and E). Dynamin reduction was CatL depen-
dent, since it did not occur when CatL was downregulated using 
siRNA (Figure 3D and Supplemental Figure 2, B and C). Together, 
these data suggest that the cytoplasmic CatL targets dynamin in 
rodent models of proteinuria.
CatL cleaves dynamin:GTP in vitro and in vivo. If dynamin is a CatL 
target in the cytoplasm, then recombinant dynamin should be 
cleavable by CatL at neutral pH. The PEPS algorithm identified 
a potential  recognition  sequence  (ELSGGA) within dynamin 
between amino acids 354 and 359. Interestingly, the ELSGGA 
motif is highly conserved among several species (Figure 4A). CatL 
did not cause significant cleavage of dynamin at pH 7.0 (Figure 4C, 
compare lanes 1 and 2). Strikingly, addition of GTP resulted in the 
generation of a prominent proteolytic fragment with a molecular 
weight of approximately 40 kDa (p40) (Figure 4C, lane 3). p40 is 
the predicted size of the N-terminal fragment after cleavage at the 
ELSGGA sequence (Figure 4A). Another fragment, p55, is observed 
in the absence of added protease (Figure 4C, lane 1). Thus, p55 
is not a precursor of p40. Furthermore, incubation of dynamin 
with CatB generated p55 in a nucleotide-independent manner 
(Figure 4C, lanes 5–8), whereas the protease furin was unable to 
cleave dynamin (Figure 4C, lanes 9–12). Thus, while p55 is pro-
duced by a number of proteases and thus represents a “hot spot” 
for proteolysis (17), p40 is generated by CatL only when dynamin 
is  in the GTP-bound conformation. Interestingly, addition of 
Figure 3
Altered dynamin staining in glomerulus after LPS treatment is CatL dependent. (A) Immunogold analysis of dynamin in podocyte FPs of rat 
glomerulus. Low-power view (left) depicts dynamin within the center of podocyte FPs (asterisk) as well as in electron-dense areas rich of 
cortical actin (a) (original magnification, ×30,000). High-power view shows gold particles, which are associated with the cytoplasmic side of 
vesicles (v) and with electron-dense actin areas (a) (original magnification, ×45,000). E, endosome; GBM, glomerular basement membrane; 
Ly, lysosome; SD, slit diaphragm; US, urinary space. (B) Immunocytochemistry of dynamin in glomeruli of WT mice before and after injec-
tion of LPS and of CatL–/– mice after injection of LPS. (C) Immunocytochemistry of samples from CatL–/– mice for glomerular dynamin and 
CatL. CatL–/– mice had been reconstituted with either Pre-Pro-CatL (left) or with short CatL (right) using transient gene transfer. Twenty-four 
hours after gene transfer, glomeruli were stained using anti-CatL and anti-dynamin hudy 1 antibody. Original magnification, ×400 (B and 
C). (D) Immunoblot of endogenous dynamin in cultured podocytes in response to LPS. Recombinant dynamin (REC), extracts of WT and 
CatL–/– podocytes, were analyzed. (E) Quantitation of dynamin in cell extracts shown in D. Dynamin signal was adjusted to actin levels.
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GTPϒS (nonhydrolyzable GTP analog) did not stimulate cleavage 
by CatL (Figure 4C, lane 4). These data can be explained in terms 
of dynamin’s oligomerization status. In its basal state, dynamin is 
a homotetramer that can self-associate into rings or spirals when 
bound to GTP (Figure 4B). These higher-order dynamin structures 
exhibit elevated GTPase activity, which in turn drives their disas-
sembly. GTPϒS stabilizes oligomerized dynamin due to inhibition 
of GTP hydrolysis (18). Dynamin oligomerization is mediated by 
the middle and GAP domains of dynamin (19), and based on a 
cryo-EM reconstruction of assembled dynamin (20), amino acids 
ELSGGA (located in the middle domain) are predicted to be inac-
cessible when dynamin is self-assembled (Figure 4B). To test the 
idea that dynamin self-assembly protects against CatL cleavage, we 
performed additional cleavage experiments at an acidic pH where 
CatL is more active. At pH 5.0 and 6.0, CatL was highly reactive 
toward recombinant dynamin, even in the absence of GTP (Fig-
ure 4D, lanes 2 and 4). Strikingly, this proteolysis was inhibited by 
addition of GTPϒS (Figure 4D, lanes 3 and 5). Together, our data 
Figure 4
Effects of the nucleotide-bound and assembly state of dynamin on CatL cleavage in vitro and in vivo. (A) Domain structure of dynamin, correspond-
ing antibodies, and amino acid sequence of predicted CatL cleavage sites. Note that the ELSGGA sequence is a highly conserved motif throughout 
the species. PH, pleckstrin homology domain; PRD, proline-arginine rich domain; Shi, dynamin homolog in Drosophila; Vsp1, dynamin homolog 
in yeast. (B) Schematic depiction of dynamin GTPase cycle. In its basal state, dynamin is a homotetramer. Self-assembly into higher-order struc-
tures such as rings or spirals can be promoted by GTPϒS and activates assembly-mediated GTP hydrolysis, which in turn drives disassembly. 
Dynamin’s middle domain is located inside the spiral. (C) Recombinant dyn1 (20 pmol) (CON) was mixed with CatL (1 pmol) (top panel), CatB 
(middle panel), or Furin (bottom panel). The reactions were performed at pH 7.0 under nonassembly conditions (200 mM NaCl). Where indicated, 
200 μM GTP or 1 mM GTPϒS was present. Proteolytic products were detected by monoclonal anti-dynamin antibody against the GTPase domain. 
(D) Silver staining of recombinant dyn1 incubated with CatL at different pHs in the presence or absence of GTPϒS. (E) Western blot analysis using 
GTPase antibody of podocyte extracts infected with various dynamin mutants before or after addition of 100 μg/ml LPS for 20 hours. Note the 
appearance of a 40-kDa fragment (arrow). When indicated, podocytes were treated with 1 μM of the selective CatL inhibitor Z-FF-FMK for the dura-
tion of the LPS treatment. (F) Western blot analysis of subcellular fractionation of podocytes expressing dynWT for 24 hours after LPS treatment. 
Extracts were blotted using antibodies against the GTPase domain (N-terminal), GAP domain (C-terminal), LAMP-2, and tubulin.
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are consistent with the hypothesis that the primary site recognized 
by CatL is within a domain that becomes inaccessible upon dyna-
min self-assembly.
To further explore CatL-mediated dynamin cleavage, we infected 
cultured podocytes with adenoviruses encoding different dynamin 
mutants (Figure 4A) and subsequently treated them with LPS. As 
expected, addition of LPS to cells expressing dynWT resulted in gen-
eration of p40 (Figure 4E, lane 6), which was inhibited by the addi-
tion of the CatL inhibitor Z-FF-FMK (Figure 4E, lane 5). Impor-
tantly, LPS treatment of podocytes expressing dynK44A (a mutant 
that cannot bind GTP) did not result in detectable levels of p40 
(Figure 4E, lane 7), consistent with our data that in vitro cleavage 
of dynamin by CatL at neutral pH is GTP dependent. To confirm 
the identity of the cleavage site, we created dynL356Q, in which the 
ELSGGA sequence was mutated to EQSVGA. The addition of LPS 
to cultured podocytes overexpressing dynL356Q yielded no p40 (Fig-
ure 4E, lane 9). Finally, we examined a GTPase-defective dynamin 
mutant carrying a mutation in its GAP domain (dynR725A). This 
mutant dynamin oligomerizes, but is impaired in assembly-stimu-
lated GTP hydrolysis (Figure 4B; ref. 19). dynR725A is therefore pre-
dicted to live longer in the assembled state. Consistent with our 
model, LPS treatment of cells expressing dynR725A did not generate 
p40 (Figure 4E, lane 8). To demonstrate that dynamin cleavage by 
CatL occurred in the cytoplasm, we performed subcellular fraction-
ation experiments. Thus, the N-terminal p40 was detected only in 
the supernatant fraction (Figure 4F, left lane, GTPase), whereas 
the C-terminal part of dynamin was found degraded in the pellet 
fraction (Figure 4F, right lane, GAP). Together, these data support 
a model in which CatL specifically targets the GTP-bound form 
of dynamin in the cytoplasm by recognizing an evolutionally con-
served ELSGGA motif and that dynamin self-assembly into higher-
order structures such as rings or spirals prevents CatL cleavage.
To demonstrate that dynamin is cleaved by cytoplasmic CatL 
during proteinuric kidney disease, we looked for p40 in mouse kid-
Figure 5
LPS-induced dynamin cleavage in mouse kidneys. (A–C) Double immunofluorescence of dyn1 (MAB-5402 antibody; red) and the podocyte 
marker synaptopodin (green). Mice were injected with podocin-driven expression vector lacking the dynamin gene (A), CMV-dyn1 expression 
vector (B), and POD-dyn1 expression vector (C). Western blot analysis of total kidney and liver extracts isolated from animals injected with dif-
ferent cDNAs as indicated in the figure. (D) Immunocytochemistry of glomeruli from mice that were injected with LPS. Twenty-four hours after 
LPS injections, animals received cDNA expressing dynWT, dynL356Q, and dynR725A and were sacrificed 14 hours later. Glomeruli were stained using 
monoclonal anti-dynamin hudy 1 antibody. Original magnification, ×400 (A–D). (E) Western blot analysis of kidney extracts after gene delivery 
of different dyn1 cDNAs using the GTPase and CatL antibody before and after addition of LPS.
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ney extracts after LPS treatment. Since the GTPase antibody, which 
recognizes p40, was not sufficiently sensitive to detect endogenous 
dynamin cleavage fragments (data not shown), we used a gene-
delivery protocol to express dynamin in mouse kidneys (15, 16). We 
delivered dyn1 because overexpression of dyn2 sometimes induces 
apoptosis (21). rt-PCR showed that podocytes normally express 
dyn2 (ubiquitous form) and some dyn3 (predominantly expressed 
in testis), but no dyn1 (neuronal isoform; Supplemental Figure 3A). 
Dyn1 was expressed from a CMV promoter (CMV-dyn) or from the 
podocyte-specific podocin promoter (POD-dyn; ref. 22). Gene-
delivered dyn1 was distinguished from endogenous dyn2 using the 
monoclonal dynamin antibody MAB-5402, which predominantly 
recognizes dyn1 (Supplemental Figure 3B). As expected, MAB-5402 
weakly stained control glomeruli (Figure 5A), whereas it strongly 
stained glomeruli 14 hours after delivery of CMV-dyn1 (Figure 5B) 
or POD-dyn1 (Figure 5C). The CMV promoter directed expression 
of dyn1 in the liver and kidney (Figure 5B, Western blot), and dyn1 
was detected in virtually all resident cell types of the glomerulus 
including podocytes, as seen from colocalization with synaptopo-
din (Figure 5B, Merge). In contrast, the podocin promoter directed 
expression exclusively in the kidney (Figure 5C, Western blot), and 
dyn1 localized predominantly in podocytes (Figure 5C, Merge). 
The presence of dyn1 in FPs of podocytes was demonstrated using 
EM (Supplemental Figure 3C). Importantly, LPS treatment led to 
altered staining of gene-delivered dyn1WT in glomeruli, whereas the 
staining of dynL356Q and dynR725A remained unchanged (Figure 5D). 
Moreover, LPS treatment resulted in generation of p40, but only in 
mice expressing dynWT (Figure 5E, lane 2) and not in mice expressing 
dynL356Q and dynR725A (Figure 5E, lanes 4 and 6). Generation of p40 
required the presence of CatL, since it was not detected in CatL–/– 
mice injected with LPS (Supplemental Figure 3D). Western blot-
ting also detected a dynamin fragment of approximately 55 kDa. 
As in cultured podocytes, the presence of this fragment was LPS 
and CatL independent (Figure 5E, lanes 3 and 5, and Supplemen-
tal Figure 3D), supporting the idea that it is generated by other 
proteases during extract preparation. These experiments extend 
our observations in the cultured podocytes and indicate that LPS 
induces CatL-dependent cleavage in live mice.
Dynamin is required for normal glomerular function. The hypothesis 
that cleavage of dynamin by CatL leads to proteinuria implies that 
Figure 6
The effects of dynamin mutants 
on proteinuria and podocyte mor-
phology. (A) Urinary protein levels 
determined using the standard 
Bradford protein assay. Urine was 
collected immediately before (0 h) 
and 14 and 24 hours after injection 
of podocin-driven expression vec-
tors containing different dynamin 
constructs as indicated in the fig-
ure. Each bar represents at least 
10 animals. (B) Cultured podo-
cytes were infected with adeno-
viruses expressing the indicated 
dynamin constructs. Eighteen 
hours after infection, cells were 
stained with hudy 1 (green) to visu-
alize dynamin and rhodamine phal-
loidin (red) to visualize F-actin. (C) 
Urinary protein levels determined 
using the standard Bradford pro-
tein assay. Mice were injected at 
0 and 24 hours with LPS to induce 
proteinuria. At 48 hours (peak 
proteinuria), mice received empty 
vector, CMV-dynWT, CMV-dynL356Q, 
or CMV-dynR725A. Urinary protein 
levels were determined 12 hours 
after injection. Each data point 
represents at least 10 animals. (D) 
Urinary protein levels determined 
using the standard Bradford pro-
tein assay. Mice were injected at 
0 and 24 hours with LPS to induce 
proteinuria. At 48 hours (peak pro-
teinuria), mice received empty vec-
tor, POD-dynWT, POD-dynL356Q, or 
POD-dynR725A. Urinary protein lev-
els were determined 12 hours after 
injection. Each bar represents at 
least 10 animals.
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dynamin is essential for podocyte morphology in healthy kid-
neys. In support of this notion, expression of dominant-negative 
dynK44A in mouse podocytes caused severe proteinuria (Figure 6A 
and Supplemental Table 1) and FP effacement (Supplemental Fig-
ure 4B, 14 hours). Proteinuria and FP effacement were maximum 
14 hours after gene delivery and returned to baseline after loss of 
dynK44A expression (Supplemental Figure 4, A and B, and data not 
shown). Expression of dynWT did not cause changes in FP architec-
ture (data not shown) or significant proteinuria (Figure 6A and 
Supplemental Table 1), demonstrating specificity of the dynK44A 
phenotype. Importantly, expression of p40 also caused proteinuria 
(Figure 6A and Supplemental Table 1), demonstrating that this 
dynamin fragment has dominant-negative characteristics with 
respect to podocyte function.
Since podocyte FP effacement is primarily driven by the rear-
rangement of the actin cytoskeleton (23), we examined actin mor-
phology in cultured podocytes expressing dynK44A and p40. Podo-
cytes were infected using an adenoviral expression system, which 
allows greater than 90% infection efficiency (24). The experiments 
were performed using the neuronal isoform of dyn1 (Figure 6B) as 
well as the ubiquitously expressed dyn2 (Supplemental Figure 5). 
The 2 isoforms yielded identical results, demonstrating that the 
observed phenotypes in podocytes were not isoform specific (com-
pare F-actin staining in cells expressing dynWT and dynK44A in Fig-
ure 6B and Supplemental Figure 5). Podocyte actin is organized in 
parallel bundles of stress fibers and a cortical ring of filamentous 
actin (Figure 6B, CON). Expression of dynWT did not significantly 
alter the F-actin staining pattern (Figure 6B, WT). In contrast, the 
expression of dynK44A or p40 abolished stress fibers while enhanc-
ing the cortical actin web, resulting in a polygonal cellular shape 
(Figure 6B). Similar actin and cell morphology phenotypes were 
associated with LPS (Figure 6B) and PAN treatments (25). Thus, 
occurrence of proteinuria in mice expressing dynK44A or p40 (Fig-
ure 6A) correlates with changes in podocyte morphology due to 
changes in actin cytoskeleton (Figure 6B).
If dynamin is a target of CatL, then dynL356Q and dynR725A, which are 
resistant to CatL cleavage, might be beneficial during LPS-induced 
proteinuria. At peak proteinuria (48 hours after initial LPS), mice 
were injected with empty vector, dynWT, dynL356Q, or dynR725A either 
from the CMV promoter (Figure 6C) or the podocin promoter (Figure 
6D), and the degree of proteinuria was analyzed 12 hours after DNA 
injection. Strikingly, expression of dynR725A led to almost complete 
resolution of proteinuria, whereas expression of dynL356Q reduced 
proteinuria by approximately 50% (Figure 6, C and D; 60-hour time 
point). Interestingly, while CMV-dynWT had no affect on proteinuria 
(Figure 6C), podocin-driven expression reduced proteinuria by 50% 
(Figure 6D). The ability of POD-dynWT to overcome proteinuria is 
likely due to the higher level of podocyte-specific dynamin expression 
expected from the podocin promoter. Indeed, kidney extracts from 
animals expressing POD-dynWT contained the same level of dynamin 
as extracts from animals expressing CMV-dynWT, even though the 
latter was expressed in all cell types in the glomerulus (Figure 5, B 
and C). Thus, while expression of a high level of dynWT can partially 
reverse LPS-induced FP effacement, dynL356Q and dynR725A are more 
potent. Interestingly, dynR725A is the most powerful, most likely due 
to restoration of optimal cellular levels of dynamin:GTP.
Discussion
In this study, we investigated the role of the protease CatL and the 
large GTPase dynamin in healthy and diseased kidney podocytes. 
We show that dynamin is normally required to maintain the ultra-
filtration barrier in kidneys, possibly via regulation of the actin 
cytoskeleton in podocytes. Using a mouse model for inducible 
kidney failure, we found that cleavage of dynamin by a cytoplas-
mic form of CatL leads to podocyte failure and proteinuria. Gene 
delivery of CatL-resistant dynamin mutants can prevent and even 
reverse proteinuria. Our data define a new role for cytoplasmic 
CatL (trigger) and dynamin (target) in the pathogenesis of glo-
merular proteinuria and open new potential avenues for pharma-
cological intervention of kidney disease.
Previous inhibitor studies suggested that CatL is involved in pro-
teinuric kidney disease (4), and our current (Figure 1D) and previ-
ous work (3) has shown that CatL is upregulated in rodent models 
for nephropathy. Consistent with these findings, we observed an 
increase in levels of glomerular CatL mRNA in a number of human 
proteinuric diseases (Figure 1A) that correlated with a dramatic 
increase in the protein level in glomeruli (Figure 1C). Using knock-
out mice, we provide definitive evidence that CatL is essential to 
cause nephropathy in response to LPS in a mouse model (Figure 1, 
D–F). Furthermore, we have shown that after LPS treatment, CatL 
appears in the cytoplasm, due to expression of the short form of 
the protein. Together, the data indicate that localization of CatL 
to the cytoplasm represents a key event in the induction of glo-
merular kidney disease. Consistent with this model, we show that 
dynamin, a cytoplasmic protein, is essential for kidney function 
and that it is cleaved by CatL after LPS treatment. Importantly, 
the dynamin p40 fragment generated by CatL cleavage functions 
as a dominant-negative inducer of proteinuria. Thus, the activity 
of the cytoplasmic CatL, in contrast to its lysosomal counterpart, 
seems to be specific and to yield a functional product (p40). These 
data argue that complete destruction of dynamin is not necessarily 
required to cause kidney failure.
Intriguingly, the CatL cleavage site is highly conserved among 
dynamin family members (Figure 4A), and its accessibility is sup-
pressed by dynamin oligomerization. Moreover, cytoplasmic CatL 
targets only the GTP-bound form of dynamin, implying that only 
a portion of dynamin is cleaved in vivo. Our previous experiments 
indicate that dynamin:GTP is the active form of the enzyme (19, 
26), so it is tempting to speculate that CatL functions to switch off 
dynamin much like the result of dynamin self-assembly. It remains 
to be seen whether this novel switch-off mechanism is ever used 
during normal cell physiology.
EM revealed 2 populations of actin in FPs of podocytes; one is 
the actin bundle running above the level of slit diaphragms, and 
the other is the cortical actin network located beneath the plasma-
lemma (27). Our data show that dynamin colocalizes with both of 
these populations (Figure 3B). It appears that FPs have the molec-
ular makeup for constant morphological rearrangement in order 
to accommodate glomerular filtration. This membrane reshaping 
is most likely driven by rapid changes in the actin network (28), 
and our study suggests that it requires functional dynamin. On 
its C terminus, dynamin contains a proline-arginine rich domain 
(PRD) that binds directly to the Src homology 3 (SH3) domains of 
multiple proteins, some of which are actin-regulating or -binding 
proteins including profilin, Nck, Grb2, syndapin, intersectin, cor-
tactin, mABP1, and tuba (reviewed in ref. 13). It is through these 
interactions that dynamin is thought to coordinate membrane 
remodeling and actin filament dynamics during endocytosis, cell 
morphogenesis, and cell migration. Despite these links between 
dynamin and actin, it is still unclear how exactly dynamin regulates 
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actin dynamics. Our results identify podocytes, with their complex 
actin dynamics, as an appropriate cell type for investigating the 
interplay between dynamin’s role in endocytosis and its ability to 
regulate the actin cytoskeleton. Indeed, formation of a cortical 
actin cytoskeleton in cells expressing dynK44A or p40 or that have 
been treated with LPS (Figure 6B) could result from the inhibition 
of endocytosis, misregulation of actin dynamics, or both. While at 
present we have no direct evidence for a direct connection between 
actin and dynamin, addition of LPS does not inhibit endocytosis 
in cultured podocytes (Supplemental Figure 6), suggesting that 
loss of endocytosis per se is not sufficient to generate a cortical 
actin network. In agreement with this conclusion are experiments 
showing that expression of a known endocytosis inhibitor, domi-
nant-negative auxilinH875Q (29), impaired endocytosis to the same 
extend as dynK44A (Supplemental Figure 6A), yet it did not alter 
actin morphology (Supplemental Figure 6B). In addition, non-
differentiated podocytes contained predominantly cortical actin 
(Supplemental Figure 6B), yet they exhibited WT levels of endo-
cytosis (Supplemental Figure 6A). In sum, there seems to be no 
correlation between levels of endocytosis and actin dynamics in 
podocytes, raising the possibility that dynamin mutants might 
primarily act on podocyte actin dynamics. This conclusion is also 
in line with the observation that CatL reduced endogenous dyna-
min by only 30% (Figure 3D), possibly maintaining dynamin’s 
role in endocytosis. Regardless of these observations, dynamin is 
clearly present on clathrin-coated pits in podocytes (Figure 3A), 
and changes in endocytosis have been implicated in some forms 
of podocyte failure (30). Clearly, more work is needed to define the 
exact role(s) of dynamin in podocytes.
Proteinuria was resolved by expression of dynR725A, dynL356Q, 
and to some degree dynWT. While our study shows that dynamin 
is efficiently delivered and expressed in podocytes, it is unlikely 
that every podocyte received dynamin. We propose that damaged 
podocytes may be particularly amenable to uptake of DNA pre-
sented in polymers (8, 31). Alternatively, it is conceivable that the 
effects of gene-delivered dynamin has multiple effects in podo-
cytes. For example, it seems possible that restoration of podocyte 
actin has a salutary effect on the slit diaphragm function. Finally, 
gene-delivered dynamin in podocytes may have a non–cell-autono-
mous effect on other resident glomerular cells such as glomeru-
lar endothelial cells. Whatever the precise mechanism, the use of 
dynamin mutants as a treatment for human kidney disease is an 
attractive subject for future experiments.
Methods
Cells, antibodies, reagents, and standard techniques. Mouse podocyte cell lines 
were grown as described previously (32). Dynamin antibodies included 
anti-dynamin (hudy 1) from Upstate Technology; mouse anti-dyn1 5402 
from Chemicon; VAM-SV041 from Stressgen. Two rabbit antisera against 
CatL were used as described previously (8, 33). CatL–/– fibroblasts were 
maintained as described previously (34). Stable CatL-knockdown cell 
lines were generated with a vector-based siRNA directed against CatL (tar-
get sequence 5′-GTGGACTGTTCTCACGCT-3′). Quantitative PCR was 
performed on an Applied Biosystems 7300 Real-Time PCR System. Fold 
expression changes were calculated using the comparative CT method for 
relative quantitation with the equation 2–ΔΔCT. Protein expression levels for 
dynamin and CatL were calculated using results of densitometric analysis 
from 7 independent experiments with Kodak 1D Image Analysis software. 
Statistical significance was assessed with the unpaired Student’s t test with 
Welch’s correction. P less than 0.05 was considered statistically significant. 
Transfections with CatL constructs were performed using Lipofectamine 
2000 (Invitrogen). Immunocytochemical analysis of cultured podocytes 
was performed as described previously (3). BIOMOL CV-CatL/B activity 
kit was utilized as described in the manufacturer’s instructions. The fluo-
rophore cresyl violet [CV-(FR)2] substrate becomes florescent after CatL/B 
cleavage of the attached Phe-Arg groups. This substrate easily penetrates 
the cell membrane and the membranes of the internal cellular organelles, 
enabling the detection of cathepsin activity within living podocytes. Immu-
noperoxidase labeling of human tissue was done on formalin-fixed kidney 
biopsy samples embedded in paraffin. Transmission electron microscopy 
and immunoelectron microscopy were performed as described previously 
(35). Subcellular fractionation was performed as described (36).
Animals and treatments. All animal studies were approved by the MGH Sub-
committee for Research Animal Care. C57BL/6 mice were obtained from 
The Jackson Laboratory. CatL–/– mice were on a pure C57BL/6 background 
(10). The mouse model LPS-induced proteinuria was utilized as previously 
described (3). The rat PAN nephrosis model was induced as described (37).
Patients and quantitative glomerular rt-PCR. Microdissected glomeruli from 
patients with proteinuric diseases and from control subjects were analyzed. 
Biopsies were obtained from patients and donors after informed consent 
and with approval of the local ethical committees. For control biopsies, 
renal tissue was derived from pretransplantation kidney biopsies during 
cold ischemia time from 7 living and 1 cadaveric donor (n = 8) (38). Statisti-
cal analysis was performed using the Kruskal-Wallis test and Mann-Whit-
ney U test. P less than 0.05 was considered statistically significant.
Processing of dynamin by CatL in vitro. Recombinant dynamin was purified 
as described previously (39). One microgram of dynamin (10 pmol) was 
diluted in buffer containing 200 mM NaCl, 10 mM HEPES pH 7.0, 2 mM 
EGTA, 1 mM MgCl2, and 1 mM DTT. When indicated, 200 μM of GTP or 
1 mM of GTPϒS was added, and dynamin was allowed to bind nucleotides for 
10 minutes on ice. The reaction was initiated by addition of 0.5 μl of purified 
CatL (specific activity 4.13 U/mg of protein from Sigma-Aldrich), and sam-
ples were placed at 37°C in the water bath for 10 minutes. Total assay vol-
ume was 20 μl. The reaction was terminated with addition of E-64d inhibi-
tor (Sigma-Aldrich) and sample buffer. For Western blot analysis, 5 μl of the 
samples was run on 10% SDS-PAGE. When CatB (specific activity 3.00 U/mg 
of protein from Sigma-Aldrich) or recombinant human furin (from R&D 
Systems) were used, 2 μl of the enzymes were added in the assay.
Adenoviral infections of cultured podocytes. Podocytes were grown to 70% 
confluency. Cells were washed twice with 1× PBS and infected with 1.2 ml 
of serum-free DMEM medium containing 100 μl transactivator virus and 
100 μl virus expressing dyn1 or dyn2. After 2 hours of infection at 37°C, 
medium containing virus was replaced with full DMEM. If cells were 
treated with LPS or PAN, 50 μg/ml of LPS or 50 μg/ml PAN was added at 
this point. Eighteen to 24 hours after infection, cells were detached using 
trypsin and either processed for subcellular fractionation or tested in the 
motility assays as described in ref. 3. When indicated, 20 μM of Z-FF-FMK 
CatL specific inhibitor (Calbiochem) was added simultaneously with LPS.
Kidney extracts. Four mouse kidneys were homogenized in buffer con-
taining 20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM MgCl2, 1 mM PMSF, 
proteinase inhibitors, calpain inhibitor (Calbiochem), and E-64d using 
Dounce homogenizer. Subsequently, cytosol was centrifuged for 10 min-
utes at 4,600 g. Proteins were solubilized by 1% Triton X, 1 hour at 4°C, 
before it was spun at 70,000 g for 1 hour.
In vivo gene delivery. CatL plasmids encoding short and long CatL (5), 
dyn1 plasmids (all pcDNA), or p2.5 podocin-promoter driven (22) were 
introduced into mice (n >10, each construct) using the TransIT in vivo gene 
delivery system according to the manufacturer’s instructions (Mirus). Pro-
teinuria was assessed using Multistix 8 SG strips (Bayer) (data not shown) 
and the Bradford protein assay (Sigma-Aldrich).
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V. EXPRESSION PATTERNS OF TRPC1 AND TRPC6 
ORTHOLOGS IN ZEBRAFISH (DANIO RERIO) 
 
V.1.  Rationale 
 
In an attempt to understand the complex functions of the kidney, investigators have 
taken advantage of tractable animal model systems. Lipopolysaccharide (LPS)-
treated mice and puromycin aminonucleoside (PAN)-treated rats are well-established 
animal models used to study kidney pathologies. Another important group of animal 
models is represented by lower vertebrates such as the frog, Xenopus laevis, and the 
zebrafish, Danio rerio.  In particular the latter is an emerging model system that 
becomes more and more widely used in basic life science research [Drummond, 
2000]. 
 
The zebrafish offers a number of experimental advantages that make it a very 
attractive system for studies of kidney development and disease. First, zebrafish 
embryos develop in freshwater outside of the mother and are transparent, allowing 
observation of internal organs without dissection. Second, development occurs 
rapidly and embryos progress from fertilized eggs to free-swimming fish larvae in 
roughy 2.5 days. Third, zebrafish can be bred in very high numbers, which makes 
high-throughput approaches such as large-scale screening studies possible. Fourth, 
the sequencing of the zebrafish genome is nearing completion and has already yielded 
a huge body of genetic information that can be directly exploited in experiments, for 
example, by targeted disruption of single genes in order to assess their function. In 
comparison to gene knock-out in mice, which is a tedious and expensive task, 
zebrafish genes can be rapidly disrupted by morpholino anti-sense knock-down. 
Together, these features make the zebrafish a useful model for studying organ 
development and progression of disease, as well as the role of particular genes in 
these processes. 
 
The simplicity of the kidney in developing zebrafish larvae, the zebrafish pronephros, 
makes the study of this organ particularly interesting [Drummond, 2003]. In contrast 
to human kidneys, which each contain up to one million nephrons organized in a very 
complex fashion, the zebrafish pronephros consists of only two nephrons with 
glomeruli fused at the midline, pronephic tubules connect directly to the glomeruli 
via a neck segment, and paired bilateral pronephric ducts that convey the blood 
filtrate outside the animal. While the functional pronepros is remarkably simple, it 
represents a fully-functioning organ and, in free-swimming larvae of fish and 
amphibians, it performs the essential kidney functions of blood filtration and 
regulation of blood pressure. This feature allows efficient mechanistic studies of the 
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kidney, looking on single nephrons. The zebrafish is a powerful tool that can be 
manipulated with ease to rapidly determine the function of genes and the importance 
of cell-cell interactions that underly the development of all kidney forms. 
 
A recent study demonstrated that nephrin and podocyte orthologs are specifically 
expressed in zebrafish pronephric podocytes and are required for the development of 
pronephric podocyte cell structure [Kramer-Zucker et al., 2005]. Disruption of 
nephrin or podocin expression in zebrafish resulted in a loss of slit diaphragms and 
failure to form normal podocyte foot processes. 
 
Based on the potential of the zebrafish model system for the study of TRPC channel 
function in the kidney, the expression of TRPC6 and TRPC1 orthologs in the 
developing zebrafish was studied. The focus was on TRPC6 due to its known 
pathogenic implications in genetic and acquired forms of glomerular kidney disease 
and its association with the slit diaphragm. TRPC1 expression was also examined as 
this is a prominent member of the counterpart TRPC1/4/5 subgroup within the TRPC 
subfamily. 
 
V.2.  Materials and Methods 
 
V.2.1  Zebrafish embryos 
 
Wild-type TL or TÜAB zebrafish lines were maintained and raised as previously 
described [Westerfield, 1995]. Embryos were reared at 28.5 °C in E3 solution with 
0.003% PTU (1-Phenyl-2-thiourea, Sigma, Saint Louis, Missouri, United States) 
added to retard pigment formation. Embryonic staging was performed as previously 
described [Westerfield, 1995]. All animal studies were approved by the 
Subcommittee on Research Animal Care of the Massachusetts General Hospital. 
 
V.2.2.  Cloning of zebrafish TRPC1 and TRPC6 
 
For zebrafish TRPC1 only hypothetical sequence information was available in public 
databases. Therefore, the TRPC1 ortholog was cloned from zebrafish total mRNA. 
Total RNA was isolated from 2-day old zebrafish embryos using Trizol reagent 
(Invitrogen, Carlsbad, California, United States) and reverse transcription was 
performed with Oligo(dT)12-18 oligonucleotide primers. Based on hypothetical 
sequence information predicted by automated computational analysis available in the 
National Center for Biotechnology Information (NCBI) CoreNucleotide database 
(http://www.ncbi.nlm.nih.gov; Accession Number XM_694363), 5’ (5’-ATGGCTG-
CTCTATATCAGG-GC-3’) and 3’ (5’-TTAGCTTCTGGGGTAGAACATG-3’) 
primers were designed to amplify the full length zebrafish TRPC1 ortholog. TRPC1 
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was subcloned into the pCRII-TOPO vector (Invitrogen, Carlsbad, California, United 
States) and four clones containing the TRPC1 open reading frame were sequenced 
using T7 and SP6 primers. The obtained sequence was aligned to known TRPC1 
homologs in other species using the ClustalW algorithm [Thompson et al., 1994]. For 
zebrafish TRPC6, sequence information recently became available (Accession 
Number NM_001030282). TRPC6 was cloned as done with TRPC1; the obtained 
sequence was identical to the entry in the NCBI CoreNucleotide database. 
 
V.2.3.  TRPC1 and TRPC6 in situ hybridization 
 
Whole-mount in situ hybridization was performed as previously described [Thisse & 
Thisse, 1998]. For TRPC1 and TRPC6 antisense probes, the templates (pCRII-
TOPO-TRPC1 and pCRII-TOPO-TRPC6) were linearized with NotI (New England 
Biolabs, Ipswich, Massachusetts, United States) and antisense riboprobes were 
transcribed using SP6 RNA polymerase (Ambion, Austin, Texas, United States). 
Embryos were hybridized with digoxigenin-labeled riboprobes. Anti-DIG-AP 
(1:5,000) and the NBT/BCIP substrate (Roche Diagnostics, Basel, Switzerland) were 
used to detect the probe. After the color reaction was stopped, embryos were washed 
with methanol and equilibrated in clearing solution (1/3 benzoyl-alcohol and 2/3 
benzoyl-benzoate) and photographed using a Leica MZ12 dissecting microscope 
(Leica, Solms, Germany). Histological analysis on embryos after in situ hybridization 
analysis was carried out after stained embryos were fixed in 4% paraformaldehyde 
then dehydrated through a series of methanol/PBST washes of 25%/75%, 50%/50%, 
75%/25%, and finally 100% methanol for 10 min each followed by embedding in JB-
4 (Polysciences, Warrington, Pennsylvania, United States). A Riechert–Jung Supercut 
2065 (Leica, Solms, Germany) microtome was used to generate 10 μm sections. A 
Nikon E800 microscope equipped with a Spot Image digital camera was used for 
photography (Nikon, Melville, New York, United States). 
 
V.3.  Results 
 
V.3.1.  Sequence analysis of zebrafish TRPC1 
 
Four different clones including the TRPC1 open reading frame were sequenced to 
obtain the full-length TRPC1 sequence. Each base was identical in at least three 
clones. This sequence was then compared to the preliminary genomic sequence from 
zebrafish clone CH211-193E5 (Accession Number CT573382) and was confirmed as 
the zebrafish TRPC1 ortholog with one base being different (A2227 vs. T103578). 
 
The TRPC1 sequence is highly conserved across species (Fig. V.1.) and zebrafish 
TRPC1 shares 81% sequence identity with human TRPC1. The zebrafish TRPC1 
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gene encodes a protein of 783 amino acids, derived from an mRNA transcript with 13 
exons. Of note, mino acid E709 encoded by the GAA codon including base A2227 is 
a highly conserved one, there is a chance that the preliminary sequence entry for 
zebrafish clone CH211-193E5 may be incorrect in position T103578 since in this 
case a GTA codon would encode V709 instead of the highly conserved E709. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V.3.2.  Expression pattern of TRPC1 in zebrafish 
 
The expression of zebrafish TRPC1 mRNA was studied by whole mount in situ 
hybridization and histological analysis of zebrafish embryos. TRPC1 expression was 
ubiquitous throughout all stages of development up to and including 24 hours post-
fertilization (hpf) (Fig. V.2.). At 56 hpf, expression was restricted to the head with no 
detectable expression in the trunk, and strong head expression of TRPC1 persisted 
until 72 hpf. At 72 hpf, expression of TRPC1 was also detected in cells surrounding 
the inflow tract of the heart. In addition, expression of TRPC1 was detected in the 
ganglion cell layer and the inner nuclear layer of the eye. 
 
 
 
Fig. V.1. Sequence analysis of zebrafish TRPC1. (A) Alignment of the zebrafish TRPC1 sequence 
to known TRPC1 homologs in other species using the ClustalW algorithm. Conserved amino acids 
are highlighted in yellow. (B) Phylogenetic tree representative of evolutionary relationships between 
the zebrafish TRPC1 ortholog and cloned full length TRPC1 channels of other species. Branch length 
is proportional to evolutionary distance. 
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V.3.3.  Expression pattern of TRPC6 in zebrafish 
 
The expression of zebrafish TRPC6 mRNA was studied by whole mount in situ 
hybridization and histological analysis of zebrafish embryos (Fig. V.3.). The 
expression of TRPC6 mRNA was ubiquitous in all stages tested up to and including 
24 hours post-fertilization (hpf) (data not shown). At 48 hpf, expression became 
restricted to the head, pectoral fins, and the area of the gut extending to the posterior 
end. This pattern of TRPC6 expression persisted to 72 hpf, where expression in the 
most posterior region of the gut remained high while more proximal regions of the 
gut showed diminished expression. The histological examination revealed that 
TRPC6 expression in the pectoral fins was restricted to the dorsal surface. Sectioning 
through the trunk of 72 hpf embryos showed that TRPC6 mRNA was expressed in 
cells lining the dorsal aorta. A closer examination of the gut revealed that TRPC6 was 
highly expressed in cells that surround and encapsulate the gut. These cells are 
believed to be precursors of intestinal smooth muscle cells. 
 
 
 
 
 
 
Fig. V.2. Expression of zebrafish TRPC1 by whole mount in situ hybridization and histological 
analysis. The expression of TRPC1 mRNA is ubiquitous in all stages tested up to and including 24 
hpf (A / data not shown). At 56 hpf, expression is restricted to the head with no detectable expression 
in the trunk (B). Strong head expression of TRPC1 persists until 72 hpf (C), in addition to detectable 
expression in the inflow tract of the heart (white arrowhead). Histological examination of 72 hpf 
embryos reveals specific expression of TRPC1 in the ganglion cell layer (gcl, red arroheads) and in 
the inner nuclear layer (inl, black arrowheads). The plane of section as denoted by the white line in 
panel C confirms the expression of TRPC1 in the inflow track (E, black arrows). A magnified view 
(F) shows a high level of expression in the cells surrounding the inflow tract (white arrowheads).  
Le=lens, e=eye, gcl=ganglion cell layer,  inl=inner nuclear layer. 
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V.4.  Discussion 
 
In zebrafish, five TRP channel genes have thus far been described. TRPM7 was 
identified as the gene defective in the mutant touchtone/nutria [Elizondo et al., 2005] 
which exhibits altered skeletal structure, a diminished response to touch, and kidney 
stones. TRPM7 is expressed in mesonephric kidney tubules, corpuscles of Stannius, 
and the liver. TRPA1 and TRPN (NOMPC) have been shown to contribute to ear and 
lateral line hair cell function [Corey et al., 2004; Sidi et al., 2003]. TRPC2, which is a 
pseudogene in humans, is expressed in the adult olfactory epithelium superficial layer 
[Sato et al., 2005]. Recently, the osmosensory channel TRPV4 has been detected in 
multiple developing organs in zebrafish [Mangos et al., 2007]. 
 
Fig. V.3. Expression of zebrafish TRPC6 by whole mount in situ hybridization and histological 
analysis. The expression of TRPC6 mRNA is ubiquitous in all stages tested up to and including 24 
hpf (A / data not shown). At 48 hpf, expression becomes restricted to the head, pectoral fins (black 
arrowhead), the area of the gut (white arrows) extending to the posterior end (black arrow). A dorsal 
view shows the extent of the expression of TRPC6 in the pectoral fins (C, black arrows). This pattern 
of TRPC6 expression persists to 72 hpf, where expression in the most posterior region of the gut 
(black arrow and inset) remains high while more proximal regions of the gut show diminished 
expression (D). Histological examination reveals that TRPC6 expression in the pectoral fins is 
restricted to the dorsal surface (E, black arrowheads). Sectioning through the trunk of 72 hpf embryos 
shows that TRPC6 mRNA is expressed in cells lining the dorsal aorta (F, black arrowheads). A closer 
examination of the gut reveals that TRPC6 is highly expressed in cells that surround and encapsulate 
the gut (G, demarcated by black arrows). 
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This study demonstrates that both TRPC1 and TRPC6 are expressed in zebrafish 
during development. In line with the published work on TRPC1 expression in the 
heart [Dietrich et al., 2007], TRPC1 expression was detected in cells surrounding the 
inflow tract of the heart. This suggest a role for TRPC1 in the zebrafish 
cardiovasculature. In addition, TRPC1 was expressed in the zebrafish eye retina, 
consistent with the general role of TRPC channels in sensory physiology [Clapham, 
2003], and the immunolocalization of TRPC1 in the chicken retina [Crousillac et al., 
2003]. TRPC1 was present  in 72 hpf embryos in the ganglion cell layer and in the 
inner nuclear layer [Dahm et al., 2007]. These structures contain neuronal cells 
appearing early on the second day post-fertilization [Hu & Easter, 1999]. This 
observation indicates that TRPC1 may play a role in zebrafish vision, analogue to the 
role of the original trp gene in Drosophila photoreceptors [Montell, 1997]. 
 
TRPC6 expression was detected on the dorsal surface of the pectoral fins. The 
pectoral fin is composed of two simple muscles, the abductor and adductor [Thorsen 
& Hale, 2005], as well as large dorsal and ventral nerve branches [Thorsen & Hale, 
2007]. It remains to be determined in which of these cell types TRPC6 is expressed. 
Further studies involving double labeling neuronal and muscle cell markers will be 
necessary to answer this question. TRPC6 was also found in cells that surround and 
encapsulate the gut at 48 hpf. Given that this is the stage in development when the 
first detectable smooth muscle cell markers were detected in the vicinity of the gut 
[Georgijevic et al., 2007], it appears that TRPC6 could be expressed in 
gastrointestinal smooth muscle cells. A possible role for TRPC6 in these cells would 
be to contribute to the stability, contractiliy and elasticity of the zebrafish gut. Finally, 
TRPC6 expression was also detected in cells lining the aorta. Based on the many 
recently published reports indicating an important role of TRPC6 for the 
cardiopulmonary vasculature [Dietrich et al., 2007], it is probable that TRPC6 fulfills 
a similar role in the zebrafish. 
 
The lack of detectable TRPC6 expression in zebrafish podocytes could be due to low 
abundance of TRPC6 channels in these cells. It is also possible that TRPC6 
expression may only be upregulated under pathophysiological conditions. Finally, 
TRPC6 expression could simply occur in later stages of development. This is the 
most likely situation given the situation in neonatal mice, where no expression of 
TRPC6 was detected. To test this, further studies of TRPC6 expression in genetic and 
inducible zebrafish models of glomerular injury will be necessary, and TRPC6 
expression must also be investigated in adult fish. 
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VI.  CONCLUDING REMARKS 
 
Focal Segmental Glomerulosclerosis (FSGS) is a condition diagnosed in around one 
fifth of all patients with end-stage renal disease (ESRD). The proportion of end-stage 
renal disease attributed to FSGS has increased more than 10-fold over the past two 
decades [Kitiyakara et al., 2004]. Therefore, identifying the molecular mechansims 
involved in the development of FSGS is of high priority. 
 
In this study five mutations in the calcium-permeable ion channel TRPC6 were 
associated with the development of familial forms of FSGS. All mutations occured in 
evolutionary conserved sequence motifs at the N-terminal and C-terminal 
intracellular tails of TRPC6, and two mutations lead to increased channel current 
amplitudes when expressed in HEK293 cells. TRPC6 was found to be in glomeruli, 
where it is located in podocytes in close proximity to the slit diaphragm. Furthermore, 
it was shown TRPC6 interacts with the slit diaphragm proteins podocin and nephrin. 
 
In addittion to NPHS1 (nephrin), NPHS2 (podocin), ACTN4 (?-actinin-4), and 
CD2AP, TRPC6 represents the fifth known gene associated with inherited nephrotic 
syndrome and FSGS. Moreover, TRPC6 is the first example of a protein suggested to 
play a dual role in both, genetic and acquired forms of glomerular disease. Finally, 
TRPC6 is the first calcium-permeable ion channel shown to be associated with the 
slit diaphragm multiprotein complex, substantiating the role of calcium signaling for 
the molecular regulation of glomerular filtration at the slit diaphragm site. 
 
It was demonstrated that wild-type TRPC6 was induced in a number of acquired 
human and experimental glomerular diseases, in particular in Membranous 
Glomerulonephritis (MGN) and in vitro and in vivo models thereof [Moller et al., 
2007]. Elevated TRPC6 levels were correlated with albuminuria and increased 
intracellular calcium in the rat puromycin aminonucleoside (PAN) model of podocyte 
injury. Overexpression of TRPC6 in cultured podocytes lead to a disruption of the 
podocyte actin cytoskeleton. TRPC6 overexpression in mice using gene delivery was 
sufficient to induce transient proteinuria. These data provide the first experimental 
evidence that TRPC6 can play a pathological role in glomerular kidney disease. 
 
The present work opens a series of questions that have to be addressed in the future. 
Due to the clinical significance of FSGS and nephrotic syndrome, the focus will be 
on the elucidation of the physiological and pathophysiological roles of TRPC6 
channels in podocyte foot processes (Fig. VI.1.). Promising future lines of 
investigation will include the study of TRPC6 protein-protein interactions, the 
identification of upstream and downstream effectors, and the screening for specific 
channel agonists and antagonists in podocytes.  
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The development of suitable model systems to study TRPC6 function is also of great 
importance. The presented work shows that, next to to genetic mouse models of 
TRPC6 dysfunction, the experimental approach of in vivo gene delivery can be a 
useful alternative. Furthermore, it is demonstrated that Danio rerio expresses at least 
two TRPC channel orthologs, TRPC1 and TRPC6, suggesting the zebrafish as an 
animal model for the study of TRPC6. 
 
The significance of the presented observations is reflected by a number of recent 
articles highlighting the importance of the questions that will have to be addressed 
with regard to the role of TRPC6 in glomerular kidney disease [Gudermann, 2005; 
Walz, 2005; Kriz, 2005; Winn et al., 2006; Mukerji et al., 2007; Oh, 2007]. Future 
studies on TRPC6 in podocytes will benefit from the increased attention that both 
areas of research, podocyte biology and TRPC6 physiology, have been receiving in 
the past years (Fig. VI.2). They will help refine the understanding of glomerular 
disease and provide hope to the many individuals affected by glomerular disorders. 
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Fig. VI.2. The number of publications returned from a PubMed search with 
the keywords “Podocyte” and “TRPC6” (http://www.ncbi.nlm.nih.gov). 
Fig. VI.1. Working Model. 
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